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Introduction
Introduction
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory
disorders collectively referred to as Inflammatory Bowel Disease (IBD). The
disease is characterized by alternating periods of flare ups (exacerbation) and
quiescent disease (remission). The inflammation in UC is confined to the
mucosal layer and affects the large bowel only, being usually superficial. CD can
affect any part of the gastrointestinal tract from mouth to anus, although the
most common sites to be involved are the terminal ileum and coecum. Unlike
UC, the inflammation in CD is not necessarily continuous and areas of ulceration
may be interspersed by relatively normal mucosa. The inflammatory process can
affect all layers of the gastrointestinal wall. In IBD patients, a wide spectrum of
disease severity is observed, with respect to the site, nature and extent of
intestinal involvement.
Descriptive epidemiology
In the United States and in Europe, IBD appears to be more common in northern
than in southern areas' .^ A recent study conducted in the Netherlands showed
incidence rates of 6.9 per 100,000 and year for CD, and 10.0 for UC,
respectively*. These age- and sex-standardized incidence rates are high
compared to studies in neighboring countries*. However, it should be kept in
mind that comparing incidence rates between different countries can be
misleading, because different diagnostic facilities and disease definitions may
have been used. The age distribution in CD shows a peak incidence between 15
and 30 years, and the reported incidence rates of CD in this age group are
higher in females than in males*. On the other hand, UC is equally distributed
between genders, although a male preponderance is frequently observed in the
older age groups**'.
The number of newly-diagnosed CD patients has increased over the last
decades, while the incidence of UC has shown a more constant picture®.
Pathogenesis
The etiology of the chronic inflammatory process in IBD remains unknown.
Family studies and genetic marker studies have supported the relevance of
genes to disease predisposition in IBD^". However, the increased incidence
since the 1950s'*'^ cannot be attributed to a change in genetic mapping in the
relatively homogeneous populations over this period of time. Environmental
factors have therefore been suggested as important etiological factors in the
pathogenesis of IBD, probably through an as yet unclear interaction with
multiple predisposing genes.
Environmental factors could comprise thrombogenic factors'*'® and
microbiological agents"'®. As nutritional habits have clearly changed over the
past decades, diet is an important environmental factor to be considered in the
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etiology of IBD. In a recent case-control study, some distinct nutritional factors
were found to be associated with IBD, and the authors suggested that this
could be the expression of a modern life-style'*. However, at this moment there
is still very little conclusive evidence regarding the role of specific dietary
components in the pathogenesis of IBD. Unfortunately, most studies were
subject to methodological limitations, and well designed studies are necessary
to confirm the hypothesis that nutritional factors play a role in the development
of IBD.
Fatty acid metabolism is involved in the immune response and inflammation
processes in IBD patients, since polyunsaturated fatty acids are precursors of
eicosanoids, which participate in the regulation of immunological and
inflammatory responses^"*'. Hence, fatty acid intake and metabolism may be
important both in the pathophysiology of IBD and in the clinical course of the
disease.
Under normal physiologic conditions, inflammatory reactions are an essential
part of host defense, playing a critical role in the eradication of foreign agents.
In healthy humans, reactive oxygen species are constantly generated, but
antioxidant defenses may regulate this process by scavenging abundant
radicals. In patients with active CD, an increased production of reactive oxygen
species has been observed (oxidative stress)"". Furthermore, an imbalance
between prooxidant and antioxidant mechanisms has been reported in IBD
patients". It is unknown whether this imbalance is a cause of inflammation in
IBD or just its result. However, recent studies support the idea that antioxidants
may be important in the pathogenesis of tissue injury in IBD" '" .
Treatment
Current therapy for IBD patients aims at local anti-inflammatory action,
immunosuppresion, prevention of complications and general support. At
present, medical therapy counteracts the inflammation rather than the
underlying cause of the disease. The efficacy of preventive medical treatment
during a phase of remission is unsatisfactory, especially in the case of CD.
Another disadvantage of current medical treatment is the side-effects of
systemically active immuno-suppresive agents. Surgical treatment is
unavoidable in some circumstances and can cure UC. In CD patients, disease
recurrence affects 50-90% of patients after surgery, depending on the definition
used^.
In CD patients, the therapeutic value of selected enteral nutrition was
observed more than two decades ago. Such enteral nutrition comprises either
an elemental diet providing nutrients in their simplest form (with the aim of
reducing the total antigenic load) or oligopeptide and polymeric formulae
containing nitrogen sources in the form of di- and tripeptides and whole protein,
respectively. In recent years, many excellent reviews*''" and meta-analyses^'^
have been published on the primary therapeutic role of selected enteral diets.
Enteral nutrition is effective at inducing remission in active CD, although there is
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insufficient data to confirm that enteral nutrition may replace drug therapy.
Enteral nutrition is especially recommended in specific subgroups, such as
children with signs of growth impairment and patients with intolerable steroid-
associated side effects. Several hypotheses have been proposed to explain the
efficacy of enteral nutrition in CD, but none of these has achieved general
acceptance". In UC, on the other hand, enteral diet seems to be less successful
in inducing remission^"".
Nutritional supplementation is indicated for repairing nutritional deficiencies,
which are frequently reported in IBD patients*"*. Furthermore, specific immuno-
modulating nutrients can be administrated, such as antioxidants or fish oil,
which may interact with the inflammatory process in IBD. Fish oil containing the
n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid may exert anti-
inflammatory activity by modifying cell membrane structure and by altering
eicosanoid metabolism in IBD patients". A diminished antioxidant status has
been reported in IBD patients*****""'" and this justifies intervention trials to
investigate the potential beneficial role of antioxidants in the clinical course of
IBD. - .,: - . ,.
IBD and nutrition . D :>'t-^ v • v *vc ; -.-.::>•.-*>;;: •;•; <
Nutrition strongly interacts with IBD, as was outlined above. Three main topics
can be distinguished in the relation between IBD and nutrition: 1) the role of
specific dietary components in the pathogenesis of IBD, 2) malnutrition as a
result of the disease process, and 3) nutritional intervention to improve the
nutritional status or to attenuate inflammatory activity.
It is known that the prevalence and severity of malnutrition are markedly
influenced by the activity and extent of the disease, especially in CD. In many
studies it is difficult to separate the effects of the disease, especially those
caused by inflammation, from those of malnutrition per se. The association
between IBD and malnutrition per se should therefore preferably be investigated
in patients during remission of the disease. ••, ? v ^ .-., •..;.;• • , •: -
This thesis attempts to provide further insights into the role of nutrition in
IBD. The following aims are addressed: : '-,c;u^ O' , nsn; v y, : r ' J '
1. Investigating the role of nutrition in the pathogenesis of IBD, with special
reference to the role of fatty acids and antioxidants.
2. Determining a comprehensive nutritional status in various groups of IBD
patients compared with controls in order to
a. study the association between CD and malnutrition per se; •;.;•<• ••••r. • n,.
b. study the association between disease duration and malnutrition;
c. study the interrelation between the various dimensions of the nutritional
status.
3. Studying the effects of n-3 fatty acids and antioxidant supplementation on
the nutritional status in CD patients.
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Outline of the thesis " '
Chapter 2 reviews current knowledge on the relation between nutrition and IBD.
The role of nutrition in the pathogenesis of UC is described in Chapter 3,
based on a case-control study design. Recently diagnosed UC patients (within 6
months of diagnosis) and age- and sex-matched population controls were
included in this study. Pre-illness diet was assessed by the cross-check dietary
history method.
In Chapter 4 the association between CD and malnutrition per se is
discussed. A comprehensive nutritional status was assessed in patients with
long-standing (>10 years) CD, currently in remission, compared with population
controls. The assessment of nutritional status comprised four different
dimensions: 1) body composition, 2) dietary intake, 3) biochemical parameters
of nutrition, 4) muscle strength.
A study investigating whether the nutritional status in IBD is already affected
at the time of diagnosis is described in Chapter 5. The comprehensive nutritional
status of newly diagnosed IBD patients (within 6 months of diagnosis) is
compared with that of population controls. ^-T5"."i;«-.. , *••'•' • jr r o^ss. > •
Chapter 6 discusses a detailed study on body composition in IBD, with
special reference to the body water distribution. Malnutrition and inflammation
may both affect body hydration by changing the size of the extracellular and
intracellular water compartments, respectively. Measurement of body water
distribution is an essential part of nutritional assessment and it may be helpful in
understanding the reported metabolic alterations in IBD.
Fatty acid metabolism is involved in the immune response and inflammation
processes in CD patients and, changes in the fatty acid profile may thus be
relevant to the clinical course of the disease. In Chapter 7, a study is presented
on qualitative and quantitative fat intake and the fatty acid profile of plasma
phospholipids and adipose tissue in various groups of CD patients and controls.
The interrelation between two important aspects of the nutritional status,
antioxidant defense (Chapters 4,5) and fatty acid profile (Chapter 7) in CD
patients, is investigated in a study described in Chapter 8.
The results observed in the above studies led to a nutritional intervention trial
in CD patients (Chapter 9). Antioxidants and n-3 fatty acids were supplemented
for three months, in addition to the regular diet, to CD patients currently in
remission. We investigated the effects of this specific nutritional supplement
primarily on nutritional status and fatty acid profile, and secundary on the
quality of life and the course of the disease.
Finally, the results of the various studies in this thesis, in relation to each
other and in the light of information from current literature, are discussed in
Chapter 10. ' '
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Introduction
Inflammatory Bowel Disease (IBD) is a chronic inflammatory process that
involves the colon in ulcerative colitis (UC) and may involve any part of the
entire gastrointestinal tract in Crohn's disease (CD). The etiology and
pathogenesis of IBD are still unclear. Nutrition plays an important role in the
pathogenesis as well as in the treatment. In the relation between nutrition and
IBD, three topics can be distinguished: the role of specific dietary components
in the pathogenesis of IBD, malnutrition in the course of the disease, and
nutritional therapy. This review evaluates dietary etiological factors, nutritional
status and nutritional therapy in IBD.
Diet and risk of IBD
IBD incidence rates in various countries show wide variations'*. Although the
role of genetic factors in the pathogenesis of IBD has been established by twin
and family studies as well as genetic linkage analysis^*, the geographical
variation in incidence suggests that environmental factors could also play a
significant role*. In addition, the incidence of CD in urban populations in the
developed countries has increased during the last decades^', whereas the
genetic background of the population has remained stable. This indicates that
environmental factors like diet may be important in the etiology of IBD.
In 1976, Martini & Brandes" and Miller et al^ were the first to report that CD
patients consumed an excess amount of sugar and sugar-containing products,
and many studies on dietary habits of IBD patients have been conducted since.
We will critically review studies on sugar, fiber, fruit, vegetables, fat and protein
consumption which have been considered to play an role in the etiology of IBD.
Consumption of sugars
The most consistent finding in all studies has been the increased sugar
consumption in CD patients^". This was also shown in a few studies to be true
for U C " ' " ' " . Intakes of sugars vary considerably across countries with the
highest intake in Israel"''". However, epidemiological studies have failed to find
correlations between the rising incidence of IBD and marked change in sugar
consumption over the last 50 years".
In a recent large epidemiological study, a greater risk for the development of
CD or UC was found among those with a high consumption of chocolate,
chewing gum and cola drinks (nutritional items share a high sugar content),
whereas a decreased risk was observed with a high intake of citrus fruits*. The
authors suggested that the nutritional items mentioned may be true risk factors
or they just might be the expression of a modern life-style also involving other
risk factors for the development of IBD.
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Since the possible role of sugar in the pathogenesis of I6D was postulated,
several dietary intervention studies have investigated the effects of a low sugar,
high fiber diet in CD patients. In a large multi-center trial of Ritchi et aP\ 190
CD patients were randomized to low sucrose, high fiber diet and 162 CD
patients to the control diet. Dietary assessment by the recall method showed
good compliance in both groups. However, no significant benefits in clinical
course were demonstrated. In a small randomized double blind study of Alun
Jones et aP, all of the 10 CD patients randomized to the low sucrose, high
fiber diet had relapsed by six months while 7 out of the 10 patients on the
exclusion diet remained in remission. In a large study of Lorenz-Meyer et al,
remission rates at 1 year in CD patients were identical in the low carbohydrate
and placebo group". Thus, these carefully designed trials did not demonstrate
any significant benefits from sucrose avoidance.
In a recent review of the association between CD and sugar consumption
however, Riordan et a l " showed that the relationship between sugars and the
onset of CD was inconsistent. Many studies have been subject to important
methodological limitations. Most of the studies investigated post-illness diet,
although dietary habits may have changed since onset of the illness. This
suggests that a high sugar intake is a consequence of the symptoms rather than
a cause of the disease. Even if questionnaires referred to pre-illness diet, only a
few studies investigated patients close to the time of diagnosis*'*". It is
known that retrospectively recalled information dating from several years before
the onset of illness has limited accurary^*.
A problem in most studies is the quality of the data analysis. A comparison
of the mean consumption of different foods/nutrients between patients and
controls does not provide any information about the magnitude of the increase
in disease risk associated with specific consumption. Instead, relative risk or
odds ratios should be obtained. Another methodological shortcome of many of
the studies is the representativeness of the control group as hospital controls
were used in most studies. These controls all suffer from disease and it is
possible that their disorders are associated with the dietary intake, in which
case they do not constitute an appropriate controls series. Therefore, randomly
chosen population controls are preferable"'".
Several studies failed to conduct a dietary interview or questionnaire
assessing the entire dietary intake. It is doubtful whether questions about the
use of added sugar to cereals and drinks or about the consumption of sweet
foods accurately reflect daily sugar intakes.
Abdominal pain or diarrhoea can affect appetite but most studies did not
report data on disease activity. In the study by Brauer et aP°, which found no
change in current sugar intake of IBD patients compared with the general
population, the majority of the patients were in remission.
In summary, although many studies have reported increased sugar
consumption in CD patients compared with controls, the methodological
limitations of most studies mean that it remains questionable whether sugar
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consumption is really associated with the onset of IBD. Future well-designed
studies may provide an answer to this question.
Dietary fiber and consumption of fruit and vegetables
Other nutrients which have frequently been studied are dietary fiber, fruit and
vegetables."•"»•i6.19.21.22.25.26.35 ^ decreased consumption of fruit, fruit juice or
vegetables was found among both CD and UC patients. The consumption of
dietary fibers and especially the consumption of fibers from fruit was also found
to be negatively associated with the risk of IBD"-"-". Most studies have
evaluated fruit and vegetables as food items, but Reif et a l " also studied
selected micronutrients (mainly minerals and vitamins). They found that fruits
and vegetables as food items were negatively associated with IBD risk. In
addition, a decreased risk of IBD was found to be associated with increased
consumption of water as well as potassium (in CD only), magnesium and
vitamin C. They proposed, however, that the effects of these vitamins and
minerals are not exclusively due to their presence in fruits and vegetables,
because vitamin A and various B vitamins (present in vegetables and fruit)
showed no clear association with IBD. In summary, keeping the above
mentioned methodological limitations of the studies in mind, the consumption of
fibre, fruit and vegetables seems to be a protective factor in the etiology of IBD.
Fat consumption
Guthy suggested that chemically processed hydrogenated fats, such as
margarine, may be important in the etiology of CD^. This hypothesis was based
on the association between the onset of margarine consumption and the first
reports of granulomatous ileitis, as well as the similarities in their geographic
distribution. The hypothesis has been investigated in a few studies. A Japanese
study found that the use of margarine showed a significant positive association
with the risk of UC". By contrast, Chuah et aP* showed no significant
differences in dietary oil consumption between Asian IBD patients and Asian
controls. However, CD patients were found to recycle their cooking oil
significantly more often than controls. Furthermore, some studies have reported
an increased relative risk of CD and UC associated with the consumption of fast
foods"* which is in line with Guthy's hypothesis that chemically modified fat
(margarine, frying or cooking fat) in fast foods may play a role in the etiology of
CD".
Some studies have investigated qualitative and quantitative overall fat intake
as a risk factor for IBD. Tragnone et al^ found no differences in fat consumption
(qualitative or quantitative) between IBD patients and controls. However, their
reported mean daily nutrient consumption was not corrected for energy intake,
and this methodological limitation could have biased the results. In a recent
study by Reif et a l " , increased fat consumption in the pre-illness period was
found among IBD patients, especially those suffering from UC. This increased
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fat consumption was found to cover all types of fats (animal fat, vegetable fat,
saturated as well as unsaturated fat, and cholesterol). Shoda et al*° reported in
an epidemiological study the qualitative fat intake and found that the increased
incidence of CD was correlated with increased intake of dietary fat, especially n-
6 fatty acids, combined with a relative decrease in the intake of n-3 fatty acids.
This type of epidemiological study has some limitations because results could be
influenced by the age of the data. The question is whether the CD incidence
should be related to dietary consumption data from the same year or to data
from 5-10 years before.
Protein consumption
Only a few studies have investigated protein intake as a risk factor for the
development of IBD. Tragnone et al* found that pre-illness total protein intake
was significantly higher in UC, but not in CD. A Japanese study showed,
however, that animal protein was related to an increased incidence of CD*°. Reif
et a l " reported that protein consumption did not seem to play a role.
Conclusion .
In summary, there is still very little conclusive evidence regarding the role of
specific dietary components in the pathogenesis of IBD. One obvious reason
could be that the dietary factors studied so far do not play a role as risk factors
for CD or UC. Another explanation is that the possible real differences in dietary
intake between patients and controls are undetected. Most studies reviewed
were subject to methodological limitations, which could have biased the results.
The study by Reif et a l " was well designed, but more of such studies will be
required to confirm the findings before dietary factors can be regarded as
important in the development of IBD.
Nutritional status in IBD
As early as 1932, Crohn described regional enteritis as muscle wasting and loss
of weight as common clinical signs of the disease*'. Since that time,
malnutrition has often been reported in IBD patients, especially in CD patients.
The multiple factors involved in the development of malnutrition are outlined in
Table 2.1. In most individual cases, more than one factor is responsible for
malnutrition. Evaluation of malnutrition in IBD has, until recently, most
frequently been performed using only anthropometric and biochemical
techniques*^'**. Weight loss has been regarded as a predominant feature; it
occurs in approximately 80% of CD patients*** and in 18-62% in UC patients*®.
However, most studies on malnutrition and IBD have been performed among
hospitalized patients and/or patients with active disease. In these patients, the
metabolic disturbances associated with malnutrition may be caused by the
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malnutrition itself and/or by the inflammation, as it is known that the prevalence
and degree of malnutrition are markedly influenced by the activity and the
extent of the disease**-*'.
What is nutritional status? One satisfactory definition has been given by
Jeejeebhoy et al**, who described nutritional status as 'an equilibrium of the
intake of a diet sufficient to meet or exceed the needs of the individual which
will keep the composition and function of the otherwise healthy individuals
within the normal range'. This equilibrium can be disturbed by decreased intake,
increased requirements and altered metabolism. Obviously, nutritional status is
influenced by several factors. Charney" stated that individual parameters may
reflect disease states rather than nutritional status.
In the following discussion, the assessment of nutritional status in IBD will be
critically reviewed in terms of how the interpretation of the measurement may
be affected by disease activity and how the markers used may be of value in
assessing nutritional status.
Table 2.1: Factors involved in the development of malnutrition in IBD
Inadequate food intake Anorexia (disease-induced),
Fear of eating due to abdominal pain
Malabsorption/maldigestion Decreased effective absorptive area due to extensive
disease or extensive resection,
Bacterial overgrowth.
Drugs: corticosteroids (calcium), sulphasalazine (folate)
cholestyramine (fat and fat soluble vitamins).
Small intestine bypass (fistulae)
Increased intestinal losses Blood loss,
Protein-losing enteropathy.
Bile salt-losing enteropathy,
Electrolytes, minerals, trace elements
Increased requirements Inflammation,
Fistula,
Increased intestinal cell turnover
Disease activity Elimination of antioxidants due to oxidative stress
Protein-energy malnutrition
A common clinical manifestation of protein-energy malnutrition in IBD is weight
loss**. Weight loss frequently occurs, however, in patients requiring hospital
admission because of acute exacerbation*". Insufficient intake is often attributed
to weight loss caused by the presence of chronic illness or fear of precipitating
abdominal pain. In addition, increased energy expenditure should also be
considered as a possible explanation for the reported weight loss*'. However,
Stokes and Hill" showed that total energy expenditure was not raised in CD
patients.
Loss of body protein mass in IBD has been reported in active CD patients*'",
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but is less common in patients in remission. Hypoalbuminemia, on the other
hand, is a very common finding in IBD patients'*^*. Low serum albumin
concentrations are not necessarily related to protein undernutrition; reduced
hepatic protein synthesis, malabsorption and anorexia ail play an role, but
hypoalbuminemia results predominantly from intestinal protein loss and
increased catabolism. Serum albumin is a marker of disease activity rather than
of nutritional status. Plasma concentrations of retinol binding protein and
prealbumin fall rapidly in protein malnutrition. These proteins have a relatively
short half-life and are more sensitive to protein or energy deprivation than
albumin".
Vitamin deficiencies
Several vitamin deficiencies have been reported in IBD patients, but many
studies only assessed one single vitamin concentration. It is especially during
the last decade that vitamins have been recognized as an important factor in
IBD.
Vitamin A is a fat-soluble vitamin and reduced levels have been found in
lßQ566o^  ^ut thgge are associated with disease activity. Janczewska et a l "
showed that serum retinol levels in patients with active IBD are secondary to
the decreased retinol-binding protein concentrations, and probably depend on
the increased protein catabolism. Plasma levels of circulating retinol are
controlled by the level of retinol-binding protein, and as this is a negative acute-
phase protein, concentrations of plasma retinol will fall in disease®'.
Furthermore, a study of patients with long-standing CD, clinically in remission,
found no difference in serum retinol concentrations between patients and
controls^. These results suggest that one should be cautious in interpreting
vitamin A deficiency in IBD patients with active disease. Serum concentrations
of ^-carotene (pro-vitamin A) have been found to be reduced in active IBD
patients" and in inactive CD patients". Steatorrhoea resulting in the
malabsorption of fat-soluble vitamins, like /7-carotene, may contribute to the
suboptimal status.
Warer- so/t/6/e ß v/ra/n/ns
A few studies have reported low serum concentrations of thiamine, riboflavin,
and pyridoxine in IBD patients, most with active disease**""". Kuroki et al"°,
however, failed to demonstrate an obvious difference in vitamin status between
active and inactive CD patients. Furthermore, there have been some rare case
reports on deficiencies of water-soluble B vitamins producing syndromes
resembling beriberi (thiamine), pellagra (niotinic acid), photophobia with
dermatological changes (riboflavin) or dermatological and neurologic changes
(pyridoxine)^ •**.
The majority of the B-vitamins are present in the tissues in the form of co-
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enzymes®'. The functions of these enzymes may be strongly influenced by
disease, and it is obvious that requirements for these nutrients may be
increased by the disease. There are no data on vitamin B concentrations in IBD
patients with inactive disease. It is, however, plausible that no deficiencies of
the water soluble B vitamins will be found in these patients.
Folate deficiency has often been described in IBD, and has been partly
ascribed to long-term use of sulfasalazine, which causes competitive inhibition
of folate absorption®''. Decreased dietary intake, increased demand and
malabsorption due to mucosal impairment are also associated with folate
deficiency". Furthermore, folate deficiency may be primary or secondary to
vitamin B-12 deficiency". Besides systemic deficiency, increased intestinal cell
turnover due to epithelial inflammation, could also result in folate deficiency in
patients with UC". It has been shown that the risk of malignant transformation
in UC patients is significantly affected by low folate status®®.
Vitamin B-12 deficiency has frequently been found in CD patients, but rarely
in UC**. Vitamin B-12 malabsorption is related to the affliction of the terminal
ileum, but studies indicate that vitamin B-12 should also be seriously considered
for any patient with CD"-" .
Anemia is present in 25-85% of CD patients and in up to two thirds of UC
patients. This may be due to the iron deficiency resulting from gastrointestinal
blood loss, folate deficiency, or vitamin B-12 deficiency or may be a
consequence of chronic inflammation**.
C
A few studies have reported lower serum vitamin C concentrations in IBD
patients compared with controls"®". In addition, Buffinton and Doe®^  showed
that in non-inflamed mucosal biopsies from IBD patients, the proportion of
reduced and total ascorbate present was very low. It has been suggested that
these low levels are partly related to reduced dietary intake® .^ Furthermore, the
ascorbate deficiency could be a factor in the pathogenesis of fistula formation
because of the importance of ascorbate in collagen synthesis.
Studies have indicated that disease activity has a major impact on vitamin C
in the blood®'. It is known that vitamin C is an pro-oxidant in the presence of
Fe. In healthy individuals, the amount of free Fe will be kept at a minimum,
since there is adequate binding capacity in the plasma in the form of transferrin.
During disease activity, however, the amount of free Fe will increase.
Thurnham®' suggested that the decreased vitamin C concentration is a response
to increased disease activity.
V/Yam/In D
Vitamin D deficiency is one of the most common nutritional deficits in CD
patients, but has also been reported in UC** '°" . Malabsorption and endogenous
loss of 25(OH) vitamin D3 are probably involved". Vitamin D metabolism is
closely related to bone metabolism, and osteoporosis is indeed a relatively
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common complication of CD". Although, the precise cause of the loss of bone
mineral density is not known, it may be due to a combination of factors,
including corticosteroids use, malabsorption, reduced dietary calcium intake,
vitamin D deficiency, or even the direct effects of chronic inflammation and
cytokine production on bone metabolism. Several studies have investigated the
relation between vitamin D status and bone mineral density, but results are
contradictory™". Furthermore, different findings have been reported on
biochemical markers of bone metabolism in patients with and without
osteopenia™^. However, it is clear that nutritional status and disease activity
affect bone metabolism, and should be taken into account in future studies for
osteoporosis in IBD".
Fat-soluble vitamin E (a-tocopherol) correlates with lipoproteins^. A few studies
have found reduced serum concentrations of o-tocopherol in patients with
active disease^®°. However, the ratio of serum vitamin E to serum cholesterol
or to total lipids did not differ significantly between patients and controls,
suggesting that the decreased vitamin E levels in CD patients could be explained
by the decreased serum concentrations of cholesterol and plasma total lipids.
Furthermore, Kuroki et al™ assessed o-tocopherol in red blood cells and did not
find a significant difference between CD patients at the time of diagnosis and
controls, suggesting that o-tocopherol is not actually depleted in CD patients.
Trace element deficiencies
Trace elements vary in their biologic function, e.g. some have antioxidant
capacities. Deficiency of trace elements in IBD patients is often recognized and
in addition, the relevance of an optimum antioxidant status in the pathogenesis
of IBD and its influence in the clinical outcome of these patients has been the
target of some studies. Specific trace elements deficiencies in IBD will be
discussed below.
Several studies have found decreased selenium concentrations in CD patients
with varying disease act iv i ty"" . Three studies did not detect decreased
selenium concentrations in CD or UC" but two of these studies were performed
in children with IBD"*". In the study by Fernändez-Banares et aF, serum
selenium values were found to show high dispersion rates compared with
controls which could have influenced the statistical outcome of the study.
Furthermore, Fernändez-Banares et al®* also reported low serum selenium
concentrations in the healthy population resident in Catalunya and it was this
population that was used as the control group. This may explain the lack of
difference between the IBD patients and the controls in their study". It has
been suggested that low selenium concentrations are caused by the use of
corticosteroids", but also the length of resected bowel has been indicated as a
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cause of selenium deficiency". Selenium is a component of glutathione
peroxidase, a seleno-protein enzyme which is important in protecting against the
development of lipid peroxides and free radicals, which can damage cell
membranes. It is known that glutathione peroxidase activity is a sensitive
indicator of selenium deficiency®'. Formation of soap complexes due to
steatorrhoea may occur in CD patients*' and divalent cations such as
magnesium, selenium or zinc may form unabsorbable subcomplexes with
malabsorbed fat.
Magnesium deficiency is a common finding in CD**®® °^. This deficiency can
result from poor intake, increased intestinal losses, malabsorption, bacterial
overgrowth or small bowel especially ileum resection'°^\ There have been some
case reports on hypomagnesemia in patients with CD*^, but most patients with
magnesium deficiency do not develop these symptoms. Magnesium depletion
may be the cause of persistent hypocalcemia despite adequate replacement of
calcium and vitamin D. Serum magnesium levels are poor indicators of
magnesium status because serum levels are kept constant by the human body
and it is therefore possible that magnesium deficiency is highly underestimated
in IBD patients. Muscle magnesium concentration is the best indicator of
magnesium status, but urinary excretion is also thought to be a sensitive index
of magnesium deficiency in IBD®'.
Z/he
Zinc deficiency has often been reported in IBD, especially in CD**'""^. Increased
losses of zinc are associated with diarrhoea/steatorrhoea and fistula drainage
and a close correlation has been found between stool weights and zinc losses*".
Whether decreased zinc absorption can be caused by malnutrition per se is
controversial^*". Zinc status is usually assessed as serum concentration.
However, acute inflammation and hypoalbuminemia may decrease serum zinc
levels in spite of a normal total body zinc content. The zinc status of a patient
remains difficult to assess, especially in the presence of inflammation, and no
single method for measuring zinc status seems entirely satisfactory^.
Alternatives to serum zinc level measurements include measurement of the
activity of zinc-dependent enzymes"^, hair and urinary zinc^', zinc content in
blood cells'°°'°' or in vitro uptake of zinc by blood cells'*". However, more
research is necessary to find a valid and clinically practical method for the
assessment of the true zinc status of IBD patients. It has been suggested that in
a patient population with quiescent disease serum zinc levels may provide
enough information about the zinc status, because circulating zinc reflects the
metabolizable or exchangeable zinc that is delivered to the metabolically active
tissues^.
26
C/japfe/- 2
Antioxidants and IBD
Nutritional deficiency can negatively affect immunocompetence'°'"°®. Evidence
is accumulating for the role of an imbalance between increased reactive
oxidative species production and reduced antioxidant defenses with regard to
the pathogenesis of tissue injury in |BD'°S.IO7.IO8_ jhere are two types of
antioxidants in the body; antioxidant enzymes and antioxidant small molecules.
The enzymes include Superoxide dismutase which uses zinc as a co-factor,
catalase which uses copper, and gluthatione peroxidase which needs selenium.
The activities of the antioxidant enzymes depend on the nutritional availability
of co-factors. The non-enzymatic antioxidants include the dietary exogenous
vitamins E and C, /?-carotene, flavonoids and the endogenous substances
glutathione, uric acid and taurine. Several studies have reported low
concentrations of circulating antioxidant vitamins" ^ ° and antioxidant minerals®"'
" " in CD patients. Furthermore, some studies have found a deteriorated
antioxidant status in patients with IBD**. Maintaining an adequate antioxidant
status by antioxidant supplementation has been suggested as a useful approach
in attenuating the cellular injury and dysfunction observed in IBD. Antioxidant
defenses are highly interactive, for instance in coupled redox reactions, and it is
therefore very important in future studies to determine the optimum amount of
the individual antioxidants needed in IBD.
Body composition
As described above, weight loss is a common finding in IBD patients, but to
quantify the magnitude of malnutrition, accurate assessment of body
composition is required.
Only a few studies have described body composition of IBD patients, and these
studies were predominantly performed in patients with high disease
activity*'-""'^. Significant losses of fat, protein and water have been
reported"""^, but the size of these compartments returned to normal after
nutritional repletion^' or when patients went into remission"".
Increased resting energy expenditure has been proposed as a possible
mechanism for the weight loss observed in active IBD patients. It has been
suggested that the higher resting metabolic rate in underweight IBD patients is
due to a proportionally greater decrease in fat with sparing of lean body mass^.
However, Stokes and Hil l" showed that total energy expenditure was not raised
in CD patients.
Disturbed body hydration and body water distribution has been reported in
children with active CD'^. This study showed an increased ratio of extracellular
to intracellular water in CD patients compared with controls. It is known that
malnutrition can influence body hydration"*. Furthermore, there is both clinical
and experimental evidence that chronic inflammation may lead to an expansion
of extra-cellular water"^.
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Muscle strength
Lopes et al discovered that skeletal muscle function was a sensitive indicator of
the nutritional status of patients"®. They further showed that functional
changes occurred before abnormalities in the values of conventional indices of
malnutrition'". In a study by Brevinge et a l ' " , exercise capacity assessed by
cycle ergometry was significantly reduced in CD patients undergoing
proctocolectomy and small bowel resection. Skeletal muscle function can be
evaluated by means of hand grip dynamometry"^, by contraction of the
adductor pollicis muscle in response to an electrical stimulus'^", or by isokinetic
dynamometry'^'. To our knowledge, muscle strength has not been assessed in
IBD patients.
Nutritional therapy in IBD
The value of nutritional support in the correction and maintenance of nutritional
status in CD is widely accepted. The primary therapeutic effect of an enteral
diet was observed more than 2 decades ago, but results remain somewhat
controversial. In recent years, many excellent reviews'" ""* and meta-
analyses'" ' " have been published on the primary role of enteral and parenteral
nutrition. Enteral nutrition is effective at inducing remission in active CD,
although there is insufficient data to suggest that enteral nutrition should
replace drug therapy. Several trials have failed to show any significant
difference in efficacy between elemental and polymeric diets'^*. Compliance
should be improved with more palatable nutrition in future studies to confirm
the effectiveness of enteral nutrition as a therapy for CD.
In this review we focus on nutritional supplements as an adjunctive therapy
in IBD patients.
Fish oil
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are
polyunsaturated acids derived from fish oil. They are n-3 fatty acids because the
first double bond is three carbons removed from the terminal methyl group. EPA
and DHA are incorporated into membrane phospholipids replacing arachidonic
acid (n-6 fatty acid). The latter acid is the substrate for the synthesis of
leukotriene B4 (LTB4), thromboxane A2 and prostaglandin E2 (PGE2) with high
inflammatory activity"". The n-3 fatty acids competitively inhibit the formation
of the prostaglandins and leukotrienes derived from arachidonic acid, while
serving as a substrate for prostaglandins and leukotrienes with lower
inflammatory activity (LTB5 and PGE3). n-3 Fatty acids have greater affinity
with the cyclooxygenase and lipoxygenase enzymes than n-6 fatty acids. Fish
oil reduces the production of LTB4 and tromboxane A2 while also inhibiting
interleukin 1/5 synthesis and tumor necrosis factor-a (TNF-o) secretion"'.
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Fish oil has been reported to be beneficial in UC patients, but results are
controversial'"'^. Three studies reported clinical improvement after fish oil
supplementation, but only Stenson et a l ' " found a significant decrease in rectal
dialysate LTB4 levels. Differences between the studies as regards dose, study
design, composition of the supplement and assessment of clinical improvement
may explain the conflicting results.
Another important aspect to be taken into account is the increase in lipid
peroxidation after fish oil supplementation'". Concomitant antioxidant
supplementation may be able to counteract this potentially adverse effect of n-3
supplementation. Most publications on fish oil supplementation fail to state the
amount of concomitant antioxidant administration.
The most recent studies on fish oil supplementation have been conducted in
CD patients. Two studies examined the role of fish oil in the prevention of
relapses in CD patients who had gone into remission with steroids" '" . In the
study by Belluzi et a l ' " , 78 CD patients with a high risk of relapse were
randomly assigned to receive enteric-coated fish oil capsules or placebo. After 1
year follow-up, 59% of patients in the fish oil group remained in remission
compared with 26% in the placebo group. In the trial of Lorenz-Meyer et a l " ,
however, remission rates after 1 year follow -up were identical in the fish oil
and placebo groups.
An experimental study revealed a different mechanism for the inhibitory
action of n-3 fatty acids on the immune system'^. When monocytes were
incubated in vitro with either EPA or DHA, the expression of major
histocompatibility complex class II molecules (HLA-DR, HLA, DP, and HLA-DQ)
and adhesion molecules (ICAM-1) was significantly reduced.
Short chain fatty acids
Short chain fatty acids (SCFA) are formed in the colon by bacterial fermentation
of non-absorbed carbohydrates, such as resistant starches or soluble fiber. The
major SCFAs in the human colon are acetate, propionate, and butyrate. Butyrate
is the preferred fuel for colonocytes, accounting for 70% of total energy
consumption. In the starved colon, the SCFAs cannot easily be replaced by
endogenous nutrients. In contrast, during starvation in small epithelial cells,
endogenous sources (glutamine and ketone bodies) can meet the energy
requirements of enterocytes through the vascular bed. It has therefore been
hypothesized that an energy-deficient state of the colonic mucosa may lead to
mucosal atrophy, diminished absorption and, eventually, colitis'*°.
It was originally suggested that the production of SCFAs in UC patients
might be reduced. In stools from active UC patients, reduced concentrations of
SCFAs were found compared with those from healthy controls or CD
patients'"'. As a result, intervention trials with SCFAs were conducted in UC
patients, and initial reports were encouraging'**. Recently, however, well-
designed placebo-controlled trials have shown no benefit of SCFAs in UC ' " '**.
An alternative hypothesis, which may explain contradictory results, is the
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observation of a reduced capacity of colonocytes in UC patients to oxidize
butyrate'**. It has been suggested that reducing sulphur compounds produced
by certain species of colonic bacteria may impair colonocyte nutrition'*'. High
prevalence rates of sulphate-reducing bacteria, increased faecal sulphide
concentration and a higher sulphite production by sulphate-reducing bacteria
have been found in UC patients compared with controls"". Sulphate-reducing
bacteria produce sulphide, which may impair mucosal butyrate oxidation and
may lead to decreased energy availability.
Glutamine
Glutamine has been shown to be an essential nutrient for many of the rapidly
proliferating cells in the intestinal mucosa. A number of studies have
demonstrated that glutamine supplementation improves the structural integrity,
function and repair of the intestine during catabolic conditions associated with
gastrointestinal disease'*'''*". To our knowledge, no studies have so far been
conducted on oral glutamine as a therapeutic agent in IBD. However, topical
glutamine supplementation in patients with pouchitis has been examined'*'.
After 21 days of glutamine supplementation, 6 of 10 patients had significantly
benefited from the treatment.
Conclusion
This review has attempted to provide further insights into the relationship
between nutrition and IBD. At the moment, there is very little conclusive
evidence regarding the role of specific dietary components in the pathogenesis
of IBD. Assessment of nutritional status in IBD is complex, as nutritional status
is influenced by several factors and it is hard to discriminate between disease-
induced and malnutrition-induced changes in nutritional parameters. Several
nutritional and functional deficiencies have been reported in patients with IBD,
especially those with CD. Improvement of nutritional status may decrease
disease activity in IBD patients, but further studies are needed to confirm this
hypothesis. There have been a number of important observations leading to new
and interesting developments in the field of nutritional therapy in IBD. It has
been suggested that treatment of certain species of colonic bacteria in the
gastrointestinal tract with specific nutrition may have protective effects against
IBD. Furthermore, studies indicate that immunonutrition with n-3 fatty acids and
antioxidants may play an important role in the nutritional treatment of IBD.
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Abstract
Background
Dietary factors have been considered as a possible risk factor for ulcerative colitis (UC),
however, data are inconsistent. The aim of the present study was evaluate the
etiological role of dietary factors in the development of UC.
Patients and methods
Recently diagnosed (<6 months) UC patients (n = 43) and age- and sex-matched
population controls (n = 43) were studied in a case-control study. The cross-check
dietary history method was used to assess dietary intake of 5 years prior to the study.
Adipose tissue fatty acid composition was used as a biomarker of long-term fat intake.
Conditional logistic regression-derived odds ratios (OR), and 95% confidence intervals
(Cl) were calculated. Dietary intake ORs were adjusted for energy intake.
Results
High intakes of monounsaturated fatty acids (OR: 33.9 (95% Cl 2.6-443.1)),
polyunsaturated fatty acids (OR: 5.1 (95% Cl 1.0-26.7)), and vitamin B6 (OR: 6.9
(95% Cl 1.6-30.7)) were associated with an increased risk to develop UC. No other
significant associations were found with UC risk.
Conclusion
High intakes of mono- and polyunsaturated fatty acids and vitamin B6 may enhance the
risk of developing UC. Whether this observation is a true risk factor in the development
of UC or rather a reflection of a certain dietary life style needs to be investigated.
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The etiology of ulcerative colitis (UC) is poorly understood. Possible
determinants include genetic factors'*, as well as environmental factors like
thrombogenic factors" and bacterial and viral agents**. In addition, for many
years, dietary factors have been considered as a possible risk factor for UC.
In patients with Inflammatory Bowel Disease (IBD), many studies on sucrose
consumption have been conducted since Martini and Brandes reported in 1976
that patients with Crohn's disease (CD) would consume an excess amount of
sugar and sugar-containing products'". However, the role of sucrose in the
etiology of UC is inconsistent"^, which may be due to the methodological
limitations of many studies^'. In addition, also for other food items i.e.
vegetables or fiber consumption, no clear association between intakes and the
risk of UC was observed'*'"™.
Recently, Reif et al'® reported that the composition of pre-illness diet was
related with subsequent development of UC. Sucrose and fat consumption were
associated with an increased risk for UC, whereas intakes of fructose, fluids,
magnesium, vitamin C and fruit were associated with reduced UC risk.
The aim of the present study was to evaluate the etiologic role of dietary
factors in the development of UC with special reference to nutrients. Since fatty
acid composition of adipose tissue has been used as a potential biomarker of
long-term dietary intake of some fatty acids, especially polyunsaturated fatty
acids" " , adipose tissue biopsies were included in this study as a biomarker of
long-term fat intake.
Subjects and methods
Subjects
Patients were recruited from the out-patient population of the Department of
Gastroenterology of the University Hospital Maastricht, the Atrium Medical
Center Brunssum and the Maasland Hospital Sittard, all located in the south of
the province of Limburg in the Netherlands. The diagnosis of UC was based on
the criteria of Truelove and Witts*®. All patients who had been diagnosed with
UC during the period June 1995-December 1997 (n=49) were asked to
participate in the study. Forty-six patients (94%) agreed to participate. All
patients had been diagnosed within 6 months prior to entering the study.
Assessable data were available in 43 patients. Characteristics of these patients
are shown in Table 3.1. Disease activity was assessed according to the
Truelove-Witts criteria and graded numerically as 6-19 corresponding to "no
disease activity", 20-32 as having "moderate disease activity" and 33-45
corresponding to "severe disease"". In addition, the concentration of C-reactive
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protein (CRP) at the time of the investigation was assessed. Patients were
included in the present study 1 to 5 months after diagnosis (median duration: 4
months). Median duration of complaints at time of diagnosis, as reported by
patients, was 2 months with a range from 1-27 months.
Table 3.1 Characteristics of subjects
Age (years)'
Gender (F/M) . . /. .. ..
Weight (kg)' , • - • ,
Smoking (%) '" '-•
C-reactive protein (mg/L) '
Truelove & Witts index'•*
Present use of - mesalazine ;
- azathioprine use
- prednisone (mg/day ± SD)
UC patients (n = 43)
37.8 ± 14.7
20/23 . ,,
68.5 ± 10.4
15.2
6.1 ±6 .4
9.6 ± 5.8
•::: K. • . 9 Ä - 4 , . •
6.5
19.5 (11.3 ± 7.0)
Controls (n = 43)
37.7 ± 14.6
20/23
71.5 ± 11.1
23.3
4.9 ± 3.7
-
" -
' Data are expressed as mean ± SD. * according to reference 29.
Confro/s
Control subjects were selected from the patient population of one large general
practice (three general practitioners) in the same study area (Table 3.1).
Controls were selected randomly from the database, corresponding to the age-
and gender-distribution of UC patients. Controls were matched for age and sex
(within 3 years) with UC patients. Subjects with a history of IBD were excluded;
no other selections regarding health care problems were performed.
Methods
D/efa/y /ma/re
The onset of disease symptoms was <5 years before the study in all patients.
In all subjects (patients and controls) the usual dietary intake at 5 years prior to
the interview was assessed using the cross-check dietary history method^".
Patients and controls were interviewed about their dietary intake in an identical
fashion during a home visit by an experienced dietician. Food quantities were
specified in household measures and usual portion sizes were estimated with
the aid of portion size models or pictures of foods. A self-administered semi-
quantitative validated food-frequency questionnaire (FFQp was used as a cross
check of the dietary history. All types of food and drink were converted into
energy and nutrients using the extended computerized version of the
Netherlands Food Table (NEVO)". The following consumption of macronutrients
subdivided into nutrient groups were noted: carbohydrates (total, mono- and
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disaccharides, and polysaccharides), protein (total, and amounts of animal and
vegetable origin), fat (total, saturated, mono- and polyunsaturated fat). The
following consumption of nutrients (linoleic acid and cholesterol) and
micronutrients are reported: total iron, potassium, sodium, calcium, retinoi,
vitamin B1, vitamin B2, vitamin B6, vitamin C, nicotinic acid.
f/ssue /iaff/ ac/tf a/?a/ys/s
Adipose tissue biopsies were taken from the outer quadrant of the right buttock
with a 19-gauge needle attached to a syringe in 41 UC patients and 41
controls. The syringe was rinsed with methanol to dissolve the fat and the
samples were stored at -80°C until analysis (<3 months). Total lipid extracts
from the adipose tissue biopsy were prepared according to the method of Bligh
and Dyer" by adding methanol and chloroform (1:1, vol: vol). The total lipid
extract was saponified and the fatty acid converted to the corresponding methyl
esters by reaction with 14% boron trifluoride in methanol at 100°C for 30
min**. To all organic solvents, butylated hydroxytoluene (50 mg/L) was added
as an antioxidant. The fatty acid composition of adipose tissue was analyzed as
described by Foreman et aF . The following fatty acid combinations were
recorded: ISAFA (sum of all saturated fatty acids), ZMUFA (sum of aii
monounsaturated fatty acids), and ZPUFA (sum of all polyunsaturated fatty
acids). The amounts of the various fatty acids were expressed as percentages
of total fatty acids on a wt/wt basis.
Statistical analysis
Results were expressed as median with 25th and 75th percentiles or as stated.
Differences in absolute dietary intake between UC patients and controls were
analyzed using the Wilcoxon matched-pairs signed -rank test. Spearman
correlation coefficients were calculated. These statistical analyses were
performed with the SPSS 7.0 for Windows package (SPSS Inc, Chicago).
Conditional logistic regression analysis adjusting for energy intake was
performed using Stata, Version 5.0 (Stata Corporation, College Station, Texas,
USA)^. Three tertiles of dietary intake (low, median, and high) were derived
based on the distribution of dietary intakes of the control population.
Subsequently, patients were classified according to these calculated tertiles of
dietary intake. Odds ratios for the dietary intake levels were calculated,
corresponding 95% confidence intervals were derived, and significance for
linear trend was estimated. P-values <0.05 were considered statistically
significant.
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Median daily dietary intake at 5 years prior to the study for patients and
controls is shown in Table 3.2. Vitamin B6 intake was significantly higher
(P<0.01) in UC patients than in controls. No other significant differences in
intake of energy or nutrients were observed between patients and controls.
Table 3.2 Daily dietary intake at 5 year prior to diagnosis'
Patients (n = 43) Controls (n = 43)
Energy intake (MJ/day)
Total protein (g)
Animal protein (g)
Total fat (g)
Saturated fat (g)
Monounsaturated fat (g)
Polyunsaturated fat (g)
Linoleic acid (g)
Cholesterol (mg)
Total carbohydrates (g)
Mono + disaccharides (g)
Fiber (g)
Alcohol (g)
Calcium (g)
Total iron (mg) ' '
Vitamin A (mg RE)
Vitamin B1 (mg)
Vitamin B2 (mg) ; ;
Nicotinic acid (mg) • •
Vitamin B6 (mg)
Vitamin C (mg)
Sodium (g) . - . , . - -
Total fluid (L)
12.0 (9.3-14.6)
89.6 (69.7-102.7)
51.7(42.8-64.9)
122.2 (96.5-157.5)
46.7 (38.5-63.2)
47.1 (36.6-61.3)
23.6 (16.9-30.9)
19.2 (14.3-27.3)
268.0 (220.0-342.0)
313.2 (246.8-396.4)
156.4 (117.2-219.6)
30.4 (24.6-37.7)
2.1 (0.1-12.4)
1.09 (0.76-1.42)
11.7 (9.2-14.3)
0.86(0.68-1.00)
1.20(0.99-1.51)
1.70(1.24-2.25)
13.5(10.4-18.0)
' 5.06 (3.56-6.59)'
81.8 (52.9-115.7)
I 3.84(3.30-5.06)
2.37 (2.00-2.85)
10.9 (8.8-15.7)
86.9 (71.8-114.9)
57.6 (45.5-72.0)
108.7 (80.9-170.2)
47.4 (34.9-67.8)
41.8 (29.9-57.1)
21.0 (14.3-30.1)
18.6 (11.5-26.5)
242.0(189.0-394.0)
307.1 (243.6-392.2)
143.1 (107.1-188.9)
29.8 (23.0-39.2)
3.3 (0.1-8.6)
1.15 (0.92-1.61)
12.5 (9.1-16.8)
0.90 (0.67-1.20)
1.29 (0.99-1.72)
1.63 (1.31-2.03)
13.0(9.1-18.4)
3.57 (2.54-5.06) '
84.8 (62.4-123.8)
3.79 (2.72-5.35)
2.37 (2.04-3.11)
' Data are expressed as median; 25th and 75th percentile in parentheses.
* Significantly different from controls (Wilcoxon matched-pairs signed-ranks test): P<0 .01 .
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Table 3.3 shows odds ratios and 95% confidence intervals for UC patients at
the intake levels of macronutrients. In addition, P-values for linear trend of OR
are reported. Carbohydrate intake (total, mono- and disaccharides,
polysaccharides, or fiber) did not show any significant association with UC risk.
High intakes of mono- and polyunsaturated fat were associated with a
significantly increased UC risk. Although the odds ratio for total fat was also
increased, this was not statistically significant (P = 0.10).
Table 3.3 Odds ratios (OR) and confidence intervals (CD for patients with ulcerative colitis at
different levels of carbohydrates, protein, and fat intakes'
Nutrients
Carbohydrates total
Mono + disaccharides
Poly saccharides
Fiber
Protein total
Protein vegetable
Protein animal
Fat total
Saturated fat
Monounsaturated fat
Polyunsaturated fat
Linoleic acid
Cholesterol
OR (CD at
Medium*
1.3 (0.4-4.4)
1.4 (0.4-4.8)
1.7 (0.5-5.8)
1.0(0.4-2.6)
0.9 (0.3-3.4)
••>• ' 1.4 (0.5-4.2)
0.5 (0.2-1.5)
3.4(1.0-12.2)
4.4 (1.1-17.5)
11.4 (1.4-95.7)
2.9(0.7-11.3)
2.1 (0.6-7.4)
2.1 (0.7-6.0)
intake levels
High'
2.2 (0.4-11.8)
3.0 (0.7-13.4)
0.9 (0.1-6.4)
0.7 (0.2-3.4)
0.2 (0.02-1.5)
2.4(0.6-10.4)
0.2 (0.04-1.1)
4.1 (0.6-28.4)
3.7 (0.4-30.9)
33.9 (2.6-443.1)
5.1 (1.0-26.7)
1.9 (0.4-8.6)
1.3 (0.4-4.8)
P-value*
0.36
0.15
0.90
0.79
0.20
0.25
0.07
0.10
0.13
0.005
0.05
0.52
0.67
' Adjusted for energy intake.
* Versus the low intake category; dietary intake categories are derived from pair-matched
population controls.
•" P-value for linear trend.
Odds ratios and 95% confidence intervals for micronutrients are shown in
Table 3.4. Of all micronutrients, only vitamin B6 was significantly associated
with an increased risk of UC.
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Table 3.4
Nutrients
/s/r /acfo/-s
Odds ratios (OR)
different levels of
and confidence intervals (CD for patients
micronutrients intakes.
OR (CD at intake
Medium'
levels
High'
with ulcerative colitis at
P-value*
Iron total
Potassium
Sodium
Calcium
Retinol
Vitamin B1
vitamin B2
Vitamin B6
Vitamin C
Nicotinic acid
Total fluid
0.8
1.1
6.6
0.9
1.7
1.3
0.7
1.5
0.8
1.8
1.0
(0.3-2.5)
(0.4-3.5)
(1.3-32.0)
(0.3-2.8)
(0.5-5.7)
(0.4-3.8)
(0.3-2.0)
(0.4-5.6)
(0.3-2.2)
(0.5-6.2)
(0.3-3.3)
0.3
1.9
5.0
0.8
0.7
0.4
0.9
6.9
0.5
4.0
0.4
(0.08-1.5)
(0.4-9.8)
(0.5-51.1)
(0.2-2.8)
(0.2-3.2)
(0.07-2.2)
(0.3-3.3)
(1.6-30.7)
(0.1-2.1)
(0.9-18.7)
(0.06-2.1)
0.16
0.48
0.08
0.69
0.65
0.49
0.82
0.009
0.37
0.08
0.28
' Versus the low intake category; dietary intake categories are derived from pair-matched
population controls.
* P-value for linear trend.
Adipose tissue fatty acid composition
The distribution of adipose tissue fatty acids are shown in Table 3.5. No
significant differences between UC patients and controls with regard to the
fatty acid composition of adipose tissue were observed. A significant correlation
was found between the PUFA intake (expressed as % of total fat intake) and
the sum of PUFA of adipose tissue, and in addition, between linoleic acid intake
and linoleic acid content of adipose tissue in patients (r = 0.66, P<0.001;
r = 0.62, P<0.001, respectively), as well as in controls (r = 0.39, P<0.01;
r = 0.48, P<0.01, respectively). No correlations were found between dietary
intake and adipose tissue content for saturated or monounsaturated fatty acids
in patients.
High adipose tissue proportions of PUFA (OR: 1.4 (95% Cl 0.4-4.8)) or
linoleic acid (OR: 1.3 (95% Cl 0.5-3.8)) were not significantly associated with
UC risk.
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Table 3.5 Fatty acid composition of adipose tissue (% of total fatty acids) in patients with
ulcerative colitis (UC) and controls'
UC patients (n-41) Controls (n = 41)
SAFA 25.6(23.1-28.9) 27.2(24.0-28.8)
MUFA 51.4(48.9-54.0) 51.3(48.5-54.5)
PUFA 19.0(17.4-21.5) 19.1(16.8-21.1) '
Linoleic acid 16.5(14.3-18.7) 16.0(14.5-17.8)
' Data are expressed as median; 25th and 75th percentile in parentheses.
SAFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated
fatty acids. ..• • •:•.. ' -.- ; ••, • • i
Discussion
The major finding in the present study was the increased risk of UC in subjects
with a high consumption of mono- and polyunsaturated fatty acids and vitamin
B6. Other nutrients were not significantly associated with UC risk.
As the incidence of UC is too low to perform an acceptable prospective
cohort study, a case-control study is the most appropriate design to study the
etiological role of dietary factors in the development of UC. However, problems
of selection and information bias in a case-control study have to be taken into
account. In this respect, it is important to note that many studies have been
subject to methodological flaws. They may have used hospital controls who
suffer from other diseases which may influence dietary intake. Randomly
chosen population controls are therefore preferable"'*. In several studies, post-
illness diet was investigated, even though it is quite clear that dietary habits
may well have changed since onset of the illness and its symptoms.
Another limitation is that many reports only provide information on mean
consumption of different food items or nutrients of patients and controls. This
does not give an indication of the magnitude of the increased disease risk
associated with different consumption levels, such as is provided by odds ratios
or relative risk ratios. Where odds ratios are presented, intake categories (low,
medium and high) have usually been based on the distribution of the combined
population of patients and controls instead of on the distribution of a reference
population, i.e. the control group'®'".
The present study was designed in an attempt to avoid these methodological
problems. The controls in our study were selected from a database of one
general practice in the same region. In the Netherlands, almost every resident is
registered by a general practitioner and the population database used in the
present study is therefore a sample frame of the population within the study
region. We studied recently diagnosed UC patients (within 6 months of
diagnosis) and used a dietary interview which covered the total pre-illness diet.
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A positive association between fat intake and UC risk was observed in a recent
study conducted in Israel^. These authors reported an increased risk for UC in
patients consuming a high fat (animal fat, vegetable fat, unsaturated fat, and
cholesterol) diet prior to the onset of disease. A Japanese study also showed
that margarine use was related to an increased risk of UC^. Guthy suggested
that chemically processed hydrogenated fats, such as margarine, might play a
role in the development of CD". He hypothesized that during the production of
chemically processed fats or during their use for frying and cooking, toxic by-
products may occur which may contribute to the pathogenesis of CD. However,
it is unclear whether this mechanism is also involved in the pathogenesis of UC.
Fatty acids are involved in the immune response and inflammatory process of
UC as they are precursors of the eicosanoids. Polyunsaturated fatty acids (fish
oil) may have anti-inflammatory activity because they compete with n-6 fatty
acids in the substrate pool of the lipoxygenase pathway, thus reducing the
production of leukotrienes with high inflammatory activity. Several placebo-
controlled crossover studies have demonstrated the efficacy of fish oil in
treating active UC^*°. Interestingly, the present study showed that
polyunsaturated fat intake (n-6 and n-3 fatty acids) was a risk factor for the
development of UC. However, it should be noted that fish consumption of more
than once per week was reported by only a few subjects in the present study.
Hence, fish consumption has a negligible contribution to total polyunsaturated
fatty acid intake of both patients and controls in the present study. Fish
consumption, which may be useful in the treatment of inflammation, can not be
considered as a risk factor for the development of UC on the basis of the
present study.
No studies on vitamin B6 intake and UC risk have been reported. Vitamin B6
is mainly absorbed in the jejunum and serves as a cofactor for more than one
hundred enzymes. Hence it can influence several processes in the human body,
including amino acid metabolism, nicotinic acid formation, nervous system
function, nucleic acid metabolism, hormone modulation and lipid metabolism'".
Furthermore, vitamin B6 dependent enzymes are involved in essential fatty acid
metabolism. This latter observation may be important as fatty acid metabolism
is involved in the immune response and inflammation processes of IBD
patients**. However, the mechanisms responsible for the increased UC risk with
high intakes of vitamin B6 needs to elucidated.
To our knowledge, this is the first study which has used adipose tissue fatty
acid composition as a biomarker for long-term fat intake in relation with the risk
of developing UC. Results showed that in both patients and controls, the
polyunsaturated fatty acids content in adipose tissue reflects the
polyunsaturated fatty acids in the diet of 5 years prior to the study. As
expected - given the endogenous synthesis of saturated and monounsaturated
fatty acids'" - we observed no correlations between adipose tissue content and
dietary intake of these two classes of fatty acids.
The increased UC risk with high consumption of polyunsaturated fatty acids
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as assessed by the dietary history method was not reflected by the adipose
tissue results in the present study: polyunsaturated fatty acids in adipose tissue
were not associated with an increased UC risk. The value of adipose tissue
biopsies as a biomarker for long-term polyunsaturated fat intake is thus limited
in the present study. The half-life time of adipose tissue in humans in energy
balance is approximately 600 days^. The fatty acid composition of adipose
tissue therefore reflects the dietary fat intake during the previous two or three
years". Subjects in the present study were interviewed about their usual dietary
intake at 5 years before the study. Consequently, the retrospective time periods
of the two methods are not completely congruent. Furthermore, although the
median duration of complaints, as reported by the UC patients, was two
months, nine patients reported duration of complaints to be >6 months.
Complaints may influence dietary intake and subsequently fatty acid
composition of adipose tissue. Also, adipose tissue biopsies were not taken on
the day of diagnosis for practical reasons but were obtained within 6 months of
diagnosis. It is therefore possible that adipose tissue composition has been
influenced by a recent alteration of dietary intake after diagnosis in some
patients. It cannot be ruled out that the medication administrated after diagnosis
to achieve remission (especially corticosteroids) have influenced the fatty acid
pattern in adipose tissue. Adipose tissue biopsies as an objective biomarker of
the long-term polyunsaturated fatty acid intake may be of limited use in
establishing dietary risk factors in UC.
The macro- and micronutrients reported with high odds ratios in the present
study may reflect a certain dietary pattern which could have increased the risk
of developing UC. In this respect it is interesting that some studies reported
certain nutritional features of modern life styles (western food, fast food) to be
risk factors in the development of U C " " * * . Future studies should address the
role of food items, additionally to specific nutrients, in the etiology of UC and
furthermore, to the disease course and prognosis of UC.
In conclusion, our data suggest that high intake of mono- and
polyunsaturated fatty acids and vitamin B6 may enhance the risk of developing
UC. Whether the reported findings are true risk factors in the development of
UC or rather a reflection of a certain dietary life-style needs to be elucidated.
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Abstract ' i
Background
Malnutrition is observed frequently and is an important complication in patients with
Crohn's disease (CD). The pathophysiology of malnutrition in this disorder is complex.
Methods
To obtain a comprehensive picture of nutritional status in long-standing CD that was
clinically in remission, we assessed four measures of nutritional status in 32 patients
(18 women and 14 men) and 32 matched healthy controls: 1) body composition, 2)
dietary intake, 3) biochemical parameters of nutrition, and 4) muscle strength (as a
functional index).
Results
Mean daily intakes of fiber and phosphorus were significantly lower in CD patients than
in control subjects. Serum concentrations of several nutrients (ß-carotene, vitamin C,
vitamin E, selenium, and zinc) and the activity of the enzyme glutathione peroxidase
were also significantly lower in CD patients, as were antioxidant status and serum
concentrations of magnesium and vitamin D. Percentage body fat and hamstring
muscle strength were significantly lower in male CD patients than in controls, whereas
muscle strength of the quadriceps was preserved.
Conclusions
In conclusion, this study showed a variety of nutritional and functional deficiencies in
patients with long-standing CD in remission, especially in male patients with a long
history of CD and a high lifetime prednisone dose. A comprehensive nutritional
assessment seems superior to the assessment of one single dimension of the nutritional
status.
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Introduction
Malnutrition is frequently observed in patients with Crohn's disease (CD) and is
a result of reduced dietary intake, maldigestion, malabsorption, elimination of
nutrients as a result of oxidative stress, and enteric loss of nutrients'. Previously
published studies focused on hospitalized CD patients or patients with active
disease^'". In these patients, the metabolic disturbances associated with
malnutrition may be caused by the malnutrition itself or by the inflammation: it
is known that the prevalence and degree of malnutrition are markedly influenced
by the activity and the extent of the disease". The association between CD and
malnutrition per se should therefore preferably be investigated in patients during
remission of the disease.
Jeejeebhoy^ described nutritional status as 'an equilibrium of the intake of a
diet sufficient to meet or exceed the needs of the individual which will keep the
composition and function of the otherwise healthy individuals within the normal
range'. This equilibrium can be disturbed by decreased intake, increased
requirements and altered metabolism. Obviously, nutritional status is influenced
by several factors. The pathophysiology of malnutrition is complex and it seems
inappropriate to assess nutritional status on the basis of a single set of
assessments, e.g., laboratory indicators or body composition. Nutritional status
should preferably be assessed by body composition, dietary intake, biochemical
indexes of nutrition, and functional indexes such as muscle strength.
The aim of our study was to assess the comprehensive nutritional status of
patients with long-standing CD during remission of the disease and compare this
with the status of healthy controls.
Subjects and methods
Subjects
The study protocol was approved by the Ethics Committee of the University
Hospital Maastricht and all subjects gave their informed consent before the start
of the study.
Par/enrs
Patients characteristics are shown in Table 4.1. Out-patients coming to the
Department of Gastroenterology for a routine visit during the period from
November 1995 to May 1996 and who fulfilled the inclusion criteria were asked
consecutively to participate in the study. Thirty-two patients (18 women, 14
men) who had CD>10 years and small bowel involvement participated in the
study. The diagnosis of CD was based on the criteria of Lennard-Jones'^.
Disease activity was assessed according to the Crohn's disease activity index
(CDAI)'* and the van Hees index'* at the time of the investigation. The median
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CDAI was 139 for all patients, 127 for women and 173 for men (Table 4.1).
Fifteen patients (7 women, 8 men) had a CDAI > 150, which implies elevated
disease activity. The high liquid stool frequency of many of the patients, all of
whom suffered from ileal dysfunction, may explain the relatively high CDAI
scores. Men complained more about stomach pain and an impaired well-being
than did women. In addition, the CDAI was high because of reported
underweight compared with the reference value'*. However, the acute phase
protein response (C-reactive protein) did not differ significantly between patients
(median C-reactive protein: 6 mg/L; women: 4.5 mg/L; men: 6 mg/L) and
control subjects (median C-reactive protein: 2 mg/L; women: 3.5 mg/L; men:2
mg/L).
All patients had stable body weights during the 3 months preceding the
study. The absence of a significant acute phase response indicated that the
patients included in the study were clinically in remission. All patients received
medical treatment during the study, including mesalazine (n = 26), azathioprine
(n = 11) and low doses (median dose: 5 mg) of corticosteroids (n = 13). Two
patients took vitamin A and D supplements daily, 10 patients used a
supplement of 2.5 mg folic acid daily, 22 patients were supplemented with
intramuscular vitamin B-12 and two patients used cholestyramine. Two patients
had an ileostomy. Twenty-two patients were current smokers, significantly
more than in the control group (13/32, P<0.05).
Table 4.1 Characteristics of patients with Crohn's disease'
Age (years)
Number with colonic involvement
Number with small bowel resection
Disease duration (years)
Total extent of small bowel resection (cm)
Lifetime prednisone dose (g)
CDAI'
van Hees index
All
(n = 32)
40.0 (34.3-54.0)
n = 18
n = 27
16.0 (11.0-19.0)
75.0 (40.0-110.0)
10.3 (4.6-24.6)
139 (86-193)
146 (127-159)
Women
(n=18)
39.0 (32.0-48.0)
n = 9
n = 13
13.0 (10.0-16.3)
45.0 (32.5-100.01
6.1 (4.1-15.5)
127 (41-200)
136 (127-150)
Men
(n = 14)
49.5 (36.5-56.8)
n = 9
n = 14
18.0 (14.0-24.5)'
80.0 (60.0-135.0)
26.6 (7.8-30.0)*
173 (118-205)
156 (138-169)
' Data are expressed as median; 25th and 75th percentile in parentheses.
* Significantly different from women, P<0.05 (one-way ANOVA).
' Crohn's disease activity index".
Thirty- two healthy volunteers (mean age: 43.8 ± 13.5 years) participated in
this study as controls. They were selected randomly from the patient population
database of a general practitioner in the same study region, which is a reliable
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dynamic sample frame of the Dutch general population. The controls were
selected according to the following criteria: age- and sex-matched with CD
patients (within 5 years of age) and no history of Crohn's disease.
Nutritional status • • ' K ^ « U - ,»m«, ••••<.-xs..i; r
All measurements, except the assessment of the dietary intake, were performed
on the day after an overnight fast.
- • - - • • • - : ; : - K ^ * - '
So*//
Body composition was assessed using anthropometry, the deuterium dilution
technique and dual-energy X-ray absorptiometry (DXA). Anthropometric
measures included body height measured to the nearest millimeter using a wall-
mounted stadiometer and body weight measured with an electronic scale with a
digital readout to an accuracy of 0.01 kilogram. Body mass index (BMI) was
calculated from weight and height (kg/m*). Skinfold thickness measurements
were taken in duplicate from the non-dominant side of the body at four different
sites (biceps, triceps, sub-scapula, supra-iliac) using a Harpender skinfold
caliper. Percentage body fat was calculated from the sum of the four skinfold
thickness values according to Durnin and Wormersley^. Circumference
measurements (of the upper arm, waist, hip and upper leg) were obtained from
the non-dominant side". Mid-arm muscle circumference (MAMC) was
calculated'".
Total body water (TBW) was assessed by deuterium (DjO) dilution. A
background urine sample was taken after an overnight fast. Subsequently,
subjects consumed a quantity of D2O (99.8 atom percent excess, Akademie der
Wissenschaften, Leipzig, Germany) corresponding to 0.1 g/L estimated TBW
mixed into = 70 ml water^. Urine samples were collected after 4 hours
equilibration. Isotopic abundances in urine were determined in duplicate using an
isotope-ratio mass spectrometer (Aqua Sira; VG Isogas, Cheshire, UK). The
deuterium dilution space was calculated from the quantity of DjO administered
and the DjO concentrations in urine after equilibration. TBW was assessed
according to the equation proposed by Deurenberg et al'^ and was calculated as
the DjO-dilution space divided by 1.04, correcting for the exchange of the
deuterium label with non-aqueous hydrogen of body solids™.
. Body fat, fat-free mass (FFM), percentage body fat, total-body bone mineral
content and T-score (total bone fracture risk) were determined by using a dual-
energy X-ray absorptiometer (DPX-L, Lunar Corp., Madison, Wl; using DPX-L
1.3 software)^. The T-score was calculated according to the following formula:
bone mineral density (subject) - mean peak bone mass (reference population)/
SD mean peak bone mass (reference population). Research on the reference
population was conducted in the US, United Kingdom and Northern Europe.
There was a 1.3% SD among geographical areas in the average density values.
A scan over the entire length of each subject's body was performed. Any
material that could attenuate the X-ray beam, eg. jewelry, watches or clothing
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with zippers, was removed before the examination.
0/erary /n
Dietary intake was assessed using the cross-check dietary history".The
subjects were visited at home by an experienced dietitian and the usual food
consumption of the previous month was assessed. During this interview, food
quantities were specified in household measures. Usual portion sizes were
estimated with the aid of portion size models or pictures of foods; frequently
consumed portions of food and common household measures were weighed on
a balance with a precision of 0.5 g. In addition, the subjects had previously
completed a self-administered, validated, semiquantitative food-frequency
questionnaire that was used as a crosscheck of the dietary history". The food-
frequency questionnaire dealt specifically with the dietary intake of fat and
antioxidants over the previous month.
All types of food and drink were coded according to the system used by the
Netherlands Nutrient Databank (NEVO) and subsequently converted into energy
and nutrients by using the extended computerized version of the Netherlands
food tabled Intake of macronutrients and alcohol was expressed as % of
energy. Cholesterol and fiber intakes were expressed as mg/MJ and as g/MJ,
respectively. Each subject's nutrient intake was compared with the Dutch
recommended dietary allowances (RDAs)".
Total energy expenditure was estimated as basal metabolic rate (BMR) x
activity level. BMR was calculated according to the equation developed by
Westerterp et a l " :
BMR (MJ/day)=0.102FFM (kg) + 0.024BF (kg) +0.85 (1)
where BF = body fat. Activity levels of 1.78 for men and 1.62 for women were applied on the
basis of calculations for free-living subjects".
ß/oc/je/77/ca/
After subjects had fasted overnight, a venous blood sample (90 ml) was
obtained and plasma and serum were stored at -80°C until analyzed. Serum
albumin, cholesterol, total protein, C-reactive protein, magnesium and whole-
blood thiamin were measured by routine methods in use at the hospital, on a
Beckman Synchron CX° system (Brea, CA, USA). Serum prealbumin was
measured using a radioimmunodiffusion technique (Beckman Immunochemistry
systems).
Vitamin B-12 and folic acid concentrations were assessed with a commercial
kit (Quantaphase* B-12/folate Radioassay; Bio-RAD Laboratories B.V.,
Veenendaal, The Netherlands). 25-Hydroxy vitamin D3 was determined using a
radioimmuno assay (INCSTAR, Stillwater, MN). Copper, zinc and selenium were
measured by Zeeman-corrected electrothermal atomic-absorption spectrometry.
The assessment of whole blood activity of glutathione peroxidase was based on
the method developed by Paglia and Valentine^®.Vitamins A and E (o-tocopherol)
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where measured with HPLC and /ff-carotene by spectrophotometric assessment
at 450 Nm. •. ,, ^ -;•
Total lipids were extracted as described by Bligh and Dyer". Total lipid
concentrations were assessed in plasma phospholipids, and the phospholipid
fraction was separated by thin layer chromatography according to van der
Vusse et aP°. Vitamin E concentrations have been found to be closely related to
serum lipids^, and the ratio of vitamin E to serum lipids was calculated to
accurately assess the vitamin E status in CD patients. Patients were considered
at risk of developing a nutritional deficiency of a trace element or vitamin if the
serum concentrations of the nutrient was less than the 1 5'* percentile of the
controls^.
M/sc/e
Strength of muscular quadriceps (extension) and the hamstrings (flexion) was
measured with an isokinetic dynamometer (Cybex II, Eagle Performance
Systems, Owatonna, MN) with angular velocities of 60° and 180°/s". Peak
torque and work capacity were calculated from a five fold measurement at each
angular velocity.
Statistical analysis
Results are expressed as means ± SD or as stated. Differences in nutritional
status between CD patients and controls were analyzed by using a paired
Student's t-test. Correlation coefficients and partial correlations were calculated
by regression analysis. All statistical analyses were performed with the SPSS
6.0 for Windows package (SPSS Inc, Chicago).
Results
Body composition
Total-body bone mineral content and mean T-score were significantly lower in
CD patients than in controls (P<0.025). There were no other significant
differences in body composition between patients and controls (Table 4.2).
However, in a sex-specific analysis, the percentage of body fat measured by
DXA or anthropometry was significantly lower in male CD patients than in male
controls. In females no significant differences were found.
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Tab!« 4.2 Body composition in Crohn's disease (CD) patients and controls'
Weight (kg)
Height (m)
BMI (kg/m')
Fat, DXA (kg)
FFM, DXA (kg)
TBW, DjO (L)
Percentage fat, DXA
Percentage, SF
BMC (kg)
Waist-to-hip ratio
Upper leg (cm)
MAMC (cm)
CD patients
(n = 32)
66.2
1.69
23.2
17.6
48.6
46.7
26.1
25.2
2.4
0.86
44.4
26.7
± 11.9
± 0.08
± 3.7
± 7.9
± 9.3
± 8.9
± 9.4
± 9.3
± 0.5'
± 0.09
± 5.7
± 3.4
All
Control
(n =
69.4
1.67
24.6
19.7
49.7
48.7
28.7
28.9
2.6
0.84
45.7
27.7
subjects
 32)
± 12.6
± 0.08
± 3.6
± 6.3
±11.6
± 9.7
± 7.5
± 7.5
± 0.5
± 0.1
± 5.3
± 4.0
Women
CD patients
(n = 18)
63.5
1.64
23.4
20.9
42.6
30.3
32.1
30.7
2.3
0.83
44.9
25.9
±
±
±
±
±
±
±
±
±
±
±
±
10.7
0.05
3.5
7.1
5.5
4.7
6.5
7.0
0.4
0.1'
6.3
2.8
Control
(n =
61.9
1.63
23.3
20.7
41.2
30.9
32.7
32.2
2.4
0.78
46.9
25.9
subjects
±
±
±
±
+
+
±
±
±
±
±
±
8.4
0.05
3.2
7.2
2.9
2.7
6.4
6.2
0.2
0.05
3.4
2.2
CD patients
(n = 14)
69.6 ±
1.76 ±
22.8 ±
13.2 ±
56.4 ±
38.8 ±
18.4 ±
18.2 ±
2.6 ±
0.91 ±
43.8 ±
27.8 ±
12.9
0.06
4.1'
7.0'
7.1
5.2
6.3'
7.0"
0.5'
0.05
5.0
4.0
Men
Control
(n =
78.9
1.73
26.4
18.4
60.5
42.3
23.5
24.7
3.0
0.92
44.2
30.2
subjects
 14)
± 10.6
± 0.08
± 3.5
± 5.0
± 8.9
± 6.0
± 5.3
± 7.1
± 0.5
± 0.08
± 6.8
± 4.6
Data are expressed as mean ± SD. DXA: dual-energy X-ray absorptiometry; FFM: fat-free mass; TBW: total body water;
DjO: deuterium dilution; SF: skinfold thickness measurement; BMC: total body bone mineral content; MAMC: mid-arm
muscle circumference.
P = 0.06 for difference between CD patients and controls.
Significantly different from controls (paired Student's t tests): ' P<0.05, *P<0 .01 , *P<0.025.
Dietary intake
The difference between mean energy intake and mean estimated total energy
expenditure was 0.62 MJ/d ± 3.11 in CD patients and -0.60 MJ/d ± 3.11 in
controls (NS). The subjects' mean daily nutrient intakes are shown in Table 4.3.
Compared with controls, CD patients had significantly lower mean daily intakes
of fiber and phosphorus (P<0.05). The mean daily intake of other nutrients did
not differ significantly between patients and controls. The percentage of
subjects who reported nutrient intakes below the RDA is shown in Table 4.4.
Vitamin A intake was below the RDA in 69% of CD patients and in 9 1 % of
controls (P = 0.01).
Table 4.3: Mean daily intake of nutrients'
Crohn's disease patients Control subjects
(n = 32) (n = 32)
Energy intake (MJ/day) 11.2 ± 3.5 10.3 ± 3.7
Total protein (% of energy) 14.4 ± 3.0' 15.9 ± 3.3
Total fat (% of energy) 35.1 ± 5.9 33.6 ± 7.7
SAFA (% of energy) 13.8 ± 3.3 12.6 ±3 .0
MUFA (% of energy) 13.0 ± 2.5 12.1 ± 3.4
PUFA (% of energy) 5.9 ± 2.5 6.6 ± 2.6
Linoleic acid (% of energy) 4.5 ± 2.4 5.3 ± 2.7
Cholesterol (mg/MJ) . 23.5 ± 5.4 23.2 ± 5.1
Total carbohydrates (% of energy) 47.8 ± 6.2 47.0 ± 8.3
Mono + disaccharides (% of energy) 24.7 ± 8.0 24.2 ± 8.4
Fiber (g/MJ) 1.5 ± 0.6' 1.9 ± 0.5
Alcohol (% of energy) 3.0 ± 4.1 3.7 ± 5.1
Phosphorus (g) 1.4 ±0.3* 1.7 ±0 .6
Calcium (g) 1.0 ±0 .3 1.2 ±0 .6
Total iron (mg) 13.3 ± 3.4 13.5 ± 4.8
Vitamin A (mg RE) 0.9 + 0.7 0.7 ± 0.3
^-Carotene (mg) , . ; 0.9 ± 0.4 1.0 ± 0.5
Thiamin (mg) '" 1.1 ± 0.3 1.2 ± 0.5
Riboflavin (mg) 1.5 ± 0.5 1.8 ± 1.5
Pyridoxine (mg) _ 1.8 ± 0.5 1.9 ± 0.7
Vitamin C (mg) 77.5 + 43.1 101.5 ± 56.7
Data are expressed as mean ± SD. SAFA: saturated fatty acids; MUFA: monounsaturated
fatty acids; PUFA: polyunsaturated fatty acids; RE: retinol equivalent.
' P = 0.06 for difference between Crohn's disease patients and controls.
'•* Significantly different from controls (paired Student's t-tests): 'P<0.01, *P<0.05.
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19
69*
34
38
53
38
19
3
100
22
91
41
38
34
47
13
3
97
Table 4.4 Percentage of subjects with nutrient intakes below or above the recommended
daily allowance (RDA)'
' •_ • - • . ' , Crohn's disease Control subjects
patients (n = 32) (n = 32)
Percentage of subjects
above the RDA . . . .
Total fat (% of energy) 40 40
Mono + disaccharides (% of energy) 56 41
Percentage of subjects below the RDA
Total protein (g)
Vitamin A (mg RE)
Thiamin (mg)
Riboflavin (mg)
Vitamin C (mg)
Total iron (mg)
Calcium (g)
Phosphorus (mg)
Fiber (g/MJ)
' Recommended dietary allowances according to reference 25.
* Significantly different from controls, P = 0.01 (Chi-square).
Biochemical analysis
The serum indexes of the subjects are shown in Table 4.5. Serum vitamin A
concentrations did not differ significantly between patients and controls, but
serum ^-carotene concentrations were significantly lower in CD patients
(P<0.001). Serum cholesterol concentrations and plasma total lipids were also
significantly lower in CD patients (P<0.001). Serum albumin was significantly
lower in CD patients (P<0.001), but serum total protein or serum prealbumin
concentrations did not differ significantly between patients and controls.
The ratio of /^-carotene to plasma total lipids was significantly lower in CD
patients (0.84±0.69 /vmol/g) than in controls (1.74±0.56 //mol/g) (P<0.001).
Concentrations of vitamin C, vitamin E, selenium, magnesium and zinc and
gluthatione peroxidase activity were also significantly lower in CD patients than
in controls (P<0.05). We found a significant correlation between concentrations
of zinc and albumin in CD patients (r = 0.37, P<0.05), but not in controls.
Significant correlations were also found between serum vitamin E
concentrations and cholesterol in both CD patients and controls (r = 0.53,
P<0.01) and between vitamin E concentration and plasma total lipids in CD
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patients and in controls (r = 0.64, P<0.01, and r = 0.58; P<0.01, respectively).
The ratio of serum vitamin E to cholesterol or to plasma total lipids was not
significantly different between the two groups. We found a significantly higher
prevalence (P<0.01) of vitamin D deficiency (vitamin D<70 nmol/L during
summer and autumn and <25 nmol/L during winter) in CD patients (56%) than
in controls (28%).
In summary, a large proportion of CD patients were found to be at risk of
developing nutritional deficiencies. The proportion of patients below the 15'"
percentile of controls for several serum nutrient concentrations^ is shown in
Figure 4 . 1 .
Table 4.5 Serum concentrations of nutritional biochemical indexes'
Reference
value*
Crohn's disease
patients (n = 32)
Control subjects
(n = 32)
Total protein (g/L) . , 60.0 - 74.0 69.2 ± 5.7 69.9 ± 4.2
Albumin (g/L) 34.0 - 45.0 37.7 ± 3.3' 42.5 ± 3.3
Prealbumin (g/L) 0.15-0.40 0.29 ± 0.07 0.27 ± 0.04
Vitamin A (/ymol/L) 0.9-2.5 2.6 ± 1.3 2.5 ± 0.6
/7-Carotene (/ymol/L) 0.40-3.20 0.98 ± 0.91* 2.33 ± 0.70
Thiamin (nmol/L) 85-155 119 ±27.5 114 ±26.4
Vitamin B-12 (pmol/L) 150-630 403 ± 282 263 ±91 .5
Vitamin C (//mol/L) 11-110 35.3 ± 25.8' 57.8 ± 22.3
Vitamin E (/vmol/L) 14 -40 29.2 ± 10.7« 34.8 ± 8.6
Folic acid (nmol/L) >4.5 14.4 ± 13.4 13.4 ± 5.88
Magnesium (mmol/L) 0.75 - 1.00 0.79 ± 0.07* 0.85 ± 0.07
Selenium (/ymol/L) 0.91-1.52 0.86 ± 0.14' 1.03 ±0 .15
Zinc (/ymol/L) 10.0- 19.0 12.0 ± 1.67' 13.4 ± 2.22
Copper (/ymol/L) 12.0-22.0 19.1 ±4.61 20.1 ±6.90
Glutathione peroxidase (U/mmolHb) 780- 1350 768 ± 232* 967 ± 296
Cholesterol (mmol/L) 4.1 -6.4 4.3 ± 0.9' 5.7 ± 1.2
Total lipid (g/L) 1.00-1.75 1.16 ± 0 . 2 ' 1.37 ± 0 . 2
' Data are expressed as mean ± SD.
* Based on normal values at our laboratory.
" Significantly different from controls (paired Student's t-tests): *P<0.001, *P<0.05,
* P<0.01.
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Figure 4.1 Proportion of patients with biochemical indexes below the 15'" percentile of
controls. GpX: gluthatione peroxidase activity; vit, vitamin. Activity of GpX was
determined in whole blood: other indexes were measured in serum.
Muscle strength
The results of the differential muscle strength measured with an isokinetic
dynamometer are shown in Table 4.6. Hamstring peak torques at both velocities
(60° and 180°/s) and hamstring work capacity measured at 180°/s were
significantly lower in CD patients than in controls (P<0.05). However, the peak
torque and work capacity of the quadriceps muscles were preserved in CD
patients. Sex-specific analysis showed that the differences in hamstring muscle
strength could be explained by the differences in muscle function between the
male patients and controls.
FFM estimated by DXA correlated significantly with peak torque and work
capacity of the quadriceps muscles measured at both velocities in both patients
and controls (P<0.001). Only controls, however, showed a significant
correlation between FFM measured by DXA and peak torque and work capacity
of the hamstring muscles (P<0.001).
Association between malnutrition and medical indexes in CD patients
We did not observe a significant correlation between nutritional status and
extent of small bowel resection or duration of disease. A significant correlation
between disease activity assessed by the van Hees index and percentage body
fat (by DXA) was found (r = -0.55, P<0.01). We also observed a significant
correlation between percentage body fat measured by DXA and serum selenium
concentrations (r = 0.57, P<0.01). A significant correlation between serum
vitamin D concentration and T-score (by DXA) was observed in CD patients
(r = 0.42, P<0.02) but not in controls. Lifetime prednisone dose was
significantly higher in males than in females (P<0.01; Table 4.1). However, we
did not observe any significant correlations between lifetime prednisone dose
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and muscle strength of the hamstring in either male or female patients.
Table 4.6 Muscle strength as measured with an isokinetic dynamometer'
Peak torque extension, 180°/s (Nm)
Peak torque flexion, 180°/s (Nm)
Peak torque extension, 60°/s (Nm)
Peak torque flexion, 60°/s (Nm)
Work capacity extension, 180°/s (J)
Work capacity flexion, 180°/s (J)
Work capacity extension, 60°/s (J)
Work capacity flexion, 60°/s (J)
Crohn's disease patients(n
81.5
45.6
123.1
71.6
367.4
210.0
513.5
382.3
= 32)
±
±
±
±
±
±
±
±
18.5
15.2'
: 27.4
22.2'
110.7
119.V
144.2
164.0
Controls(n
88.7
59.3
136.5
87.6
397.4
298.4
571.2
440.5
= 32)
±
±
±
±
±
±
±
±
39.7
31.9
53.8
33.4
220.5
212.4
272.7
205.5
Data are expressed as mean ± SD. Quadriceps muscle strength is measured by peak torque
or work capacity extension, and hamstring muscle strength by peak torque or work capacity
flexion.
Significantly different from controls (paired Student's t-tests): *P<0.05, 'P<0.02.
Discussion
It is generally accepted that malnutrition is a serious problem in patients with
active CD and that is has a negative effect on the morbidity and mortality of
hospitalized patients''". Malnutrition also has a negative effect on the general
health and well-being of many CD outpatients'*. In the present study, nutritional
status was assessed by four different measurements (body composition, dietary
intake, biochemical indexes, and muscle strength), all reflect the outcome of
nutrition in a special way. Except for a significant correlation between serum
selenium and percentage body fat, we found no significant associations
between the various dimensions determining nutritional status. This implies that
assessing just one dimension of the nutritional status is a poor predictor of other
indexes of nutritional status.
Decreased dietary intake, resulting from a combination of postprandial
abdominal pain and dietary restrictions, is an important cause of malnutrition in
CD. Decreased intake is frequently observed in CD patients with high disease
activity"^. In our patient population we found that energy intake was not
decreased, but actually tended to be higher, which agrees with a study by
Lanfranchi et a l " . In patients, the difference between mean energy intake and
estimated total energy expenditure was 0.62 MJ/d. This suggests that CD
patients in remission increase their energy intake to compensate for possible
maldigestion or malabsorption. It has been assumed that weight loss in CD
patients could be caused by increased resting metabolic expenditure'. However,
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Stokes and Hil l" showed that total energy expenditure was not raised in CD
patients.
The present study showed that the nutrient intakes were below the RDA in a
high percentage of both patients and controls, with no significant differences
between the groups except for vitamin A. Intake of vitamin E were in fact more
inadequate in control subjects than in patients. This result stresses the
importance of including a control group in a nutritional survey. Compared with
controls, CD patients had significantly lower intakes of fiber and phosphorus.
Although daily nutrient intakes of CD patients were not significantly different
from those of control subjects, patients had low serum concentrations of
nutrients of a variety of nutrients. Besides impaired absorption of nutrients in
CD (small bowel resection or mucosal damage)", intraluminal factors may play
a role in the decreased absorption of nutrients. Formation of soap complexes
due to steatorrhoea may be important^ and divalent cations such as
magnesium, selenium or zinc may form unabsorbable subcomplexes with
malabsorbed fats; also, decreased concentrations of fat-soluble vitamins may
occur in'patients with steatorrhoea.
Reactive oxygen and nitrogen species seem to be involved in the tissue
damage occurring in CD*°*^. Abundant production of these reactive species (ie,
oxidative stress) has been observed in the bowels of CD patients with active
disease. Under normal physiological conditions, antioxidant defenses protect
tissues against the damaging effects of these reactive species, but chronic gut
inflammation promotes an imbalance between prooxidant and antioxidant
mechanisms**. In patients, we found low serum concentrations of nutritional
antioxidants (/?-carotene, vitamin C, vitamin E, selenium, zinc) and low activity
of the enzyme glutathione peroxidase. The patient population had no signs of
active disease; therefore, these deficiencies cannot be completely explained by
elimination of nutrients as a result of oxidative stress. However, the fact that
significantly more patients than controls were current smokers may have
contributed to the patients' reduced antioxidant status.
In the present study the ratio of serum vitamin E to serum cholesterol and to
total lipids did not differ significantly between patients and controls, suggesting
that the decreased vitamin E levels in CD patients could be explained by the
decreased serum concentrations of cholesterol and plasma total lipids^'*^.
However, the ratio of /7-carotene to total lipids was significantly decreased in
CD patients compared with controls. /?-Carotene depletion is thus not explained
by hypolipidemia.
Several studies found decreased selenium concentrations in CD patients with
moderate or high disease activity**'". Our study, comprising CD patients in
remission, also found decreased selenium concentrations as well as reduced
gluthatione peroxidase activity, which is thought to be a sensitive indicator of
selenium deficiency*'. Whereas Rannem et al*^ found a significant reduction of
selenium concentrations and gluthatione peroxidase activity in CD patients with
a small bowel resection >200 cm, such a correlation was not found in the
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The zinc status of patients is difficult to assess, especially in the presence of
inflammation, and no single measurement of zinc status is entirely
satisfactory*®. Acute inflammation and hypoalbuminemia may decrease serum
zinc concentrations, despite normal total-body zinc content'". However, serum
zinc concentrations may provide enough information about the zinc status in our
patient population with quiescent disease, because circulating zinc reflects the
metabolizable or exchangeable zinc that is delivered to metabolically active
tissues*. The decreased albumin concentrations in CD patients may, however,
be a confounding factor in this respect.
Osteopenia is a common problem in CD, as was recently reported in a
population-based study*°. We observed a significant correlation between serum
vitamin D concentrations and total-body bone fracture risk in this patient
population. Our data suggest that the significantly decreased dietary intake of
phosphorus and the significantly decreased serum concentrations of magnesium
and vitamin D could be risk factors for the development of osteopenia in
patients with long-standing CD.
Underweight has been reported in 65-75% of CD patients'*^*\ However,
only a few studies have described the body composition of CD patients and
these studies were predominantly performed in patients with high disease
activity*-^. Patients in the present study had stable body weights and were not
catabolic. Except for the decreased total bone mineral content no other
differences in body composition were observed. However, sex-specific analysis
showed that male CD patients had a significantly reduced percentage of body
fat, measured by both DXA and anthropometry, compared with controls. Life
time prednisone dose was significantly higher in males than in females
(P<0.05), but this cannot explain the decreased percentage of body fat found
in male patients, because prednisone use tends to increase body fat. Disease
history was significantly longer in males than in females, however, and hence
may have been a contributing factor to the observed difference in body
composition. More research is required to provide a full explanation of this
apparent sex difference of body composition in CD patients.
We observed reduced strength of the hamstring muscles in CD patients
whereas the strength of the quadriceps muscles was preserved. The hamstring
muscle has a higher percentage of type Mb muscle fibers than does the
quadriceps muscle", and it is known from />? v/Vo and />? v/Yro studies that
corticosteroid therapy induces selective type Mb fiber atrophy". Eighty-four
percent of our patients had been treated with corticosteroids and the lifetime
prednisone dose was significantly higher in males than in females. The use of
corticosteroids could therefore be involved in the etiology of the reduced
hamstring muscle strength. Although, we did not find any significant
correlations between life-time prednisone dose and hamstrings muscle strength
in either males or females, this may be explained by the fact that corticosteroid-
induced muscle atrophy is a partially reversible process*'". Other factors may
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be involved in the pathophysiology of the observed muscle dysfunction.
Malnutrition is known to be associated with muscle fatigue"'". The lower
percentage body fat in male patients compared with controls may be an
important explanation for the decreased hamstring muscle strength observed. It
is unknown, however, whether malnutrition selectively affects certain muscle
fiber types. Further research will therefore be required to elucidate the etiology
of the reduced hamstring muscle strength in CD.
This study revealed the importance of using comprehensive measures of
nutritional status in patients with long-standing CD that is clinically in remission.
Many patients in the present study were at risk of developing nutritional
deficiencies, especially of antioxidants. This may imply a deteriorated
antioxidant status in patients with long-standing CD and hence an increased
susceptibility to oxidative tissue damage. Antioxidant supplementation may thus
be justified and may be of therapeutic value. The observed nutritional
deficiencies are important because malnutrition is associated with immune
dysfunction", decreased quality of life**, and increased susceptibility to
oxidative tissue damage". We found that male patients, who had suffered
significantly longer from CD and had a significantly higher mean lifetime
prednisone dose than females, were particularly at risk for nutritional
deficiencies. More research is needed to elucidate the effect of malnutrition and
of nutritional supplementation on the course of CD in this group of patients.
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Abstract
Introduction
Malnutrition is observed frequently in patients with Inflammatory Bowel Disease (IBD).
Knowledge about the nutritional status in patients with recently diagnosed IBD is
limited.
Methods
To obtain a comprehensive picture of the nutritional status in recently diagnosed IBD
patients, we assessed four measures of nutritional status in 69 IBD patients (23
Crohn's disease (CD) and 46 with ulcerative colitis (UC)) and 69 age- and sex-matched
population controls: 1) body composition, 2) dietary intake, 3) biochemical indexes of
nutrition, 4) and muscle strength.
Results
Body weight and body mass index were significantly lower in UC patients compared
with controls. The mean daily intake of carbohydrates was significantly higher in CD
patients and the intakes of protein, calcium, phosphorus, and riboflavin significantly
lower in UC patients compared with controls, respectively. Serum concentrations of
several nutrients (/?-carotene, magnesium, selenium and zinc) were significantly lower in
UC patients compared with controls. Serum vitamin B12 concentration was
significantly lower in CD patients. Muscle strength did not significantly differ between
IBD patients and controls.
J- >:"• * " k •":' k . ••'*
Conclusions
In conclusion, this study showed that the nutritional status of IBD patients was already
affected negatively at time of diagnosis. It needs to be elucidated whether nutritional
supplementation in recently diagnosed IBD patients may improve the clinical course of
the disease.
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Introduction "' • • .1 >
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder that
involves the colon in ulcerative colitis (UC) and may involve any part of the
entire gastrointestinal tract in Crohn's disease (CD). In these patients
malnutrition is often reported, especially in CD patients with active disease'".
In a recent study, we found several nutritional and functional deficiencies in
patients with long-standing CD, currently in remission'*. It is known that
malnutrition is associated with immune dysfunction'^" and increased
susceptibility to oxidative tissue damage'®. Adequate nutritional support may be
an important therapeutic tool in improving the nutritional status and attenuating
the inflammatory process in these patients.
In chronic disease, the nutritional status is the result of various physiological
and pathophysiological processes'^. It is therefore important to assess a
comprehensive nutritional status, measuring body composition, dietary intake,
biochemical indexes of nutrition, and functional indexes such as muscle
strength'*.
There is only one study, to our knowledge, regarding nutritional status in CD
patients at initial diagnosis'®. This study, however, was restricted to the
assessment of vitamin E status. Hence, the knowledge about the
comprehensive nutritional status of newly diagnosed IBD patients is very
limited. This knowledge could be important as achieving an optimal nutritional
status may be beneficial for the clinical course of the disease in recently
diagnosed IBD patients. The aim of the present study was to assess the
comprehensive nutritional status of recently diagnosed IBD patients and to
compare this with the status of controls.
Subjects and methods
The study protocol was approved by the Ethics Committee of the University
Hospital Maastricht and all subjects gave their informed consent before the start
of the study.
Patients
Patients were recruited from the out-patient population of the Department of
Gastroenterology of the University Hospital Maastricht, Atrium Medical Center
Brunssum and the Maasland Hospital Sittard, all located in the south of the
province Limburg in the Netherlands. The diagnosis of IBD was based on the
criteria proposed by Lennard-Jones'^. All patients who had been diagnosed with
IBD (n = 76) during the period June 1995-December 1997 were asked to
participate in the study. Sixty nine patients (23 CD, 46 UC) agreed to
participate (91%). All patients (mean age 35.4 years ± 13.6) had been
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diagnosed within 6 months prior to entering the study. Patient characteristics
are shown in Table 5.1. Disease activity for CD patients was assessed
according to the Crohn's disease activity index (CDAI)*° as well as by the
concentration of C-reactive protein (CRP) at the time of the investigation. For
UC patients, disease activity was assessed according to the Truelove and Witts
criteria and was graded numerically as 6-19 corresponding to "no disease
activity", 20-32 as having "moderate disease activity" and 32-45 corresponding
to "severe disease"*'. In addition, the concentration of CRP at the time of the
investigation was assessed.
Table 5.1 Characteristics of patients with Crohn's disease (CD) and ulcerative colitis (UC)'
Age (years)
Gender (F/M)
Small bowel involvement (%)
Small bowel resection (% (mean ± SD))
Mesalazine use (%)
Azathioprine use (%)
Prednisone use (% (mean ± SD))
CDAI*
Truelove & Witts index*
C-reactive protein (mg/L)
Smoking (%)
CD patients
(n = 23)
30.4 ± 10.2'
15/8
87.0
17.3 (21.3 cm ± 8.1)
100
4.0
26.0 (9.5 mg ± 5.6)
96.9 ± 66.5
- *
17.1 ± 19.9*
34.7
UC patients
(n = 46)
37.8 ± 14.7
21/25
o
0
93.4
6.5
19.5 (11.3 ± 7.0)
9.6 ± 5.8
6.4 ± 6.1
15.2
' Data are expressed as mean ± SD or as stated
* Crohn's disease activity index"
' According to reference 21
* Significantly different from UC patients (one-way ANOVA): * P<0.05
Controls
Sixty-nine volunteers (mean age 35.4 years ± 13.7) participated in this study
as controls. They were randomly selected from the patient population database
of a general health care center (3 general practitioners) located in the same
study area. The controls were age- and sex-matched with IBD patients (within 3
years of age). Subjects with a history of IBD were excluded.
Nutritional status - .
All measurements, except the assessment of dietary intake, were performed
during one day after an overnight fast at the University Hospital Maastricht.
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Body composition was assessed using anthropometry and dual-energy X-ray
absorptiometry (DXA). Body height was measured to the nearest millimeter with
a wall-mounted stadiometer and while body weight measured with an electronic
scale with a digital readout to an accuracy of 0.01 kilogram. Body mass index
(BMI) was calculated from weight and height (kg/m*). Mid-arm muscle
circumference (MAMC) was assessed".
Body fat, fat-free mass (FFM), percentage body fat and total body bone
mineral content (BMC) were determined using a dual-energy X-ray
absorptiometer (DPX-L, Lunar Corp., Madison, Wl; using DPX-L 1.3 software)".
Research on the reference population was conducted in the US, United Kingdom
and Northern Europe. There was a 1.3% SD among geographical areas in the
average density values. A total body scan over the entire length of a subject's
body was performed. Any material that could attenuate the X-ray beam, e.g.
jewelry, watches or clothing with zippers, were removed before the
examination.
D/efa/y /nfa/re •' ' ' ; •
Dietary intake was assessed using the cross-check dietary history**.The
subjects were visited at home by an experienced dietitian and the usual food
consumption of the previous month was assessed. During this interview, food
quantities were specified in household measures. Usual portion sizes were
estimated with the aid of portion size models or pictures of foods; frequently
consumed portions of food and common household measures were weighed on
a balance with a precision of 0.5 gram. In addition, the subjects had previously
completed a self-administered semi-quantitative validated food-frequency
questionnaire (FFQ), which was used as a cross check of the dietary history".
The FFQ dealt specifically with the dietary intake of fat and antioxidants over
the previous month. All types of food and drink were coded according to the
system used by the Netherlands Nutrient Databank (NEVO), and subsequently
converted into energy and nutrients by using the extended computerized version
of the Netherlands Food Tabled Intake of macronutrients and alcohol was
expressed as % of energy intake. Cholesterol and fiber intakes were expressed
as mg/MJ and as g/MJ, respectively.
S/oc/?em/ca/ ana/yses
After subjects had fasted overnight, a venous blood sample (90 ml) was
obtained and plasma and serum were stored at -80°C until analyzed. Serum
albumin, cholesterol, total protein, C-reactive protein (CRP) , magnesium and
whole blood thiamin were determined by routine methods in use at the hospital,
on a Beckman Synchron CX* system (Brea, CA, USA). Serum prealbumin was
measured using a radioimmunodiffusion technique (Beckman Immunochemistry
systems, (Brea, CA, USA). Serum vitamin B-12 and folic acid concentrations
were assessed by means of a commercial kit (Quantaphase* B-12/folate
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Radioassay; Bio-RAD Laboratories B.V., Veenendaal, The Netherlands). Serum
copper, zinc and selenium were determined by Zeeman-corrected electrothermal
atomic absorption spectrometry. The assessment of whole blood activity of
glutathione peroxidase was based on the method developed by Paglia and
Valentine".Serum vitamins A and E (a-tocopherol) were determined with High
Pressure Liquid Chromatography (HPLC) and serum ^-carotene by
spectrophotometric assessment at 450 Nm.
The concentration of vitamin E has been found to be closely related to serum
lipids^, and the ratio of serum vitamin E to serum cholesterol was applied to
accurately assess the vitamin E status in IBD patients.
Mt/sc/e
Prior to testing each subject underwent a 5-min warm-up period of aerobic
ergometer cycling. The subjects were then fixed to the testing apparatus, an
isokinetic dynamometer (Cybex II, Eagle Performance Systems, Owatonna,
MN)". The strength of m.quadriceps (extension) and of the hamstrings (flexion)
were measured. They completed a few sub-maximal warm-up muscle actions at
each angular velocity, and then 5 maximal muscle actions. Peak torque was
determined from a five fold measurement at velocities of 60 and 180°/s. In
addition, the flexor/extensor ratio at each velocity was calculated.
Statistical analysis
Results were expressed as mean ± SD or as stated. Differences in nutritional
status between IBD patients and controls were analyzed using a paired
Student's t-test. Correlation coefficients and partial correlations were calculated
by regression analysis. All statistical analyses were performed with the SPSS
7.0 for Windows package (SPSS Inc, Chicago).
Results
Body composition
The body composition results of the subjects are shown in Table 5.2.
CD par/enfs
Patients were significantly (P<0.05) longer than controls and FFM was
significantly higher in CD patients compared with controls. Furthermore, BMC
was significantly (P<0.05) lower in CD patients. We did not find other
significant differences between patients and controls.
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Table 5.2
Weight (kg)
Height (m)
BMI (kg/m*)
Fat, DXA (kg)
FFM, DXA (kg)
Percentage fat,
BMC (kg)
MAMC (cm)
Body composition
(UC)'
of patients with
CD patients
Crohn's
Patients Controls
(n =
67.4
1.74 :
22.2
18.5
48.9
DXA (%) 27.5
2.6 :
26.4
= 23) (n =
± 10.3 65.9
t 0.09* 1.70
± 2.7 22.7
± 6.5 19.0
± 9.8* 46.9
± 8.4 28.7
± 0.6* 2.8
± 2.5 26.5
 23)
± 10.4
± 0.11
± 2.7
± 6.8
± 8.9
± 8.7
± 0.5
± 2.5
disease (CD) and ulcerative colitis
UC patients
Patients
(n = 46)
68.6 ± 10.2*
1.72 ± 0.09
23.1 ± 3.0'
17.5 ± 7.2
51.1 ± 10.5'
25.5 ± 9.6
2.8 ± 0.5
26.8 ± 2.8
Controls
(n = 46)
72.3 ± 12.0
1.71 ± 0.08
24.7 ± 3.5
19.3 ± 6.7
53.0 ± 11.1
26.9 ± 8.0
2.8 ± 0.6
27.9 ± 3.9
' Data are expressed as mean ± SD. DXA: dual-energy X-ray absorptiometry; FFM: fat-free
mass; TBW: total body water; BMC: total body bone mineral content; MAMC: mid-arm
muscle circumference;
' P = 0.06 for difference between patients and controls.
'•* Significantly different from controls (paired Student's t-tests): 'P<0.01, * P<0.05.
t/C paf/ente
Body weight and BMI were significantly (P<0.05) lower in the total group of
patients than in controls. Sex-specific analysis showed that alterations in body
composition were predominantly observed in male UC patients. BMI was
significantly (P<0.01) lower in male patients (23.3 kg/m*±2.9) than in controls
(25.7 kg/m^±3.2); body weight and fat mass were significantly (P<0.05) lower
in male patients (73.4 kg ±8.7 and 13.7 kg ±4.8) than in controls
(78.5kg±9.7 and 17.2 kg±5.4). Body height was significantly (P<0.05)
higher in male patients (1.78 m±0.08) than in controls (1.75 m±0.08). We
observed no significant differences in body composition between female UC
patients and controls.
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Dietary intake •- 5 >
The subjects' mean daily nutrient intakes are shown in Table 5.3.
Table 5.3 Mean daily intake of nutrients'
Energy intake (MJ/day)
Total protein' (%)
Total fat' (%)
SAFA'(%)
MUFA' (%)
PUFA' (%)
Linoleic acid' (%)
Cholesterol (mg/MJ)
Total carbohydrates' (%)
Mono + disaccharides' (%)
Fiber (g/MJ)
Alcohol' (%)
Phosphorus (g)
Calcium (g)
Total iron (mg)
Vitamin A (mg RE)
/9-Carotene (mg)
Thiamin (mg)
Riboflavin (mg)
Pyridoxine (mg)
Vitamin C (mg)
Crohn's
Patients
(n = 23)
11.0
14.7
34.0
12.6
12.8
6.1
4.5
22.1
51.0
26.7
1.6
0.9
1.6
1.3
13.0
0.8
1.0
1.2
1.7
1.9
103.0
± 3.4
± 2.2
± 7.6
± 2.8
± 3.5
± 2.3*
± 2.2
± 5.9
± 7.4*
± 6.6'
± 0.5
± 1.3'
± 0.7
± 0.8
± 4.9
± 0.5
± 0.9
± 0.5
± 1.2
± 0.6
± 84.2
disease
Controls
(n = 23)
10.8 ± 3.5
14.7 ± 2.8
36.4 + 6.8
12.9 ± 2.4
13.8 ± 3.2
7.4 ± 2.8
5.9 ± 2.6
22.2 ± 4.9
46.0 ± 7.2
22.9 ± 8.6
1.8 ± 0.5
4.0 ± 4.7
1.6 ± 0.5
1.1 ±0 .4
13.7 ± 4.0
0.7 ± 0.2
0.9 ± 0.5
1.3 ± 0.5
1.6 ± 0.7
1.9 ± 0.6
91.5 ± 39.6
Ulcerat
Patients
(n = 46)
10.3 ± 2.6
14.8 ± 2.5*
35.2 ± 6.3
12.8 ± 2.7
12.9 ± 2.7
7.0 ± 2.4
5.3 ± 2.5
21.7 ± 4.8
49.3 ± 7.7
23.6 ± 8.0
1.9 ± 0.5
1.8 ± 3.0'
1.5 ± 0.4*
0.9 ± 0.3*
13.7 ± 0.4
0.7 ± 0.3
1.0 ± 0.7
1.2 ± 0.4
1.4 ± 0.5*
1.8 ± 0.6
88.9 ± 47.1*
ive colitis
Controls
(n = 46)
10.3
16.1
33.7
12.3
12.4
6.6
5.5
22.1
47.9
23.9
2.0
3.4
1.7
1.3
14.0
0.7
1.1
1.4
1.8
2.0
113.7
± 3.5
± 2.8
± 7.6
± 3.0
± 3.4
± 2.4
± 2.2
± 6.5
± 7.3
± 7.7
± 0.6
± 4.3
± 0.6
± 0.5
± 4.7
± 0.3
± 0.7
± 0.8
± 1.3
± 0.7
± 58.8
' Data are expressed as mean ± SD. SAFA: saturated fatty acids; MUFA: monounsaturated fatty acids;
PUFA: polyunsaturated fatty acids; RE: retinol equivalent.
' % of energy
' P = 0.06 for difference between patients and controls.
** Significantly different from controls (paired Student's t-tests): * P<0.01, * P<0.05.
CD paf/enfs
The mean daily total carbohydrate intake was significantly (P<0.05) higher in
CD patients at time of diagnosis than in controls (Table 5.3). This might be
explained by a tendency of higher mono- and disaccharides intake in CD
patients compared with controls (P = 0.06). CD patients with high disease
activity (CDAI>150) showed a significantly (P<0.025) higher total
carbohydrate intake (56.4% ± 5.4) than CD patients in remission (48.7% ±
5.8). The difference in mono- and disaccharides intake between patients with
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active CD (31.1% ± 5.5) and patients with no disease activity (24.9 % ± 6.1)
did not reach significance (P = 0.08).
PUFA and alcohol intakes were significantly (P<0.05) lower in CD patients
than in controls.
L/C paf/e/7fs
The mean daily intake of total protein, phosphorus, calcium, riboflavin, and
vitamin C were significantly (P<0.05) lower in UC patients than in controls.
Biochemical analysis
The serum indexes of the subjects are shown in Table 5.4.
CD paf/e/7fs
Serum albumin and vitamin B-12 concentrations were significantly (P<0.05)
lower in CD patients than in controls. The activity of the enzyme glutathione
peroxidase was lower in CD patients compared with controls, however, this did
not reach significance (P = 0.06). We found significant correlations between
cholesterol and /?-carotene concentration (r = 0.38, P<0.05) and vitamin E
concentration (r = 0.52, P<0.01), respectively.
t/Cpar/e/ifs
Serum albumin, ^-carotene, magnesium, zinc and selenium concentrations were
significantly (P<0.05) lower in UC patients than in controls. The ratio of /?-
carotene to serum cholesterol concentration was significantly (P<0.05) lower in
UC patients (0.39 pmol/g ± 0.14) than in controls (0.47 pmol/g ± 0.17). The
ratio of serum vitamin E concentration to cholesterol concentration did not
significantly differ between patients and controls. Significant correlations were
found between cholesterol and /?-carotene concentration (r = 0.58, P<0.001)
and vitamin E (r = 0.77, P<0.001), respectively. A significant correlation
between concentration of zinc and albumin was observed in patients as well as
in controls (r = 0.41, P<0.01; r = 0.33, P<0.01, respectively). We found a
significant correlation between the activity of glutathione peroxidase and
selenium concentration in UC patients (r = 0.39, P<0.01) but not in controls
(r = 0.10, P = 0.53; Figure 5.1).
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Table 5.4 Serum concentrations of nutritional biochemical indexes'
; * - ' ,. nt *'j v« ";
Total protein (g/L)
Albumin (g/L)
Prealbumin (g/L)
Vitamin A (/vmol/L)
/^-Carotene (/ymol/L)
Thiamin (nmol/L)
Vitamin B-12 (pmol/L)
Vitamin C (//mol/L)
Vitamin E (jumol/L)
Folic acid (nmol/L)
Magnesium (mmol/L)
Selenium (//mol/L)
Zinc (pmol/L)
Copper (pmol/L)
Glutathione peroxidase
(U/mmolHb)
Cholesterol (mmol/L)
Crohn's
Patients
(n = 23)
71.6 ± 5.0
38.2 ± 4.4'
0.24 ± 0.06
2.2 ± 0.8
1.8 ± 0.7
109 ± 277
225 ± 60.7*
47.6 ± 17.7
28.8 ± 5.8
10.7 ± 9.1
0.79 ± 0.09
0.92 ± 0.16
12.3 ± 3.0
23.6 ± 8.9
786 ± 276'
4.6 ± 0.8
disease
Controls
(n = 23)
71.2 ±
42.7 ±
0.27 ±
2.4 +
2.2 ±
115 ±
270 ±
54.5 ±
30.4 ±
12.4 ±
0.82 ±
0.99 ±
12.9 ±
22.2 ±
949 ±
5.1 ±
3.0
3.8
0.03
0.6
1.3
15.2
88.2
22.9
8.7
5.6
0.06
0.16
1.3
7.4
218
1.2
Ulcerative
Patients
(n = 46)
71.4
40.5
0.26
2.3
2.0
109
269
51.9
29.6
11.4
0.79
0.91
12.6
21.2
878
5.1
± 4.3
± 3.5'
± 0.04
± 0.6
± 0.9"
± 22.1
± 87.9
± 21.4
± 7.7
± 8.6
± 0.07*
± 0.18*
± 1.7*
± 7.1
± 272
± 1.1
colitis
Controls
(n = 46)
70.5 ±
42.5 ±
0.28 ±
2.6 ±
2.4 ±
117 ±
264 ±
57.9 ±
32.5 ±
13.1 ±
0.83 ±
1.00 ±
13.3 ±
20.1 ±
946 ±
5.4 ±
4.0
3.1
0.04
0.6
0.7
24.5
89.7
20.6
9.1
6.7
0.07
0.17
2.1
6.4
314
1.3
' Data are expressed as mean ± SD.
* P = 0.06 for difference between patients and controls.
' * Significantly different from controls (paired Student's t-tests): 'P<0.01, * P<0.05.
6 8 1.0 1.2
serum selenium concentration (umol/L)
Figure 5.1 Correlation between serum selenium and activity of glutathione peroxidase in UC
patients (closed circles and straight line: r = 0.39, P<0.01) and controls (closed
triangles and dotted line: r = 0.10, P = 0.53)
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Muscle strength
The results of differential muscle strength measured with an isokinetic
dynamometer are shown in Table 5.5. We did not found any significant
differences in peak torques of hamstrings or quadriceps muscles between
patients and controls. The flexor/extensor ratio at both velocities did not
significantly differ between patients and controls. Peak torque of the flexor and
extensor muscles correlated significantly (P<0.01) with FFM estimated by DXA
in both patient groups and controls (Figure 5.2).
Table 5.5 Muscle strength as measured with an isokinetic dynamometer'
Crohn's
Patients
(n = 13l
disease
Controls
<n=13)
Ulcerative
Patients
(n = 30)
colitis
Controls
(n = 30|
Peak torque extension 180°/s(Nm) 81.5 ± 25.7 93.2 ± 37.2 96.1 + 30.7 100.5 ± 38.4
Peak torque flexion 180°/s(Nm) 46.8 ± 25.3 57.8 ± 22.0 58.6 ± 21.3 64.8 ± 30.4
Peak torque extension 60°/s(Nm) 127.5 ± 33.4 142.4 ± 33.2 148.8 ± 44.6 155.7 ± 50.0
Peak torque flexion 60<7s (Nm) 74.9 ± 23.5 86.8 ± 19.8 89.7 ± 31.9 98.5 ± 37.3
Flexor/extensor ratio 180°/s 0.56 ± 0.18 0.64 ± 0.20 0.61 ± 0.12 0.64 ± 0.14
Flexor/extensor ratio 60°/s 0.62 ± 0.11 0.59 ± 0.11 0.60 ± 0.09 0.63 ± 0.11
' Data are expressed as mean ± SD. Quadriceps muscle strength is measured by peak torque extension,
and hamstrings muscle strength by peak torque flexion.
I ,,
0 1 O 2 O 3 O 4 0 5 0 6 O 7 0 8 O 9 0
FFM
Figure 5.2 Correlation between peak torque of hamstring (flexor) muscles measured at
60°/sec and fat-free mass (FFM) estimated by dual-energy X-ray absorptiometry
(DXA) for controls (closed squares, semi dotted line; r = 0.73, P<0.001), UC
patients (open squares, straight line; r = 0.72, P<0.001) and CD patients (closed
triangles, dotted line; r = 0.72, P<0.01), and correlation between peak torque of
m. quadriceps (extensor) measured at 60°/sec and FFM estimated by DXA for
controls (r = 0.83, P<0.001), UC patients (r = 0.81, P<0.001) and CD patients
(r = 0.80, P<0.01).
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Disease activity
83% of CD patients and 92% of UC patients were clinically in remission
according to the CDAI criteria (CDAK150) and Truelove and Witts criteria
(Truelove and Witts <19), respectively. One patient with active CD
(CDAI > 150) and one patient with active UC (Truelove and Witts > 19) were
treated with steroids.
Discussion
The present study showed that the nutritional status of IBD patients is already
affected at time of diagnosis. Nutritional status was assessed by four different
measurements (body composition, dietary intake, biochemical indexes, and
muscle strength), all of which reflect the outcome of nutrition in a special way.
IBD patients in the present study differ from controls concerning the four
different measurements of the nutritional status, resulting in a deteriorated
nutritional status. To our knowledge, the present study is the first to report a
comprehensive nutritional status in recently diagnosed IBD patients.
Weight loss is often reported in IBD patients, especially in patients with
active C D * ' ° ' ° " . The significantly higher body length of CD patients in the
present study could explain the significantly higher amount of FFM in these
patients compared with controls. Hence, relative measurements of body
composition, e.g. percentage body fat, are appropriate indicators of possible
differences between CD patients and controls. However, no such differences
were observed between CD patients and controls. This could also be due to the
small number of patients studied, which may have induced a type II error (/?-
error).
There is only one study, to our knowledge, which evaluated a comprehensive
body composition in UC patients^. These authors did not show any significant
differences regarding body composition parameters between patients with
inactive UC and controls, in contrast with results of our study. It should be
noted, however, that the study population and the used methods differed from
ours. We studied recently diagnosed UC patients, whereas the disease duration
is unknown in the study of Capristo et al. Secondly, we used age- and sex-
matched population controls and performed gender specific analyses of body
composition changes which may have increased the power of our study.
Thirdly, in the study of Capristo et al body composition was measured by
bioelectric impedance with the assumption of a constant TBW/FFM ratio of
0.732. We showed in a previous study that body hydration of female IBD
patients differs from that of controls". In the present study, the height of UC
patients was comparable with controls and in this group we found a reduced
body weight and body mass index compared with controls. Sex- specific
analysis showed that the differences in body composition between male UC
patients and controls contributed to the differences in body composition. These
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data are in line with our previous observation in which we showed that body
composition differences were predominantly found between male patients with
long-standing CD, clinically in remission and controls'*. Some studies suggested
that gender differences may play a role in the efficiency of energy metabolism
under metabolic stress'". Furthermore, gender-specific hormonal responses after
metabolic stress may be a possible mechanism for the observed sex differences
in body composition^. However, more studies in humans are necessary to
elucidate the observed gender-specific differences concerning disease- induced
alterations of body composition. '- i , ? • • • • •• •• .*" '•• -t ..i -.
The dietary energy intake of IBD patients in the present study did not differ
from controls. The majority of the patients did not have a strongly elevated
disease activity which may explain their normal energy intake'*. An interesting
finding however, was the significantly higher intake of total carbohydrates in CD
patients compared to controls. Many studies postulated that sugar intake may
be a risk factor in the development of CD^'^. It is suggested however, that the
greater consumption of sugars in CD patients may be a result rather than a
cause of the disease. Furthermore, it was recently suggested by Riordon et al,
that the reported increased current sugar intake of CD patients may be a
consequence of active disease*". In the present study, 4 CD patients scored a
CDAI above 150, indicating active disease. The total carbohydrate intake
expressed as percentage of energy was significantly higher in the patients with
high disease activity than in patients with a CDAI below 150. Furthermore, if
the CD patients with high disease activity were excluded from the analyses, we
did not find significant differences between the total carbohydrate or mono- plus
disaccharides intakes between CD patients and controls. This is in line with
studies which reported similar intakes of energy and sugars in CD patients in
remission compared with randomly selected controls'*'*'. It is known that sugar-
containing foods are found to be more palatable which may explain the high
carbohydrate intake during active disease. It was suggested that zinc deficiency
may depress taste acuity, which may cause an increased sugar intake.
However, studies were unable to show impaired taste acuity in CD patients**.
Total energy intake was not found to be different between CD patients and
controls. A dietary advice for CD patients is often to reduce their fat intake. In
the present study we showed that the fat intake of CD was lower compared
with controls, however not significantly.
In UC patients, we found significantly lower intakes of phosphorus, calcium,
riboflavin, and protein than in controls. This may be a contributing factor to the
development of osteoporosis in UC patients*^.
In a recent study, we reported that patients with long-standing CD, currently
in remission, were at risk of developing nutritional deficiencies, especially of
antioxidants'*. In the present study, we also found significant reductions of
several serum antioxidants (/?-carotene, selenium and zinc), especially in UC
patients. Serum selenium concentrations were significantly correlated with the
activity of glutathione peroxidase in UC patients, but not in controls. This
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suggests that the selenium requirement for enzyme activity was met in the
majority of the controls and not in the UC patients****. The decrease in serum
antioxidants of UC patients may be explained by increased consumption of
antioxidants by the recently inflamed tissue rather than by impaired digestion
and absorption of nutrients which is unlikely in UC patients. Studies showed
that the antioxidant defense may be depleted by increased reactive oxidative
species found in inflamed mucosa of IBD patients*®*^. It is therefore possible
that the antioxidant status in UC patients of the present study was not
completely restored after the recent inflammation period. In CD patients, the
reductions in serum antioxidants did not reach significance which could have
been caused by a type II error.
The majority of the patients in the present study showed no strongly
elevated disease activity; we found that 83% of CD patients and 92% of UC
patients were clinically in remission during the study. Furthermore, the reported
deteriorated antioxidant status in these patients, especially UC patients, could
not be explained by a reduced dietary intake or smoking (15.2% of UC patients
were current smokers vs 23.3% of matched controls).
The present data support the hypothesis that in IBD patients an imbalance
exist between increased reactive oxidative species production and reduced
antioxidant defenses with regard to the pathogenesis of tissue injury in
lgQi4,49.5o |,_| g recent study, we were able to improve the antioxidant status of
patients with long-standing CD, clinically in remission, by three months'
supplementation with antioxidants and/or n-3 fatty acids in addition to their
regular diet*'. However, it needs to be elucidated, whether improvement of
antioxidant status by supplementation, is beneficial for the clinical course of
IBD.
Vitamin B-12 deficiency is frequently observed in CD patients, however
rarely in UC patients'°^°. In the present study, we also found that vitamin B-12
concentrations were significantly lower in CD patients compared with controls,
however, no differences were found between UC patients and controls. Vitamin
B-12 is absorbed in the distal ileum, and it is generally thought that
malabsorption of this vitamin occurs due to ileal resection or after prolonged
small bowel inflammation'. The present study showed that each CD patient,
even at time of diagnosis deserves serious attention concerning the vitamin B-
12 status.
It has been shown that skeletal muscle function seems to be sensitive
indicator of nutritional status in patients", as functional changes occurred
before abnormalities in conventional indices of malnutrition were observed*-". In
patients with long-standing CD, currently in remission, we observed a
significantly reduced strength of the hamstrings muscles (with a high
percentage of type lib fibers), whereas the strength of the quadriceps muscles
was preserved'^. It is known that corticosteroids therapy and also malnutrition
may induce selective type Mb fiber atrophy"-**. Furthermore, malnutrition is
associated with altered energy generation in the mitochondria (i.e., impaired
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rephosphorylation of ADP in the muscle)" and with relative loss of muscle
creatine and phosphorus in relation to ATP". Jeejeebhoy suggested that ATP
generation in muscle may be abnormal despite normal body composition in
these patients". In the present study, muscle strength was not significantly
different between IBD patients and controls. This suggests that in the patients
at time of diagnosis, muscle strength is not already affected. Malnutrition and
steroid use may affect muscle strength as the disease is progressing. Physical
fitness may also alter muscle strength. Physical activity of patients and controls
was not taken into account in our study, however, none of the patients was
hospitalized during the study and both patients and controls were sedentary,
with a few of them performing regular physical activity. Further studies are
required to elucidate the effect of malnutrition, corticosteroid therapy and
physical activity on the selective reduction in muscle function of IBD patients.
This study revealed that IBD patients already at time of diagnosis were at risk of
developing several nutritional deficiencies, especially that of antioxidants.
Nutritional status was comprehensively assessed in four different dimensions.
More research is needed to elucidate the effect of nutritional supplementation
on the clinical course of patients with recently diagnosed IBD.
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Gender specific alterations
of body composition in
patients with Inflammatory
Bowel Disease compared
with controls
Geerling BJ, van Marken Lichtenbelt WD, Stockbrügger RW,
Brummer R-JM
ft/ropea/7 ^/ot/ma/ of C///7/ca/
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Abstract
Background
Body hydration and the distribution of the body water compartments were assessed in
defined populations of patients with Inflammatory Bowel Disease (IBD) compared with
those of matched healthy controls.
Patients and methods
52 Patients with IBD at time of diagnosis (20 patients with Crohn's disease (CD-new)
and 32 patients with ulcerative colitis (UC-new)), 40 patients with long-standing CD
(CD-long) and 2 matched healthy control groups (n = 52 and n = 40) were recruited for
the study. Total body water (TBW) and extracellular water (ECW) were measured by
deuterium oxide and bromide dilution, respectively. Intracellular water (ICW) was
calculated as TBW-ECW. In addition, hydration of fat-free mass (FFM) and the
ECW:ICW ratio were calculated. FFM, body fat and percentage body fat were assessed
by dual-energy X-ray absorptiometry.
Results
In female IBD patients, the ECWHCW ratio was significantly (P<0.05) higher than in
controls (CD-new: 0.89 ± 0.11 vs 0.79 ± 0.08, P<0.01; UC-new: 0.85 ± 0.15 vs
0.77 ± 0.10, P<0.05; CD-long: 0.86 ± 0.14 vs 0.80 ±0.10, P<0.05). In these
female patients, the ICW:FFM ratio was significantly (P<0.05) lower than in controls.
Fluid shifts were especially pronounced in female patients with recently diagnosed CD.
In male patients with recently diagnosed UC and in those with long-standing CD, body
weight, body mass index, body fat and percentage body fat were significantly
(P<0.05) lower than in controls. No differences in body hydration or body water
distribution were observed between male patients and controls.
Conclusions
An altered body water distribution and body hydration were observed in female IBD
patients, especially in female patients with recently diagnosed CD.
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Introduction v-
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder that
involves the colon in ulcerative colitis (UC) and may involve any part of the
entire gastrointestinal tract in Crohn's disease (CD). Malnutrition has often been
reported in these patients, especially in CD patients'". Assessment of the
degree of malnutrition in IBD requires accurate measurements of body
composition.
Body composition can be assessed by a simple model in which the body is
divided in two main compartments: body fat (BF) and fat-free mass (FFM). FFM
can be assessed by deuterium dilution assuming a constant hydration ratio of
73%'*. Studies have shown however, that malnutrition influenced body
hydration". Furthermore, malnutrition may result in a reduced body cell mass
(BCM), accompanied by an increase in extracellular water (ECW)'*. There is
both clinical and experimental evidence that chronic inflammation may lead to
an expansion of ECW'^ and a decrease in intracellular water (ICW)
compartments'^. This phenomenon can be elucidated by measuring ECW and
ICW compartments. ICW is the greatest part of BCM, which is the metabolically
active part of the human body, and can be calculated by subtracting ECW from
total body water (TBW). Changes in the ECW:ICW ratio may give important
information about body water distribution and fluid shifts.
Measurement of body water compartments is an essential part of nutritional
assessment and it may be helpful in understanding the metabolic alterations
(that is, changes in energy metabolism, substrate oxidation and nutritional
status) in IBD.
The aim of this present study was to assess the body hydration and the
distribution of the body water compartments in defined populations of IBD
patients compared with those of matched healthy controls.
Subjects and methods
The study protocol was approved by the Ethics Committee of the University
Hospital Maastricht, and all subjects gave their informed consent before the
start of the study.
Subjects
Characteristics of the patients are shown in Table 6.1. They were recruited from
the out-patient population of the Department of Gastroenterology. The diagnosis
of IBD was based on the criteria proposed by Lennard-Jones". Disease activity
for CD patients was assessed according to the Crohn's disease activity index
(CDAI)'® as well as by the concentration of C-reactive protein (CRP) at the time
of the investigation. For UC patients, disease activity was assessed according
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to the Truelove and Witts index'^ and graded numerically as 6-19 corresponding
to "no disease activity", 20-32 as having "moderate disease activity" and 32-45
corresponding to "severe disease". In addition, CRP concentrations were
measured at the time of investigation.
Table 6.1 Characteristics of patients with Inflammatory Bowel Disease (IBD)'
IBD-new (n = 52)
CD-new* (n = 20) UC-new* In = 32) CD-long* (n = 42)
Age (years)
Small bowel involvement
Small bowel resection
Disease duration (years)
CDAI*
Truelove & Witts index'
C-reactive protein (mg/L)
29 (21-38)
n = 18
n = 4
0.3 (0.2-0.3)
99 (44-126)
-
10.0 (6.0-30.0)
32 (25-48)
n = 0
n = 0
0.3 (0.2-0.5)
-
6.0(6.0-14.0)
6.0 (2.0-8.0)
40(31-53) '
n = 42 '
n = 30 '
14 (10-19)'
124 (73-190)
-
7.0(7.0-11.0)
' Data are expressed as median; 25th and 75th percentile in parentheses
* Patients with recently diagnosed Crohn's disease (within 6 months of diagnosis)
•" Patients with recently diagnosed ulcerative colitis (within 6 months of diagnosis)
* Patients with long-standing (>10 years) Crohn's disease
' CDAI, Crohn's disease activity index"
" According to reference 19.
' Significantly different from other patient groups (Chi-square and one-way ANOVA):
P<0.001.
Paf/'enfs iv/f/j rece/7f// tf/agnosec/ /SO
All patients who had been diagnosed with IBD during the period June 1995-
December 1997 were asked to participate in the study. Ninety-one percent
agreed to participate. All patients had been diagnosed within 6 months before
the study. Fifty-two patients (20 CD, 32 UC) were included. Three CD-new
patients scored a CDAI > 150, which is regarded as active disease'®. Acute
phase protein response did differ significantly (P<0.05) between CD-new
patients (median C-reactive protein: 10 mg/L; females 10 mg/L; males 8 mg/L)
and controls (median C-reactive protein: 3.5 mg/L; females 7 mg/L; males 2
mg/L). Two UC-new patients scored a Truelove & Witts index>20, which is
regarded as active disease". However, acute phase protein response did not
differ significantly between UC-new patients (median C-reactive protein: 6
mg/L; females 7 mg/L; males 2 mg/L) and controls (median C-reactive protein: 2
mg/L; females 5 mg/L: males 2 mg/L). All patients used medication during the
study, including mesalazine (n = 52) and azathioprine (n = 3). Thirteen patients
(25%) used corticosteroids (median dose 10 mg). A dose of ^10 mg/day was
prescribed to 7 IBD-new patients (4 females, 3 males).
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Patients who had been suffering from CD with small bowel involvement for
more than 5 years and who were clinically in remission, were consecutively
asked to participate in the study during a visit to the outpatient clinic of the
Department of Gastroenterology in the periods November 1995-May 1996 and
April 1997-July 1997. Forty patients (23 females, 17 males) participated in the
study. Median CDAI was 124 for all patients, 110 for females and 135 for
males, respectively. Fourteen patients (7 females, 7 males) scored a
CDAI > 150, which is regarded as active disease'®. The high liquid stool
frequency of many of these patients, all of whom suffered from ileal
dysfunction, may explain the relatively high scores on the CDAI. However,
acute phase protein response did not differ significantly between patients
(median C-reactive protein: 7 mg/L; females 7 mg/L; males 9 mg/L) and controls
(median C-reactive protein: 4 mg/L; females 6 mg/L; males 2 mg/L). All patients
had stable body weights during the 3 months preceding the study. The absence
of a significant acute phase response indicated that these patients were
clinically in remission. Most patients (92%) used medication during the study,
including mesalazine (n = 35), azathioprine (n = 12), cholestyramine (n = 7) and
low doses (median dose 5 mg) of corticosteroids (n = 13). Two patients had an
ileostomy.
Confro/s
The controls were randomly selected from the patient population database of a
general practitioner in the same study region, which is a reliable dynamic
sampling frame of the Dutch general population. They were selected according
to the following criteria: age- and sex-matched with IBD patients (within 3 years
of age) and no history of IBD. Two healthy control groups, one group (n = 52)
matched with IBD-new (median age 32 years) and another control group
(n = 40) matched with CD-long (median age 38 years), participated in the study.
Methods
Body composition was assessed using anthropometry, deuterium and bromide
dilution techniques and dual-energy X-ray absorptiometry (DXA).
Body height (BH) was measured to the nearest millimetre using a wall-mounted
stadiometer, while body weight (BW) was measured using an electronic scale
with a digital readout to an accuracy of 0.01 kilogram. Body mass index (BMI)
was calculated from weight and height (kg/m*).
Subjects consumed a cocktail containing a quantity of deuterium (99.8 atom
percent excess, Akademie der Wissenschaften, Leipzig, Germany) corresponding
to 0.1 g/L estimated TBW, and 60 mg sodium bromide/L predicted TBW mixed
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into = 70 ml water™.
of TßtV -
TBW was assessed using deuterium oxide. A background urine sample was
taken after an overnight fast. After consumption of the deuterium/bromide
cocktail, urine was collected after 4 hours of equilibration. Isotopic abundances
in urine were determined in duplicate using an isotope-ratio mass spectrometer
(Aqua Sira; VG Isogas, Cheshire, UK). Deuterium dilution space was calculated
from the quantity of deuterium administered and the urine deuterium
concentrations after equilibration. TBW was assessed according to the equation
proposed by Deurenberg et aP° and was calculated as the deuterium-dilution
space divided by 1.04, correcting for the exchange of the deuterium label with
non-aqueous hydrogen in body solids^.
of FCW
ECW was assessed using bromide dilution. A background serum sample was
taken after an overnight fast. After consumption of the deuterium/bromide
cocktail, serum samples were collected after 4 hours of equilibration. Bromide
concentration in serum ultrafiltrate was determined by HPLC using the anion-
exchange Chromatographie method". ECW was estimated from the corrected
bromide space"" .
of /CM/
ICW was calculated according to the equation: ICW = TBW-ECW.
Di/a/-e/7eAyy X-ray
Fat-free mass (FFM), body fat and percentage body fat were determined using a
dual-energy X-ray absorptiometer (DPX-L, Lunar Corp., Madison, Wl; using DPX-
L 1.3 software)". A total body scan over the entire length of a subject's body
was performed. Any materials that could attenuate the X-ray beam, for example
jewelry, watches or clothing with zippers, were removed before the
examination.
Statistical analysis
Results are expressed as mean ± SD or as stated. Differences in body
composition between IBD patients and matched controls were analyzed using a
paired Student's t-test, and ANOVA was used to analyze differences in body
composition parameters between different IBD groups. Correlation coefficients
were calculated by regression analysis. All statistical analyses were performed
with the SPSS 7.0 for Windows package (SPSS Inc, Chicago).
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Results
CD-new patients
Table 6.2 shows body composition results for CD-new patients compared with
controls. No significant differences in body weight, BMI, body fat or percentage
body fat were observed between patients and controls. However, CD-new
patients were significantly (P<0.05) taller and FFM was significantly (P<0.02)
higher than in controls. The ECW:ICW ratio was significantly (P<0.02) higher in
CD-new patients, while the ICW:FFM ratio was significantly (P<0.02) lower
than in controls. Gender-specific analysis showed that these differences in body
water distribution could be explained by differences between female CD- new
patients and controls. In males, we did not observe any significant differences
in body composition parameters between the CD-new patients and the controls.
UC-new patients
Body composition results of UC-new patients are shown in Table 6.3. Body
weight, BMI, and body fat were significantly lower in UC-new patients than in
controls. The ECW:ICW ratio was significantly (P<0.05) higher in female UC-
new patients.
In male patients, body weight, BMI, body fat and percentage body fat were
significantly (P<0.05) lower than in controls. No differences in FFM hydration
or body water distribution were found between male patients and controls.
CD-long patients
Results for patients with long-standing CD are shown in Table 6.4. FFM and the
ICW:FFM ratio were significantly (P<0.05) lower in CD-long patients than in
controls. The ECWMCW ratio was significantly (P<0.05) higher in patients. This
difference in ECW:ICW ratio was only observed in female CD-long patients
compared with controls.
In male patients, body weight, BMI, FFM, body fat, percentage body fat were
all significantly (P<0.05) lower than in controls. However, the male CD-long
patients did not differ significantly from the controls as regards body hydration
and body water distribution.
Disease activity indices showed no significant correlation with body composition
parameters in any patient group.
Body composition differences between UC and CD
We did not find any significant differences in body composition parameters
between CD-new, UC-new or CD-long patients (Table 6.2-6.4).
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Table 6.2
Weight (kg)
Height (m)
BMI (kg/m*)
FFM (kg)
Body fat (kg)
Body composition of patients with recently diagnosed (within 6 months of diagnosis)
compared with age- and sex- matched controls'
CD-new
(n = 20)
68.6
1.69
22.7
49.2
19.4
Percentage body fat 28.3
TBW:FFM
ECW:FFM
ICW:FFM
ECW:ICW
0.71
0.32
0.39
0.83
± 10.1
± 0.11*
± 2.5
± 9.9'
± 6.3
± 8.3
± 0.03
± 0.03
± 0.03'
±0 .13 '
All
Controls
(n = 20)
66.3
1.74
23.0
46.8
19.5
29.2
0.73
0.31
0.42
0.76
± 10.9
± 0.09
± 2.8
± 8.9
± 7.0
± 8.6
± 0.05
± 0.02
± 0.04
± 0.08
Females
CD-new
(n=13)
64.0 ± 7.6
1.63 ± 0.05'
22.5 ± 2.6
42.8 ± 2.4
21.1 ± 6.6
32.5 ± 6.7
0.72 ± 0.03
0.34 ± 0.02*
0.38 ± 0.03'
0.89 ± 0.11'
Controls
(n = 13)
60.7 ± 8.5
1.69 ± 0.04
22.9 ± 3.1
40.8 ± 2.8
19.9 ± 7.2
32.0 ± 7.4
0.74 ± 0.05
0.32 ± 0.01
^ 0.41 ± 0.05
0.79 ± 0.08
Crohn's disease (CD-new)
Males
CD-new
(n = 7)
77.3 ± 8.7
1.82 ± 0.07
23.1 ± 2.4
61.1 ± 6.5
16.1 ± 4.7
20.6 ± 4.7
0.70 ± 0.02
0.29 ± 0.01
0.41 ± 0.01
0.71 ± 0.03
Controls
In = 7)
76.6
1.83
23.2
57.7
18.9
24.0
0.72
0.30
0.42
0.72
± 6.8
± 0.07
± 2.1
± 4.5
± 7.2
± 8.8
± 0.04
± 0.02
± 0.03
± 0.07
' Data are expressed as mean ± SD. BMI: body mass index; FFM: fat-free mass assessed by dual-energy X-ray absorptiometry;
Body fat: assessed by dual-energy X-ray absorptiometry; TBW: total body water; ECW: extracellular water; ICW: intracellular water.
TBW:FFM, ratio of TBW and FFM; ECW:FFM, ratio of ECW and FFM; ICW:FFM, ratio of ICW and FFM; ECW:ICW, ratio of ECW and ICW.
*•'•* Significantly different from controls (paired Student's t-tests): * P<0 .01 , ' P<0.02, *P<0.05.
Table 6.3
Weight (kg)
Height (m)
BMI (kg/m')
FFM (kg)
Body fat (kg)
Body
age-
Percentage body fat
TBW:FFM
ECW:FFM
ICW:FFM
ECW:ICW
composition of patients with
and sex- matched controls'
UC
(n;
66.4
1.71
22.7
49.6
16.8
25.7
0.71
0.31
0.40
0.78
-new
= 32)
± 9.6"
± 0.09
± 2.4'
± 10.8
± 6.2"
± 9.4
± 0.03
± 0.04
± 0.03
± 0.14
All
recently
Controls
(n = 32)
71.1
1.69
24.7
51.7
19.5
27.8
0.71
0.30
0.41
0.74
± 12.4
± 0.07
± 3.4
± 1 1 . 6
± 5.4
± 7.0
± 0.03
± 0.03
± 0.03
± 0.11
diagnosed (within 6 months
UC
ln =
61.2
1.66
22.3
41.3
19.8
32.2
0.72
0.33
0.39
0.85
Females
-new
 18)
± 7.3
± 0.05
± 2.6
± 3.5
± 5.8
± 5.8
± 0.03
± 0.03
± 0.03*
± 0.15*
of diagnosis)
Controls
(n = 18)
64.2 ± 9.0
1.66 ± 0.08
23.2 ± 2.4
43.2 ± 4.9
20.9 ± 5.1
32.3 ± 4.2
0.72 ± 0.03
0.31 ± 0.03
0.41 ± 0.03
0.77 ± 0.10
ulcerative colitis (UC-new) compared with
Males
UC-new
(n=14)
73.2 ± 8.0*
1.73 ± 0.05*
23.2 ± 2.2'
60.3 ± 6.8
12.9 ± 4.6'
17.4 ± 5.9*
0.70 ± 0.04
0.29 ± 0.03
0.41 ± 0.02
0.70 ± 0.08
Controls
(n = 14)
80.1 ± 10.4
1.77 ± 0.08
26.7 ± 3.6
62.5 ± 8.2
17.7 ± 5.3
22.0 ± 5.4
0.70 ± 0.03
0.29 ± 0.03
0.41 ± 0.04
0.72 ± 0.12
' Data are expressed as mean ± SD. BMI: body mass index; FFM: fat-free mass assessed by dual-energy X-ray absorptiometry;
Body fat: assessed by dual-energy X-ray absorptiometry; TBW: total body water; ECW: extracellular water; ICW: intracellular
water. TBW:FFM, ratio of TBW and FFM; ECW:FFM, ratio of ECW and FFM; ICW:FFM, ratio of ICW and FFM; ECW:ICW,
ratio of ECW and ICW.
*•*•* Significantly different from controls (paired Student's t-tests): * P<0 .01 , ' P<0.02, * P<0.05.
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Table 6.4 Body composition of patients with long-standing (>10 years) Crohn's disease (CD-long) compared with .
matched controls'
Weight (kg)
Height (m)
BMI (kg/m*)
FFM (kg)
Body fat (kg)
Percentage body fat
TBW:FFM
ECW:FFM
ICW:FFM
ECW:ICW
All
CD-long
(n = 40)
64.8
1.69
22.8
47.1
17.7
26.7
0.71
0.31
0.39
0.81
± 12.0
± 0.07
± 4.0
± 8.7*
± 8.7
± 10.6
± 0.04
± 0.03
± 0.04*
± 0.14*
Controls
(n = 40l
68.9 ± 12.4
1.69 ± 0.08
24.0 ± 3.3
49.9 ±11.0
18.9 ± 4.9
27.7 ± 6.3
0.71 ± 0.04
0.31 ± 0.02
0.41 ± 0.04
0.77 ± 0.12
Females
CD-long
(n = 23)
63.3 ±11.0
1.65 ± 0.04
23.2 ± 3.8
41.6 ± 4.5
21.7 ± 7.4
33.4 ± 7.2
0.72 ± 0.03
0.33 ± 0.03*
0.39 ± 0.04
0.86 ± 0.14*
Controls
(n = 23)
61.2 ± 7.3
1.65 ± 0.06
22.4 ± 2.2
42.2 ± 4.3
19.0 ± 4.5
30.7 ± 4.8
0.71 ± 0.04
0.31 ± 0.02
0.40 ± 0.04
0.80 ± 0.10
age- and sex-
Males
CD-long
(n = 17)
67.0 ± 13.2*
1.75 ± 0.06
22.1 ± 4.1'
54.6 ± 7.4*
12.4 ± 7.0'
17.5 ± 6.7'
0.69 ± 0.04
0.30 ± 0.03
0.40 ± 0.04
0.75 ± 0.13
Controls
(n = 17)
79.2 ±
1.74 ±
26.2 ±
60.3 ±
18.9 ±
23.7 ±
0.71 ±
0.30 ±
0.41 ±
0.72 ±
10.2
0.06
3.3
8.6
5.4
5.8
0.03
0.03
0.04
0.12
' Data are expressed as mean ± SD. BMI: body mass index; FFM: fat-free mass assessed by dual-energy X-ray absorptiometry;
Body fat: assessed by dual-energy X-ray absorptiometry; TBW: total body water; ECW: extracellular water; ICW: intracellular
water; TBW:FFM, ratio of TBW and FFM; ECW:FFM, ratio of ECW and FFM; ICW:FFM, ratio of ICW and FFM; ECW:ICW,
ratio of ECW and ICW.
* P = 0.06 for difference between CD-long patients and controls.
' * Significantly different from controls (paired Student's t-tests: ' P<0 .01 , * P<0.02, * P<0.05.
Steroid use versus non-steroid use fiv? a;;;; -X'i
Steroid therapy did not significantly influence differences in body hydration or
ECW:ICW ratios between patients and controls. Figure 6.1 shows gender-
specific values of percentage body fat between patients with steroid or without
steroid therapy, respectively, and controls. Females with steroids tended to
have a higher percentage body fat compared with controls. In males an opposite
trend was observed.
females with steroids females without steroids
males with steroids
LC-new CO-bng
n-12 n-18
males without steroids
CO-bng
n-7
Figure 6.1 Percentage body fat measured by dual-energy X-ray absorptiometry (DXA) in
patients (open bars) with recently diagnosed Crohn's disease (CD-new),
ulcerative colitis (UC-new) and in patients with long-standing CD, clinically in
remission (CD-long), respectively, compared with controls (solid bars). The
total number (n) of patients is shown for each analysis and patients were age-
and-sex matched with controls (n). Data are shown as mean ± SD, separately
' for females and males, with and without corticosteroid therapy, respectively.
= - • • Significance level for differences in % body fat between patients and controls
(paired student t-tests): *P<0.05 .
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Discussion • •
This study revealed an altered distribution of body water compartments in
female IBD patients compared with controls. Fluid shifts were observed in
female patients with recently diagnosed CD and UC, but also in female patients
with long-standing CD compared with controls. In male IBD patients, however,
a different alteration in body composition was seen, comprising decreased body
fat, BMI and percentage body fat, which was especially pronounced in male
patients with long-standing CD.
Weight loss has often been reported in IBD patients, especially in patients
with active C D ^ ' ° " " . There is only one study, to our knowledge, which
evaluated body composition in UC patients^. These authors did not show any
significant differences regarding body composition parameters between patients
with inactive UC and controls, in contrast with results of our study. It should be
noted, however, that the study population and the used methods differed from
ours. Firstly, we studied recently diagnosed UC patients, whereas the disease
duration is unknown in the study of Capristo et al. Secondly, we used age- and
sex-matched population controls and performed gender specific analyses of
body composition changes which may have increased the power of our study.
Thirdly, in the study of Capristo et al body composition was measured by
bioelectric impedance with the assumption of a constant TBW/FFM ratio of
0.732. Our study showed that body hydration of female IBD patients differs
from that of controls.
It has been suggested that the decreased body weight, frequently observed
in IBD patients, represents a proportionally larger decrease in body fat, sparing
FFM'. However, available data about body water compartments of FFM in IBD
patients are limited. Measurement of extracellular water and intracellular water
may give important information about metabolic changes in chronic
inflammatory disorders as chronic inflammation may lead to an expansion of
ECW'* and cell shrinkage'".
In the present study, all patients were matched with controls according to
age and sex, though not to body mass index. If controls would have been
matched according to body mass index, this would probably have resulted in
over-matching and consequently to a loss of power in our study, as we tried to
reveal differences in body composition between patients and controls. Hence, in
the present study it is not useful to compare absolute sizes of body
compartments between patients and controls. Hence, this may explain the
significantly higher absolute size of FFM in CD patients at time of diagnosis,
because these patients were significantly taller than controls.
An increased ECW:FFM ratio and ECW:ICW ratio and a decreased ICW:FFM
ratio were observed in female IBD patients compared with controls. The fluid
shifts were especially pronounced in female patients with recently diagnosed
CD. The recent acute inflammatory process in these patients could be a
determinant of the disturbed body water distribution observed in these patients.
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The absence of an acute phase response in patients with long-standing CD
indicated that these patients were clinically in remission. The body composition
alterations observed in the latter patients are more likely to be associated with
malnutrition per se. It is known that ECW may increase as a consequence of
malnutrition". Several nutritional and functional deficiencies have been reported
in patients with long-standing CD in remission, although these patients were
weight stable and not catabolic". Consequently, the increased ECW:ICW ratio
in female patients with long-standing CD in remission may be caused by
malnutrition. Dietary intake did not significantly differ between patients and
controls". Hence, the body composition alterations of the patients in the
present study are probably disease-induced rather than caused by limited food
intake^.
A few studies have reported fluid shifts in patients with chronic inflammatory
disorders. In children with active CD, the ECW:ICW ratio was found to be
significantly higher than in controls^. The ECW:ICW ratio was significantly
decreased to normal values after treatment with either enteral nutrition or
prednisone. It should be noted however, that the gender distribution in this
study was not equal between patients and controls, which may have influenced
the outcome. Baarends et al found a significantly increased ECWrlCW ratio in
depleted patients (FFM/height* <15 kg/m*) with chronic obstructive pulmonary
disease (COPD) compared with non-depleted COPD patients'". In patients with
juvenile rheumatoid arthritis, a significantly higher ECW:ICW ratio was found
compared with controls'". In this study too, however, gender was not equally
distributed between patients and controls. The increased presence of certain
cytokines (interleukine-1ß and tumour necrosis factor-cr) was found to be
inversely correlated with the amount of FFM in patients with rheumatoid
arthritis" and the authors suggested that rheumatoid cachexia is at least partly
driven by inflammation.
Flear and Singh suggested that cell membrane function may be changed by
disease, which may cause fluid shifts". The pathogenesis of tissue injury in IBD
involves an imbalance between increased reactive oxidative compounds
production and reduced antioxidant defenses, resulting in oxidative stress^".
Evidence has been presented that inhibition of Na*-K* -2CI cotransport occurs
in response to oxidative stress in vascular endothelial cells, which tend to shrink
under these circumstances"*®. This cell shrinkage may result in a decreased
intracellular hydration of FFM, as we observed in the present study. The results
of our study suggests that the increased ECW:ICW ratio found in female IBD
patients may predominantly be the result of a decreased intracellular hydration
of FFM. It is assumed that the ICW compartment is a constant fraction of
BCM". We did not directly measure BCM, but our data suggests that BCM - the
metabolically active part of the human body-, may be decreased in female IBD
patients.
In male patients, we did not observe any significant differences in body
water distribution compared with controls. However, body weight, and
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consequently body fat and FFM were significantly lower, except for patients
with recently diagnosed CD. This latter observation could be due to a ß-error in
the small group studied. The body water distribution of FFM in male patients
was not disturbed, as was shown by their normal hydration ratios. The
proportionally decreased ECW and ICW compartments may have resulted in a
normal ECW:ICW ratio.
Corticosteroids may influence body composition by stimulating food intake",
promoting fat deposition^, or by reducing energy expenditure^. In the present
study population, corticosteroid therapy did not significantly influence dietary
intake" or body hydration. However, percentage body fat tended to by higher in
those females with steroid therapy compared with controls. In males, an
opposite trend was observed.
Although small but homogenous patients groups were studied, the observed
differences between males and females in the present study are interesting and
have not often been described. Medical treatment and disease activity did not
differ between males and females. To our knowledge, only one previous study
reported gender differences in the change of body water compartments due to
inflammation or malnutrition-associated disease^. An elevated ECW:ICW ratio
was shown in depleted females with COPD compared with non-depleted
females, while no such difference was found in males with COPD. Data
suggests that there may be gender differences in the efficiency of energy
metabolism under metabolic stress. This hypothesis was tested in rats in a
study by Cortright et al^ and it was found that daily exercise reduced fat,
protein and body mass in male but not in female rats despite a more negative
estimated energy balance in female rats. The authors mentioned gender-specific
hormonal responses as a possible mechanism for their findings. However, the
cause of the altered body water distribution in female patients compared with
controls observed in the present study is not yet clear. It should be noted
however, that we did not standardise for menstrual cycle. This may have
caused an increase in variation (standard deviation) in the results of the females.
In summary, female patients with IBD showed a significantly increased
ECW:ICW ratio, and a decreased intracellular hydration of FFM was observed.
Fluid shifts were most pronounced in female patients with recently diagnosed
CD, which suggests that an recent acute inflammatory process, besides
malnutrition, could be a major contributing factor to the altered body
composition. In male IBD patients, no significant changes in body water
distribution were observed. Our findings stress the importance of a
comprehensive measurement of body composition in IBD patients, and further
studies are warranted to elucidate the observed disease-induced differences in
body composition between female and male IBD patients.
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Abstract
Background
Fatty acid metabolism is involved in the immune response and inflammation processes
in patients with Crohn's disease (CD). Fatty acid changes may be relevant to the
clinical course of the disease. The aim of this study was to compare the qualitative and
quantitative fat intake and the fatty acid composition of plasma phospholipids and
adipose tissue in a defined population of CD patients with those in matched controls.
Methods
Dietary fat intake and fatty acid profile of plasma phospholipids and adipose tissue
were assessed in two patient populations: 20 patients with recently diagnosed CD and
32 patients with longstanding (>10 years) CD clinically in remission, matched for age
and gender with healthy controls.
Results
We observed no significant differences in quantitative or qualitative fat intake between
CD patients and controls. Percentages of linoleic acid and o-linolenic acid in plasma
phospholipids or adipose tissue were not significantly different between patients and
controls. However, we observed a significantly (P<0.05) lower percentage of the sum
of the n-3 fatty acids, with significantly (P<0.01) higher levels of clupanodonic acid
(22:5n-3) and significantly (P<0.05) lower levels of docosahexaenoic (22:6n-3) and
arachidonic acid (20:4n-6). The aberrant fatty acid profile was more evident in patients
with longstanding CD than in patients with recently diagnosed CD.
Conclusions . . - . . . , • ..
The aberrant fatty acid profile found in these CD patients is a result of altered
metabolism rather than of essential fatty acid malabsorption. The reported findings may
be important in the pathophysiology of CD and hence in the choice of fatty acids to be
used when therapeutic supplementation is considered in CD patients.
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Chapter 7
Introduction
The fatty acid patterns in plasma and tissue in patients with Crohn's disease
(CD) have become the focus of increasing interest, because the long chain
polyunsaturated fatty acids (PUFA) are the precursors of eicosanoids, which
participate in the regulation of immunological and inflammatory responses'-*.
Supplementation with n-3 PUFAs, as in fish oil, leads to the production of
leukotrienes and prostaglandins with attenuated inflammatory effects^* in
comparison to the leukotrienes and prostaglandins produced from n-6 PUFA.
Recently, studies have been conducted on fish oil supplementation in CD
patients, but the results are controversial".
It is known that acute inflammation alters fatty acid metabolism due to
increased demands for essential fatty acids (EFA) necessary for tissue repair and
membrane formation®, which may lead to EFA deficiency. In addition, fat
malabsorption in CD could also cause EFA deficiency'. Furthermore, studies
indicate that malnutrition, which is a common feature in CD'°'*, and especially
zinc deficiency, influence PUFA metabolism*'®".
Knowledge of fatty acid metabolism in CD patients is limited. There have
been a few studies that showed changes in fatty acid profile*-'*'**. However,
results have been equivocal, which may be explained from the use of different
methods to analyze fatty acid (FA) composition and assessment in different
body compartments. In addition, different CD populations were studied. Most
studies did not measure dietary fat intake, although this significantly affects
serum FA profile".
More knowledge of tissue FA composition in CD patients may have both
pathophysiological and therapeutic implications.
The aim of the present study was to assess the qualitative and quantitative
fat intake, as well as the fatty acid composition of plasma phospholipids and
adipose tissue, in a defined population of CD patients, compared with those of
matched healthy controls. In addition, the relation between changes in fatty
acid composition and disease duration was studied by comparing the fatty acid
composition of plasma phospholipids and adipose tissue in patients who were
recently diagnosed with CD (<6 months) and in patients with longstanding CD
(> 10 years).
Subjects and methods
The study protocol had been approved by the Ethics Committee of the
University Hospital Maastricht and all subjects gave their informed consent
before the start of the study.
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Patients .--.;-•;
Characteristics of the patients are shown in Table 7.1. They were recruited from
the outpatient population of the Department of Gastroenterology. The diagnosis
of CD was based on the criteria of Lennard-Jones^. Disease activity was
assessed by C-reactive protein (CRP) and according to the Crohn's disease
activity index (CDAI)" and the index of van Hees^ at the time of the
investigation.
Table 7.1 Characteristics of two Crohn's disease (CD) patient populations'
Gender (F/M)
Age (years)* :
Colonic involvement
Small bowel resection
Disease duration (months)'
Total extent of small bowel resection (cm)'
Lifetime prednisone dose (gP
C-reactive protein (mg/U*
CDAI"
van Hees index'*
Smoking
CD-new
(n = 20)
13/7
29.5 (23.0-37.5)
n = 9
n = 4
3.0 (2.0-3.0)
20.0(14.0-30.0)
1.5 (0.5-1.6)
9.0 (6.0-19.3)
99 (47-142)
145 (127-177)
n = 6
CD-long
(n = 32)
18/14
40.0 (34.3-54.0)
n = 18
n = 27
192 (132-228)*
75.0(40.0-110.0)
10.3(4.6-24.6)*
6.0 (2.0-9.0)
139 (86-193)
146 (127-159)
n = 22*
' CD-new: CD patients diagnosed within 6 months before the study; CD-long: patients with
longstanding CD (>10 years).
* Data are expressed as median; 25th and 75th percentile in parentheses.
' Crohn's disease activity index"
* According to reference 28
' Significantly different from CD-new (Mann-Whitney U test and Chi-square): * P<0.01.
w/r/) recenr/y cr/agwosec/ CD
All patients, who were diagnosed with CD with small bowel involvement during
the period June 1995-September 1997, were asked to participate in the study.
Ninety-one percent agreed to participate. All patients had been diagnosed within
6 months before the study. Twenty patients (13 women, 7 men) were included.
All patients used medication during the study, including mesalazine (n = 17) and
low doses (median dose, 2.5 mg) of corticosteroids (n = 3). One patient used a
supplement of 2.5 mg folic acid every day and four patients were supplemented
with intramuscular vitamin B-12.
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Patients suffering from CD with small bowel involvement for >10 years and
who were clinically in remission, were consecutively asked to participate in the
study during a visit to the outpatient clinic of the Department of
Gastroenterology during the period November 1995-May 1996. Thirty-two
patients (18 women, 14 men) participated in the study. Median CDAI was 139
for all patients, 127 for females and 173 for males. Fifteen patients (7 women,
8 men) scored a CDAI > 150, which is regarded as active disease. The high
liquid stool frequency of many of the patients, all of whom suffered from ileal
dysfunction, may explain the relatively high scores on the CDAI. However,
acute-phase protein response did not differ significantly between patients
(median CRP, 6 mg/L) and controls (median CRP, 2 mg/L). All patients had
stable body weights during the 3 months before the study. The absence of a
significant acute-phase response indicated that these patients were clinically in
remission. All patients used medication during the study, including mesalazine
(n = 26), azathioprine (n = 11) and low doses (median dose, 5 mg) of
corticosteroids (n = 13). Ten patients used a supplement of 2.5 mg folic acid
every day, 22 patients were supplemented with intramuscular vitamin B-12 and
two patients used cholestyramine. Two patients had an ileostomy.
Controls
The controls were randomly selected from a patient population database of
general practitioners in the same study region, which is a reliable dynamic
sample frame of the Dutch general population. They were selected on the
following criteria: age- and sex-matched with CD patients (within 3 years of
age) and no history of Crohn's disease. Two healthy control groups, one
(n = 20) matched with CD-new (median age, 29 years; range, 19-53 years) and
the other (n = 32) matched with CD-long (median age, 39.5 years; range 24-69
years), participated in this study.
Dietary intake
Dietary intake was assessed using the cross-check dietary history method which
is a validated method to assess dietary intake"'". The subjects were visited at
home by an experienced dietician and the usual food consumption of the
previous month was assessed. During this interview, food quantities were
specified in household measures. Usual portion sizes were estimated with the
aid of portion size models or pictures of foods; frequently consumed portions of
food and common household measures were weighed on a balance with a
precision of 0.5 g. In addition, the subjects had previously completed a
validated self-administered semiquantitative Food-Frequency Questionnaire
(FFQ), which was used as a cross-check of the dietary history*'. The FFQ dealt
specifically with the dietary intake of fat and antioxidants over the previous
month. All types of food and drink were coded according to the system used by
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the Netherlands Nutrient Databank (NEVO), and subsequently converted into
energy and nutrients using the extended computerized version of the
Netherlands Food Table^.
Plasma phospholipids fatty acid analysis
After an overnight fast, a venous blood sample (2 ml) was obtained and plasma
was stored at -80°C until analysis. A total lipid extract from 100 /yl plasma was
prepared according to the method of Bligh and Dyer, by adding 2 ml methanol
and 2 ml chloroform (1:1, vokvol)". L-o-dinonadecanoyl was used as an internal
standard. Plasma phospholipid fractions were isolated by solid phase extraction
on an aminopropyl-silica column". The plasma phospholipids were saponified
and the fatty acids were converted to the corresponding methyl esters by
reaction with 14% boron trifluoride (BF3) in methanol at 100°C for one hour'*,
with butylated hydroxytoluene (50mg/L) was added as an antioxidant. Tempera-
ture-programmed GC-FID (Gas Chromatograph-Flame lonization Detector) on a
50m x 0.25 mm CP-Sil 5 CB, df = 0.12 //m column (Chrompack®, Middelburg,
The Netherlands), with Nj as the carrier gas, was used for the analysis of fatty
acid methyl esters.
In total, 27 fatty acids were identified, but fatty acids percentages < 0 . 1 %
were not recorded; therefore 20 fatty acids were reported. The following fatty
acid combinations were recorded: ZSAFA (sum of all saturated fatty acids),
IMUFA (sum of all monounsaturated fatty acids), IPUFA (sum of all polyun-
saturated fatty acids), In-6 (sum of all n-6 fatty acids), In-6 LCP (sum of the
long chain polyunsaturated fatty acids (LCPs) formed from the parent linoleic
acid (18:2n-6) by alternate desaturation and elongation), In-3 (sum of all n-3
fatty acids), and In-3 LCP (sum of the LCPs formed from the parent cr-linolenic
acid (18:3n-6) by alternate desaturation and elongation). In addition, the
following indices were calculated: the unsaturation index (Ul) which is defined
as the sum of the number of double bounds multiplied by the percentage of
fatty acids; the saturation index (SI), which is the sum of all saturated fatty
acids divided by the unsaturation index; EFA status (In-6 + n-3/In-7 + n-9)^;
EFA deficiency index (EFADI), which is defined as (20:3n-9/20:4n-6)". The
amounts of the various fatty acids were expressed as percentages (wt/wt).
Adipose tissue fatty acid analysis
Adipose tissue biopsies were taken by needle biopsy from the outer quadrant of
the buttock and samples were stored at -80°C until analysis (<3 months).
Total lipid extracts from the adipose tissue biopsy were prepared according to
the method of Bligh and Dyer" by adding methanol and chloroform (1:1, vol:
vol). The total lipid extract was saponified and the fatty acid were converted to
the corresponding methyl esters by reaction with 14% BF3 in methanol +0.2
ml toluene and 0.55 ml methanol at 100°C for 30 min". The fatty acid
composition of adipose tissue was analyzed as described earlier for the plasma
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phospholipids. In total, 23 fatty acids were identified, but fatty acids
percentages < 0 . 1 % were not recorded; thus 12 fatty acids were reported. The
following fatty acid combinations were recorded: ISAFA, IMUFA, IPUFA,
In-6, Zn-3, and EFA status.
Serum zinc
Zinc was determined by Zeeman-corrected electrothermal atomic absorption
spectroscopy.
Statistical analysis
Results are expressed as median with 25th and 75th percentile in parentheses
or as stated. Differences between CD patients and matched controls in the fatty
acid patterns of plasma phospholipids and adipose tissue or in fat intake were
analyzed using a Wilcoxon matched-pairs signed-rank test because variables
were not normally distributed. The Mann-Whitney U test was used to test
differences in variables between CD-new and CD-long patients. Spearman's
correlation coefficients were calculated by linear regression analysis. All
statistical analyses were performed with the SPSS 7.0 for Windows package
(SPSS Inc, Chicago).
Results
Fatty acid profile of plasma phospholipids
Percentages of the various fatty acids in plasma phospholipids in CD patients
(CD-new and CD-long) and matched controls are shown in Table 7.2. The
saturated fatty acids 22:0, 23:0 en 24:0 were significantly lower (P<0.05) in
CD-long patients than in controls. Of the n-9 series, oleic acid (18:1n-9) was
significantly higher (P<0.01) and arachidonic acid (20:4n-6), one of the n-6
series, was significantly (P<0.05) lower in CD-long patients, compared with
controls. Interestingly, CD-long patients showed a higher percentage of
clupanodonic (22:5n-3) and a lower percentage of docosahexaenoic acid
(22:6n-3) in the n-3 series compared with controls. IMUFA and SI were
significantly higher, while IPUFA, In-3, In-3LCP, Ul and EFA status were
significantly (P<0.05) lower in CD-long patients than in controls. CD-new
patients showed a similar trend in fatty acid composition as CD-long patients,
though these differences did not reach significance except for the significantly
higher SI and significantly lower Ul compared with controls (P<0.05).
The saturated fatty acids 22:0, 23:0 and 24:0 were significantly lower in
CD-long patients compared with CD-new (P<0.05). Oleic acid (18:1n-9) and
mead acid (20:3n-9) of the n-9 series, and 22:5n-3 of the n-3 series showed
significantly higher percentages in CD-long patients compared with CD-new
(P<0.05).
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Table 7.2 Fatty acid composition of plasma phospholipids (% of total fatty acids) in two different patient populations with CD (patients
with recently diagnosed CD (within 6 months prior to the study), indicated as CD-new, and patients with longstanding
(>10 years), indicated as CD-long), compared with matched healthy controls'.
Controls In - 32)'
1372(1257-1530)
27.3 (26.4-29.3)
13.0(11.6-13.5) ;
1.73(1.45-1.95) .-
0.67 (0.58-0.74)
1.42 (1.29-1.63) ^
0.37 (0.25-0.56)
1.17(1.06-1.27) ;»;
7.65 (6.42-8.57) :"
0.15 (0.13-0.19)
21.8(20.3-23.6)
0.34 (0.32-0.41)
2.86 (2.50-3.48)
9.13 (8.13-10.4)
0.31 (0.28-0.35)
0.26 (0.21-0.31)
0.18 (0.12-0.23)
0.14(0.11-0.16)
0.65 (0.44-0.88)
0.86 (0.69-0.94)
3.00 (2.42-3.82)
Total (mg/L)
16:0
18:0
22:0
23:0
24:0
16:1n-7
18:1n-7
18:1n-9
20:3n-9
18:2n-6
20:2n-6
20:3n-6
20:4n-6
22:4n-6
22:5n-6
18:3n-3
20:4n-3
20:5n-3
22:5n-3
22:6n-3
CD-new (n = 20)
1200 (997-1 300)*
28.2 (26.9-29.1)
12.2 (10.8-13.0)
1.67(1.48-1.83)*
0.60 (0.52-0.67)'
1.29 (1.24-1.44)'
0.32 (0.27-0.45)
1.18 (0.99-1.28)
7.93 (7.25-8.54)«
0.12(0.09-0.16)"
21.9 (19.9-22.7)
0.36 (0.31-0.39)
3.06 (2.64-3.43)
9.05 (7.16-9.71)
0.33 (0.27-0.41)
0.26 (0.20-0.38)
0.23 (0.11-0.32)
0.14 (0.09-0.16)
0.60 (0.38-0.91)
0.80 (0.57-0.98)'
2.91 (2.29-3.88)
Controls (n = 20)
1370 (1038-1561)
28.3 (26.6-29.7)
12.1 (11.0-13.4)
1.52 (1.40-1.94)
0.55 (0.48-0.63)
1.36 (1.15-1.67)
0.43 (0.30-0.62)
1.19(1.05-1.31)
7.85 (6.63-8.55)
0.16 (0.12-0.20)
21.7 (20.0-24.0)
0.38 (0.31-0.41)
3.10 (2.48-3.47)
9.49 (8.19-10.03)
0.34 (0.27-0.39)
0.29 (0.22-0.34)
0.15 (0.11-0.23)
0.15 (0.11-0.19)
0.65 (0.40-0.74)
0.69 (0.57-0.92)
3.09 (2.44-3.52)
CD-long (n = 32)
1150 (998-1292)*
28.4 (27.1-29.3)
12.3 (11.8-13.0)
1.47 (1.30-1.67)'
0.49 (0.40-0.611=
1.19 (1.01-1.32)*
0.35 (0.22-0.51)
1.10 (1.02-1.33)
8.52 (7.89-9.30)*
0.15 (0.14-0.18)
21.6 (19.5-23.7)
0.31 (0.27-0.37)
2.94 (2.44-3.62)
8.49 (7.06-9.91)*
0.33 (0.25-0.42)
0.24 (0.19-0.28)
0.20 (0.11-0.30)
0.13 (0.11-0.18)
0.74 (0.58-0.88)
0.95 (0.76-1.11)*
2.71 (2.11-3.06)*
!V
ISAFA
IMUFA
ZPUFA
In-6
In-6LCP
In-3
In-3LCP
SI
Ul
EFA index
EFADI
CD-new (n = 2OI
46.3 (45.2-46.9)
12.3 (11.3-13.1)
39.8 (38.4-41.1)
34.9 (32.8-36.1)
12.7 (10.4-13.9)
4.75 (3.97-5.89)
4.46 (3.79-5.79)
0.35 (0.33-0.38)*
130 (124-136)'
3.20 (2.94-3.52)
0.01 (0.01-0.02)
Controls <n = 20)*
46.3 (45.7-46.6)
12.2 (10.3-12.8)
40.3 (39.3-42.0)
35.0 (34.3-35.8)
12.5 (11.8-14.0)
4.80 (4.20-6.38)
4.68 (4.01-6.12)
0.35 (0.33-0.36)
133 (130-139)
3.29 (3.04-3.98)
0.02 (0.01-0.02)
CD-long (n = 32)
46.4 (45.6-47.1)
12.3 (1 1.3-13.2)*
39.9 (38.9-40.8)*
34.9 (33.1-36.4)
11.8 (10.2-13.7)
4.62 (4.15-5.36)'
4.43 (3.94-5.13)'
0.36 (0.34-0.37)'
128 (126-135)*
3.16 (2.95-3.45*
0.02 IO.O2-0.O3)
Controls (n = 32)'
46.6 (45.7-47.3I
11.5 (10.3-12.6)
40.9 (39.7-41.7)
35.1 (33.1-36.8)
12.3 (10.4-13.7)
5.15 (4.41-7.04)
4.93 (4.13-6.86)
0.35 (0.33-0.36)
133(131-139)
3.51 (3.08-3.98)
0.02 (0.01-0.02)
' Data are expressed as median; 25th and 75th percentile in parentheses.
ZSAFA: sum of all saturated fatty acids; IMUFA: sum of all monounsaturated fatty acids; ZPUFA: sum of all polyunsaturated fatty
acids; In -6 : sum of all n-6 fatty acids; In-6 LCP: sum of the long chain polyunsaturated fatty acids (LCPs) formed from the parent
linoleic acid (18:2n-6) through alternate desaturation and elongation; In-3: sum of all n-3 fatty acids; In-3 LCP: sum of the
LCPs formed from the parent o-linolenic acid (18:3n-6) through alternate desaturation and elongation; Ul: sum of (number of double
bounds X percentage of fatty acid)); SI: sum of all saturated fatty acids/ unsaturation index; EFA index (essential fatty acid
status): In-6 + n-3/In-7 + n-9; EFADI (EFA deficiency index): 20:3n-9/20:4n-6.
* matched with CD-new. "; •
' matched with CD-long. ,. ' • ;
*•' Significantly different from controls (Wilcoxon matched-pairs signed-ranktest: * P<0.05, * P<0.01
'• ' Significantly different from CD-long (Mann-Whitney U test): ' P<0.05; ' P < 0 . 0 1 . ^
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Fatty acid profile of adipose tissue
Percentages of the different fatty acids in adipose tissue in CD patients (CD-
new and CD-long) and matched controls are shown in Table 7.3. The saturated
fatty acid 16:0 was significantly (P<0.05) higher in CD-long, whereas dihomo-
Hinolenic (20:3n-6) and docosahexaenoic acid (22:6n-3) were significantly (P<
0.01) lower in CD-long patients than in controls.
Fat intake
Table 7.4 shows the daily qualitative and quantitative fat intake in CD patients
(CD-new and CD-long) and matched controls. There were no significant
differences in energy intake or fat intake (total fat, saturated fatty acids,
monounsaturated fatty acids, polyunsaturated fatty acids or linoleic acid)
between CD patients and controls.
Correlations with clinical parameters
We observed no significant correlation between length of resected small bowel,
lifetime prednisone dose, CDAI, van Hees index, or elevated acute-phase
response (CRP>9) and fatty acid profile in CD patients (CD-new and CD-long).
Zinc and fatty acid profile
Serum zinc concentration was significantly (P<0.05) lower in CD-long patients
(12.0 //mol/L (10.8-13.2)) than in controls (13.1 //mol/L (12.0-14.2)). We
observed no significant differences in serum zinc concentrations between CD-
new (12.4 //mol/L (11.0-13.2)) and controls (13.0 //mol/L (12.1-14.8))
(P = 0.08). We found no significant correlation between serum zinc and fatty
acid profile in CD patients. In addition, CD patients who were considered zinc
deficient (serum zinc concentration < reference value of 10 //mol/L) showed no
significantly different fatty acid profile compared with CD patients without zinc
deficiency.
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Table 7.3 Fatty acid composition of adipose tissue (% of total fatty acids) in two different
patient populations with CD (patients with recently diagnosed CD (within 6 months
prior to the study), indicated as CD-new, and patients with longstanding (>10
years) CD, indicated as CD-long), compared with matched healthy controls'.
16:0
18:0
16:1n-7
18:1n-7
18:1n-9
18:2n-6
20:2n-6
20:3n-6
20:4n-6
18:3n-3
22:5n-3
22:6n-3
ISAFA
IMUFA
ZPUFA
Zn-6
In-3
EFA index
CD-new (n = 15)
19.6 (17.3-20.5)
3.95 (3.46-4.56)
4.88 (3.77-5.82)«
1.91 (1.75-2.21)
43.5 (41.6-45.2)
16.1 (14.8-16.5)
0.20 (0.15-0.22)
0.16 (0.12-0.21)
0.31 (0.26-0.39)
0.78 (0.67-1.06)
0.14 (0.09-0.18)
0.11 (0.07-0.19)
25.4 (22.3-27.7)
53.0 (51.5-54.5)
18.7 (17.6-19.1)
17.1 (16.2-17.8)
1.24 (0.91-1.32)
0.34 (0.32-0.37)
Controls* (n = 15)
19.1 (17.6-20.8)
3.27 (2.67-4.04)
5.61 (4.49-6.84)
2.19 (1.93-2.32)
42.5 (41.4-44.0)
15.6 (13.4-17.6)
0.22 (0.19-0.24)
0.18 (0.17-0.22)
0.38 (0.31-0.47)
0.93 (0.74-1.10)
0.15 (0.12-0.19)
0.15 (0.10-0.20)
24.3 (22.6-26.2)
53.5 (51.2-55.6)
18.5 (16.4-21.1)
16.6 (14.8-19.1)
1.29 (1.16-1.541
0.34 (0.27-0.39)
CD-long (n = 28)
19.7 (18.4-21.7)'
3.68 (3.02-4.49)
5.85 (4.85-7.36)
2.01 (1.70-2.45)
43.0 (41.9-45.8)
15.0 (13.1-17.5)
0.15 (0.13-0.22)
0.12 (0.10-0.17)*
0.33 (0.23-0.41)
0.68 (0.55-0.99)
0.19 (0.08-0.24)
0.11 (0.07-0.16)'
25.9 (23.9-29.0)
52.4 (49.7-54.4)
17.5 (15.7-19.8)
15.6 (14.0-18.2)
1.16 (0.90-1.42)
0.33 (0.27-0.36)
Controls' (n = 28)
19.1 (17.3-19.8)
3.93 (3.30-4.66)
5.49 (4.83-6.49)
1.93 (1.77-2.27)
41.9 (40.9-44.4)
15.7 (13.2-18.8)
0.21 (0.17-0.24)
0.21 (0.16-0.26)
0.41 (0.30-0.47)
0.77 (0.69-0.97)
0.19 (0.13-0.23)
0.15 (0.12-0.22)
24.7 (22.0-27.3)
52.4 (50.4-55.4)
18.9 (16.1-21.6)
17.1 (14.4-20.0)
1.36 (1.11-1.48)
0.35 (0.30-0.41)
' Data are expressed as median; 25th and 75th percentile in parentheses.
* Matched with CD-new;
' Matched with CD-long;
Abbreviations and *'' as in Table 7.2.
Discussion
In patients with longstanding CD, clinically in remission, the sum of the n-3
fatty acids was significantly lower than in controls, leading to a lower EFA
status. In these patients, however, the percentage of clupanodonic acid
(22:5n-3), an elongation product of eicosapentaenoic acid, was significantly
higher, and the percentage docosahexaenoic acid (22:6n-3) was significantly
lower, than in controls. Furthermore, we found a significantly higher percentage
of MUFA in patients with longstanding CD, compared with controls.
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Table 7.4 Daily nutrient intake in two different patient populations with CD (patients with recently diagnosed CD
(within 6 months prior to the study), indicated as CD-new, and patients with longstanding (>10 years) CD,
indicated as CD-long), compared with matched healthy controls'.
Energy intake (MJ/day)
Total fat (%)
SAFA (%)
MUFA (%)
PUFA (%)
Linoleic acid (%)
Protein (%)
Total carbohydrates (%)
Mono and disaccharides (%)
CD-new
(n = 20)
11.2 (8.5-13.4)
34.7 (31.6-43.2)
12.9 (10.4-14.1)
13.0 (11.1-14.8)
5.8 (5.0-7.2)
4.2 (3.7-5.6)
14.2 (12.7-16.3)
51.3 (45.6-52.8)'
26.1 (22.0-29.4)*
Controls
(n = 20)
9.9 (8.6-13.1)
34.8 (28.4-40.3)
12.4 (11.6-14.2)
13.0 (12.0-15.5)
7.1 (5.7-8.4)
5.3 (4.2-6.8)
14.6 (12.6-15.8)
44.3 (38.5-51.7)
19.1 (16.4-26.4)
CD-long
In = 32)
10.7 (8.9-13.2)
34.2 (30.5-38.7)
12.8 (11.4-15.7)
13.0(10.9-14.9)
5.5 (4.1-7.4)
4.0(2.8-5.7)
14.1 (12.0-16.3)
48.0 (43.4-52.5)
26.1 (19.2-29.4)
Controls
(n = 32)
9.3 (8.4-12.6)
34.5 (31.8-39.1)
13.2 (10.8-14.3)
12.1 (10.5-14.2)
6.3 (4.2-7.8)
4.7 (3.1-6.5)
15.2 (13.9-18.3)
47.4(39.8-52.1)
21.6 (18.0-29.2)
' Data are expressed as median; 25th and 75th percentile in parentheses.
SAFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; %: % of total energy intake.
^ Significantly different from controls (Wilcoxon matched-pairs signed-rank test): P< 0.05.
Chapter 7
A few studies have assessed fatty acids patterns*'®^^8.39 ^ QQ patients. To
our knowledge, however, ours is the first matched-control study in CD patients
to analyze fatty acid patterns in both plasma phospholipids and in adipose tissue
and to include a comprehensive quantitative and qualitative fat intake analysis.
Assessment of fat intake is important, as dietary fats are known modulators of
fatty acid distribution". We did not observe any significant differences in the
quantitative or qualitative daily fat intake between patients with recently
diagnosed or longstanding CD and their respective controls. Furthermore, in
plasma phospholipids and adipose tissue, the percentages of linoleic acid and a-
linolenic acid, the precursors of the n-6 and n-3 fatty acid series, were not
significantly different between patients and controls, which suggests that
preferential EFA malabsorption did not occur in these patients. Consequently,
the aberrant fatty acid profile found in these CD patients must be a result of
altered metabolism (i.e., altered hepatic plasma phospholipid metabolism) rather
than malabsorption of EFA. It should be noted, however, that quantitative fat
malabsorption can not be excluded, because the total fatty acids concentration
in plasma phospholipids of CD patients was significantly lower than in controls.
In addition, in patients with gross malabsorption of EFA (e.g., in patients with
extensive small bowel resection or with active disease), a different fatty acid
profile may be found.
The EFA index was found to be significantly lower in patients with
longstanding CD than in controls. However, the classic EFA deficiency index
(triene/tetraene ratio) was not significantly different between patients and
controls. We used the EFA index because the classic EFA deficiency index does
not account for changes in A-5 desaturase^.
We found a significantly lower percentage of docosahexaenoic acid (22:6n-3)
in patients with longstanding CD in remission. However, Esteve-Comas et al " • "
found increased plasma concentrations of a-linolenic acid and docosahexaenoic
acid in patients with active and nonactive CD. There are several reasons that
may explain the observed discrepancy between the studies of Esteve-Comas et
al and our study. In the studies of Esteve-Comas et al, the proportions of total
(both free and bound) fatty acids in plasma were determined. However,
although triacylglycerols, cholesterol esters and free fatty acids all contribute to
the plasma total fatty acid profile, the most important quantitative sources of
both circulating and membrane PUFA are the phospholipids^*. We therefore
assessed the fatty acid profile in plasma phospholipids. Secondly, the method
used by Esteve-Comas et al is less accurate than the method in our study. They
used a 30-m column and a fast (short) method for peak separation which
probably could not prevent superimposement of fatty acids peaks. Thirdly,
dietary fats are known modulators of fatty acid distribution. Esteve-Comas et al
did not assess dietary fat intake and could not excluded that the dietary intake
of CD patients differed from that of controls (i.e. with respect to fish intake).
A disturbed fatty acid profile was not as evident in the patients with recently
diagnosed CD as in the patients with longstanding CD. The results indicate that
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disease duration may be an important factor regarding the disturbed fatty acid
profile, but steroids use or malnutrition may also affect the fatty acid pattern (as
discussed later). It is possible, however, that the results are obscured by the
small number of patients with recently diagnosed CD, suggesting the possibility
of a /ff-error.
The aberrant fatty acid profile found in CD patients may be explained by
changes in the activities of desaturases or elongation enzymes (Figure 7.1). It is
shown that steroid therapy depresses protein synthesis*". The significantly
higher percentage of clupanodonic acid (22:5n-3) and the lower percentage of
docosahexaenoic acid in patients with longstanding CD, compared with controls
might be explained by the depression of A-6 desaturase due to steroid therapy.
The other substrates of A-6 desaturase were not significantly different from
controls. However, all patients used low doses of steroids in the present study.
More research is required to elucidate the effect of steroids on the fatty acid
synthesis in CD patients. Another explanation for the observed aberrant fatty
acid profile could be that CD patients have a deficiency in one or more
peroxisomal enzymes. A decreased peroxisomal /^-oxidation may result in low
levels of docosahexaenoic acid, and hence provoke an accumulation of
clupanodonic acid*'.
Nutritional factors may also modify the activity of desaturases. A protein-
deficient diet or a carbohydrate-rich diet might cause EFA deficiency as a
consequence of decreased desaturases activities'"'**. However, dietary intake of
protein and carbohydrate (except in patients with recently diagnosed CD) did
not significantly differ between patients and controls. Zinc plays a role in lipid
metabolism, modulating long-chain fatty acid desaturation and elongation"^.
Belluzi et al'® showed that zinc supplementation normalized the fatty acid
profiles in CD patients. We found significantly lower serum zinc concentrations
in patients with longstanding CD, but did not find any significant differences in
fatty acid patterns between patients with or without zinc deficiency.
Supplementation with n-3 fatty acids has been regarded as beneficial in CD
patients, but the results are controversial. Experiments by Dias and Parsons"^
showed that supplementation with eicosapentaenoic acid in the human
intestinal CaCo-2 cell line inhibited both A-6 and A-5 desaturase activity,
resulting in a decrease in arachidonic acid levels. The patients in the present
study received no eicosapentaenoic acid supplementation, but the
eicosapentaenoic acid content was higher than that in controls, with
significantly lower levels of arachidonic acid (20:4n-6). One may hypothesize
that these patients develop a mechanism to regulate eicosanoid synthesis in
order to remain in remission. It is therefore important to note that any
supplementation with fatty acids in CD patients requires a careful choice of n-3
fatty acids'. In addition, the quantitative balance between the availability of n-6
and n-3 fatty acids for metabolism may be of importance.
To summarize, we found no significant differences in quantitative or
qualitative fat intake between CD patients and controls. In plasma phospholipids
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and adipose tissue, the proportions of linoleic acid and a-linolenic acid were not
significantly different between patients and controls. However, we observed a
significantly lower percentage of the sum of the n-3 fatty acids, with
significantly higher levels of 22:5n-3 and significantly lower levels of
docosahexaenoic acid, in patients with longstanding CD compared with
controls. Consequently, the aberrant EFA profile found in these CD patients is a
result of altered metabolism rather than of EFA malabsorption. The reported
findings may be important with regard to immune response and inflammation in
CD patients. These results could influence the choice of fatty acids when
therapeutic supplementation is considered. More research is necessary to
improve the understanding of the control of long-chain fatty acid biosynthesis
and especially the role of desaturases and elongation enzymes activities in CD.
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The relation between
antioxidant status and
alterations in fatty acid profile
in patients with Crohn's
disease and controls
Geerling BJ, van Houwelingen AC, Badart-Smook, A,
Stockbrügger RW, Brummer R-JM
Iß-csrotene, vitamin E and giutathione peroxidase) in CD patients, however not in
controls.
Conclusion
The fatty acid profile in CD patients is significantly associated with disease activity and
serum antioxidant concentrations. This observation, along with the diminished
antioxidant defense in patients with active and inactive CD, indicates that antioxidants
shouid be considered in the therapy of inflammation in CD.
•* Ü
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Crohn's disease (CD) is a chronic inflammatory process, which may affect any
part of the gastrointestinal tract. The etiology of CD is still unknown, but
studies indicate that oxidative stress may be important in its pathogenesis'.
Reactive oxygen species (ROS) such as Superoxide (O2*), the hydroxyl radical
(OH'), hydrogen peroxide (HJOJ) and hypocholorous acid (HOCL) are produced in
excess by activated neutrophils and monocytes in the circulation and in the
inflamed mucosa of patients with Inflammatory Bowel Disease (IBD)'^.
Oxidative stress in IBD may result from either excessive activation of radical
producing systems (e.g. mucosal phagocytic leukocytes), or from a pro-oxidant
effect of tumour necrosis factor-o produced by activated macrophages*^. In
these cases, oxidative stress is the consequence of disease activity. However,
depletion of endogenous antioxidant defenses may also cause oxidative stress.
Several studies have reported reduced antioxidant concentrations in patient
groups with active^® or inactive CD^" compared with controls. It is unclear,
however, if the antioxidant defense in patients with active CD is significantly
different from that in CD patients who are clinically in remission.
Endogenous antioxidant systems and adequate nutritional intake of
antioxidants, especially vitamin E, vitamin C and selenium, are essential in the
control of membrane damage initiated by ROS'*. Polyunsaturated fatty acids
(PUFAs) are the main target of ROS. The fatty acid profile might be influenced
by antioxidants because they prevent lipid peroxidation in cell membranes.
Consequently, excessive ROS production or a depleted antioxidant defense
system leads to lipid peroxidation. PUFAs are also the precursors of
eicosanoids, which play an important role in the inflammatory process in CD,
and may be mediators in its pathophysiology'''. Several studies have reported an
altered fatty acid profile in CD patients'* " .
Although dietary intake can significantly affect fatty acid profile and serum
antioxidant concentrations^, most studies on fatty acid profile or antioxidant
status in IBD patients did not report dietary intake data.
In healthy subjects, a significant relation between the fatty acid profile and
serum antioxidants has been found'^, but knowledge about the fatty acid profile
in relation to antioxidant status and disease activity in CD patients is lacking.
The aim of the present study was therefore to assess dietary intake, antioxidant
status and the fatty acid profile in plasma, and red blood cell phospholipids in
patients with active CD and to compare them with those of CD patients
clinically in remission and with population controls. In addition, associations
between these variables were determined for both CD patients and controls.
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Subjects and methods
The study protocol had been approved by the Ethics Committee of the |
University Hospital Maastricht and all subjects gave their informed consent
before the start of the study.
Patients
The study included 12 CD patients with small bowel involvement who were
admitted to the University Hospital of Maastricht, the Netherlands due to an
exacerbation of CD. Of these, 8 patients were re-evaluated during the
subsequent phase of clinical remission. Patients were included in the study ,;
before they received high doses of corticosteroids or other medication to
suppress the inflammatory process. Characteristics of these 8 patients are
shown in Table 8.1. In addition, 50 consecutive patients suffering from CD with
small bowel involvement but who were clinically in remission were asked to
participate in the study as they visited the outpatient clinic of the Department of
Gastroenterology. Characteristics of these patients are shown in Table 8.2. The
diagnosis of CD was based on the criteria of Lennard-Jones^°. Disease activity
was assessed using the Van Hees index*\ In addition, C-reactive protein levels
and erythrocyte sedimentation rates (ESR) were determined in all patients. ;
Table 8.1 Characteristics of patients with Crohn's disease (CD) during an episode of
exacerbation and subsequent remission j
pat 1 (F)
pat 2 (Fl
pat 3 (M)
pat 4 (F)
pat 5 (F)
pat 6 (M)
pat 7 (F)
pat 8 (F)
age
32
18
33
53
50
59
33
40
CRP
(mg/L)
25
11
119
98
218
33
34
110
Exacerbation
ESR
(mm/h)
10
15
32
47
49
66
40
34
Van Hees
index'
154
152
258
215
289
187
160
169
weight
(kg)
72
75
73
58
62
66
92
57
CRP
(mg/L)
8
7
8
6
9
9
17
28
Remission
ESR
(mm/h)
4
13
2
19
6
9
11
11
van Hees
index'
126
115
132
123
130
140
124
142
weight
(kg)
72
84
85
60
67
68
92
62
' van Hees index". ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; pat: patient number;
F: female; M: male. Median time between exacerbation and remission was 4.5 months.
Controls
Seventy volunteers (Table 8.2) were randomly selected from a population
database of one general practice (3 general practitioners) in the same study
region, which is a reliable dynamic sample frame of the Dutch general
population. Subjects with a history of CD were excluded.
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Table 8.2 Characteristics of patients with Crohn's disease (CD) and controls
CD-active CD-inactive Controls
(n = 12) (n = 50) (n = 70)
Sex
Age (years)'
Current smoking
Disease duration (years)'
Colonic involvement
Small bowel resection
Total extent of small bowel resection (cm)'
Present use of - mesalazine
- azathioprine
ig, - prednisone (mgl' ,
van Hees index'
Erythrocyte sedimentation rate (mm/h)'
C-reactive protein (mg/L)'
8F, 4M
33 (22-52)
n = 6
2.0 (0.1-13)
n = 8
n = 2
40 and 75
n = 11
n = 1
5.0 (2.5-10)
205 (160-258)
34.0 (18.0-47.0)
59 (27-117)
31F, 19M 39F, 31M
40 (32-53) 36 (26-49)
n=22 n=37
13.0 (6.8-20)' - ' ._,, ,
n = 25 - , , ;.AJI-. r,.;-.-:
n = 30' •- •!.. r
40 (20-84) " -
n = 39 - ' / '
n-18' , -
5.0(2.5-10) ,,
140(128-149)' , -
11.5(6.0-19.0)'
8.0(7.0-12)' 6.0(2.0-7.0)'
' Data are expressed as median; 25th and 75th percentile in parentheses.
" Significantly different from active CD (Mann-Whitney U test, Chi-square): * P<0.001, 'P<0.05
Methods
sfaft/s
After an overnight fast, a venous blood sample (90 ml) was obtained and
plasma and serum were stored at -80°C until analysis. Antioxidant status was
assessed by serum concentrations of ß-carotene, copper, vitamin A, vitamin C,
vitamin E, selenium, zinc, and by enzyme activities in whole blood of
glutathione peroxidase (GpX) and Superoxide dismutase (SOD). Serum C-
reactive protein, copper, zinc and selenium were determined by Zeeman-
corrected electrothermal atomic absorption spectrometry. The assessment of
whole blood activity of GpX was based on the method developed by Paglia and
Valentine", while SOD (copper/zinc) activity was assessed using a RANSOD kit
(RANDOX Laboratories Ltd., Antrium, United Kingdom). Vitamins A and E (a-
tocopherol) were determined with High Pressure Liquid Chromatography (HPLC)
and jff-carotene by spectrophotometric assessment at 450 Nm. In addition, Total
Antioxidant Status (TAS) was measured using the Randox Total Antioxidant
Status Kit (RANDOX Laboratories Ltd., Antrium, United Kingdom) in CD patients
who were evaluated twice (n = 8), during an episode of exacerbation and during
subsequent remission. As vitamin E concentrations have been found to be
closely related to fatty acids", the ratio of vitamin E to serum cholesterol
concentration was calculated to accurately assess vitamin E status.
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After an overnight fast, a venous EDTA blood sample (2 ml) was obtained. The
plasma was separated from the red blood cells (RBCs) by centrifugation. RBCs
were washed twice with EDTA-containing saline (NajEDTA. 2 H2O, 28.64 g;
NaCI, 7.00 g; HjO, 1000 ml). The tubes containing plasma or RBC suspension
plus butylated hydroxytoluene (as an antioxidant) were closed under a stream of
nitrogen to prevent oxidation and stored at -80°C until analysis. At the start of
the analysis, 1,2-cr-dinonadecanoyl phosphatidylcholine (PC-( 19:0)2) and 10-
heptadecenoic acid (C17:1) was added to every sample as an internal standard.
Total lipid extracts of plasma and RBC were prepared using a modified Folch
extraction; 200 /yl samples of plasma or RBC suspension were added to 3 ml
methanol-chloroform (1:2, vokvol)^*". The phospholipid fraction was isolated
by solid phase extraction on an aminopropyl-silica column^. The plasma
phospholipids were saponified and the fatty acids were converted to the
corresponding methyl esters by reaction with 14% boron trifluoride (BF3) in
methanol at 100°C for one hour". Fatty acid methyl esters were analyzed with
a temperature-programmed Gas Chromatograph-Flame lonization Detector on a
50m x 0.25 mm CP-Sil 5 CB, df = 0.12 //m column (Chrompack®, Middelburg,
The Netherlands), using Nj as the carrier gas.
In total, 27 fatty acids were identified. The following fatty acid combinations
were recorded: I SAFA (sum of all saturated fatty acids), IMUFA (sum of all
monounsaturated fatty acids), and ZPUFA (sum of all polyunsaturated fatty
acids). In addition, the following indices were calculated: the unsaturation index
(Ul), which is defined as the sum of the number of double bounds multiplied by
the percentage of fatty acids; the saturation index (SI), which is the sum of all
saturated fatty acids divided by the unsaturation index; EFA status (Zn-6 + n-
3/In-7 + n -9 ) " " . Fatty acids percentages < 0 . 1 % were not recorded. The
amounts of the various fatty acids were expressed as percentages (wt/wt). In
controls, fatty acid pattern was assessed only in plasma phospholipids.
D/efa/y
Dietary intake was assessed using a food-frequency questionnaire (FFQ)^°. The
FFQ was specifically developed to assess the dietary intake of fat (total fat,
saturated fatty acids (SAFA), mono-unsaturated fatty acids (MUFA),
polyunsaturated fatty acids (PUFA), linoleic acid (LA) and antioxidants Off-
carotene, vitamin C and zinc) over the previous month. All types of food and
drink were coded by an experienced dietician according to the system used by
the Netherlands Nutrient Databank (NEVO), and subsequently converted into
nutrients by using the extended computerised version of the Netherlands Food
Table^V Dietary intake data were not available from control subjects.
Statistical analysis
Data are expressed as median (25th and 75th percentile) or as indicated.
Differences in antioxidant status and fatty acid profile between groups were
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analyzed using the Krusal Wallis test, adjusting for multiple comparisons. If
variables showed statistical significance, the Mann-Whitney U test was used to
analyze these differences between the three different groups. The Wilcoxon
matched-pairs signed-rank test was used to test differences in variables
between those CD patients who were investigated twice, i.e., during an episode
of exacerbation and after they went into remission (paired analysis). The
relations between antioxidant parameters, disease activity and plasma
phospholipid fatty acid pattern were multivariately assessed by stepwise
multiple linear regression analyses. All statistical analyses were performed with
the SPSS 7.0 for Windows package (SPSS Inc, Chicago).
Results
Disease activity was significantly lower in patients with inactive disease
compared with active disease, as was indicated by significantly lower levels of
C-reactive protein, ESR and the van Hees index (P<0.001) (Tables 8.1 and
8.2).
Antioxidant status
Serum /?-carotene concentration was significantly (P<0.02) lower, while copper
concentration and SOD activity were significantly (P<0.05) higher in patients
with active CD compared with patients with inactive CD (Table 8.3). Vitamin A,
/ff-carotene, vitamin C, selenium concentrations and GpX activity were
significantly lower in patients with active disease compared with controls.
In patients with inactive CD, ^-carotene, vitamin E, vitamin C, zinc, selenium
concentrations and the activity of GpX were significantly (P<0.05) lower than
in controls (Table 8.3).
The paired analysis of CD patients who went into remission after an episode
of exacerbation (n = 8) is shown in Figure 8.1: copper concentration decreased
significantly (28.5 //mol/L (22.4-38.8) to 21.2 /vmol/L (19.6-27.0)), while
concentrations of ^-carotene and vitamin A increased significantly after patients
went into remission.
We found cholesterol concentrations of 5.0 /vmol/L (3.1-5.7), 4.4 //mol/L (3.7-
5.1), and 5.3 yumol/L (4.5-6.3) in patients with active CD, inactive CD and
controls, respectively. The ratio of vitamin E to cholesterol was significantly
(P<0.01) lower in patients with inactive CD (6.5 //mol/g (5.7-7.8)) compared
with controls (6.0 /ymol/g (5.1-6.8)), but did not significantly differ between
active CD (6.4//mol/g (5.0-9.0)) and inactive CD or controls, respectively.
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Table 8.3 Antioxidant parameters in patients with active Crohn's disease (CD), inactive CD and controls'
Vitamin A (//mol/L)
/?-Carotene (//mol/L)
Vitamin E (//mol/L)
Vitamin C (//mol/L)
Copper (//mol/L)
Zinc (//mol/L)
Selenium (//mol/L)
SOD (U/mmol Hb)
GpX (U/mmol Hb)
active CD
(n = 12)
1.80 (1.33-2.48)
1.04 (0.71-1.54)
30.0(25.3-33.5)
23.0(16.0-50.0)
26.2 (21.3-38.8)
10.9 (10.3-14.4)
0.80 (0.69-0.92)
16.9 (15.0-20.2)
746 (658-1012)
P-value*
0.23
0.017
0.98
0.07
0.009
0.57
0.20
0.035
0.45
inactive CD
(n = 50)
2.25 (1.80-2.83)
1.74 (1.28-2.45)
29.0 (23.8-34.0)
38.0 (26.8-57.0)
19.9 (17.1-23.7)
12.4 (10.8-13.5)
0.87 (0.76-1.02)
15.5 (13.8-17.3)
815 (707-945)
P-value**
0.11
0.003
0.05
0.002
0.14
0.007
0.000
0.002
controls
(n = 70)
2.40 (2.00-3.00)
2.24 (1.80-2.86)
31.0 (27.0-38.3)
54.0 (40.8-70.0)
18.0 (15.1-25.2)
13.1 (12.2-13.9)
1.00 (0.89-1.12)
NR
972 (784-1163)
P-value* • •
0.03
0.000
0.20
0.001
0.007
0.06
0.000
-
0.02
Data are expressed as median; 25th-75th percentiles in parentheses.
SOD: Superoxide dismutase; GpX: glutathione peroxidase; Hb: hemoglobin; NR: not assessed.
P-value*: significance levels for difference in antioxidant parameters between CD patients with active
with inactive disease (Mann-Whitney U test); P-value**: inactive CD patients compared with controls;
CD patients compared with controls.
disease and those
P-value* * * : active
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Figure 8.1 Serum antioxidant parameters in CD patients (n = 8) during an episode of
exacerbation (active) and during subsequent remission (inactive); TAS (total
antioxidant status) was assessed using the Randox Total Antioxidant Status Kit
(RANDOX Laboratories Ltd., Antrium, United Kingdom).
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Plasma phospholipid fatty acid profile in patients with active CD significantly
differed from that of patients with inactive CD and controls (Table 8.4). ISAFA
and the SI were significantly (P<0.01) higher in patients with active CD
compared with inactive disease and controls. Linoleic acid (18:2n-6), IPUFA,
Ul, and EFA index were significantly (P<0.05) lower in patients with active CD
compared to inactive CD and controls.
In patients with inactive CD, ISAFA and SI were significantly higher, while
arachidonic acid (20:4n-6), a-linolenic acid (18:3n-3), Ul and EFA index were
significantly lower than in controls.
The paired analysis in CD patients who went into remission after an episode
of exacerbation (n = 8) showed a trend similar (Table 8.5) to the results of the
comparison between active and inactive CD patients.
The multiple linear regression equations obtained to predict the values of
different fatty acids indices of plasma phospholipids in CD patients are shown in
Table 8.6. After adjusting for the linear effects of all the serum antioxidants,
serum /?-carotene and vitamin E concentrations and GpX activity were
significantly correlated with IPUFA and EFA status, respectively. However,
serum yS-carotene and vitamin E concentrations were inversely related to
IMUFA. Furthermore, disease activity measured by CRP levels, and age were
inversely related to IPUFA and ISAFA, respectively.
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Table 8.4 Fatty acid profile of plasma phospholipids (% of total fatty
inactive CD and controls
Q,f ptWfm Wt:h s.:
active CD
(n = 10)
P-value* inactive,
Total lipid (mg/L)
18:2n-6
20:4n-6
18:3n-3
2O:5n-3
22:6n-3
ZSAFA
ZMUFA
ZPUFA
SI
Ul
EFA index
1377 (1106-1614)
20.4 (18.0-22.3)
8.79 (8.07-9.06)
0.16(0.14-0.27)
0.46 (0.34-0.62)
2.70 (1.70-3.22)
49.0 (47.7-50.2)
11.6 (11.1-13.1)
37.6 (36.6-39.1)
0.40 (0.38-0.43)
121 (117-125)
3.17 (2.74-3.42)
0.27
0.007
0.36
0.60
0.06
0.82
0.003
0.09
0.001
0.003
0.02
0.02
1255 (1064=1 Hii:i
23.2 (20.Ö-H.4)
8.17(7.11,1, !^
0.19 (0.14-ij. j i i
0.62 (0.45-0,931
2.56 (2.16,WÜÜ
47.2 (46.4-4M)
11.2 (1O.4=13,1|
40.3 (39.2-41JI
0.37 (0.350JÜI
129 (123 193)
3.52 (3.22-3J3)
«-.98
8,19
0,04
e,s*
0,00«
0,00?
0,*0
0,1?
0,000
0,000
0,90
ii,«<&&3&n <a,^
# ,1^M%,1§J^ e.M
Q,«l {(3,43,0,?«t ^ ft,ill
3,1H ö: ,4 i ,S,« ft.,13.
41,« (;4&*4?.J! QaQQ
1V» (10*14,811 Q,S«
134 H 31 -14«! <Si,TO'
Data are expressed as median; 25th-75th percentiles in parentheses.
ZSAFA: sum of all saturated fatty acids; ZMUFA: sum of all monounsatur§ted fatty SlildSJ JEPUFA! »Mm «I
fatty acids; Ul: sum of (number of double bounds X percentage of fatty aeiffi!)),: SI; sum Of «ill S3t:W«tef) fatty
unsaturation index; EFA index (essential fatty acid status): In-6 + n-3/In-7 + tv§,
P-value*: significance levels for difference in antioxidant parameters between CO patient» With SBtiV«
with inactive disease (Mann-Whitney U test); P-value**: inactive CD paticint.» TOmpafB«! With
CD patients compared with controls.
8Table 8.5 Fatty acid profile of plasma phospholipids (%
an episode of exacerbation of Crohn's disease
of total fatty acids) of patients during
(CD) and subsequent remission'
Exacerbation (n = 8) Remission (n = 8)
Total lipid (mg/L)
18:2n-6
20:4n-6
18:3n-3
20:5n-3
22:6n-3
ZSAFA
ZMUFA
IPUFA
SI
Ul
EFA index
1343 (1146-1499)
20.7(18.8-22.7)
8.41 (7.61-8.99)
0.16 (0.15-0.50)
0.37 (0.33-0.50)
2.96(2.38-3.21)
49.2 (48.1-50.5)*
11.6 (11.2-13.0)*
37.7 (35.7-39.1)
0.40 (0.39-0.44)*
120 (114-123)
3.23 (2.76-3.38)
1202 (1170-1453)
23.1 (22.5-25.6)
7.57 (6.98-9.80)
0.22 (0.16-0.32)
0.65 (0.40-0.81)
2.87 (2.56-3.08)
46.5 (45.7-48.6)
11.2 (10.5-11.8)
39.8 (38.2-41.8)
0.37 (0.35-0.40)
129 (118-132)
3.53 (3.22-3.93)
' Data are expressed as median; 25th-75th percentiles in parentheses.
Abbreviarions as in Table 8.4.
*P = 0.07 for difference between exacerbation and remission (Wilcoxon matched-pairs signed-
rank test).
Table 8.6 Summary of multiple regression equations assessed in patients with Crohn's
disease
IPUFA
IMUFA
ISAFA
EFA index
Multiple
R
0.66
0.49
0.49
0.57
regression equation
P-value
0.000
0.000
0.000
0.000
Covariates
Age
^-carotene
CRP
GPX
Vitamin E
Constant
/?-carotene
Vitamin E
Constant
CRP
Constant
/S-carotene
GPx
Vitamin E
Constant
Beta
-0.25
0.22
-0.33
0.28
0.23
36.45
-0.37
-0.28
13.93
0.49
46.91
0.36
0.31
0.23
1.85
P-value
0.024
0.049
0.003
0.01
0.039
0.000
0.002
0.019
0.000
0.000
0.000
0.002
0.008
0.046
0.000
ISAFA: sum of a// saturated fatty acids; IMUFA: sum of a// monounsaturated fatty acids;
IPUFA: sum of a//polyunsaturated fatty acids; EFA index (essential fatty acid status): In-6 + n-
3/In-7 + n-9; CRP: C-reactive protein; GpX: glutathione peroxidase.
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In controls, the multiple linear regression analysis did not show any
significant correlations between antioxidant concentrations and fatty acid
pattern.
Fatty acid profile of red blood cell phospholipids
We did not observe any significant differences in the fatty acid profile in red
blood cell phospholipids. However, a trend similar to that for plasma
phospholipids was found between patients with active and inactive CD. In
particular, linoleic acid and the EFA index were lower (P = 0.08) in active CD
(11.3 (10.5-11.8); 1.60 (1.50-1.67), respectively) compared with inactive CD
(12.9 (11.9-13.4); 1.82 (1.50-1.91), respectively) and the sum of MUFA was
higher (P = 0.08) in active CD (20.1 (19.2-21.1) than in inactive CD (19.0
(18.4-20.5)).
Dietary intake
We did not observe any significant differences in dietary intake between
patients with active and inactive CD (Table 8.7).
In 6 CD patients, dietary intake data were available during an exacerbation of
CD and subsequent remission. The absolute intake of total fat, SAFA, MUFA,
and PUFA did not significantly differ between patients with an exacerbation and
subsequent remission; total fat intake 69.8 g (59.4-101) during exacerbation
and 100 g (67.6-142) during remission; SAFA intake 25.7 g (19.9-43.6) and
35.8 g (20.9-48.6); MUFA intake 26.0 g (21.1-33.9) and 39.5 g (26.4-63.6);
PUFA intake 14.6 g (11.4-17.6) and 18.7 g (11.4-28.8), respectively.
Table 8.7 Dietary intake of patients with Crohn's disease (CD)'
patients with active CD patients with inactive CD
(n=10) (n = 45)
Total fat (g) 79.7(60.1-96.8) 97(74.8-124)
SAFA (g) 30.5 (20.2-39.8) 35.9 (27.8-47.4)
MUFA (g) 30.0(21.5-35.4) 35.1(28.2-48.1)
PUFA (g) 12.8(11.7-18.2) 17.5(12.2-22.4)
Linoleic acid (g) 9.8(8.7-14.8) 13.3(9.0-19.4)
^-Carotene (mg) 0.52 (0.32-0.86) 0.50 (0.34-0.75)
Vitamin C (mg) 58.1(22.3-89.9) 59.1(35.2-104)
Zinc (mg) 8.5(7.3-9.6) 8.8(7.2-10.9)
' Data are expressed as median; 25th-75th percentiles in parentheses. SAFA: saturated fatty
acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.
136
Chapter S
Discussion
The present study revealed a diminished antioxidant defense in patients with
active CD compared with CD patients who were clinically in remission. The
plasma phospholipid fatty acid profile differed significantly between patients
with active compared with inactive disease, as was illustrated by the increased
sum of the saturated fatty acids, the decreased sum of the unsaturated fatty
acids and the decreased EFA status in the former group. A similar trend of
changes in antioxidant defense and fatty acid profile was observed for CD
patients during exacerbation and subsequent remission. Furthermore, serum
concentrations of several antioxidant parameters as well as disease activity
were significantly correlated to the plasma phospholipid fatty acid profile in CD
patients.
The observed lower concentrations of antioxidants in patients with active CD
could be explained by a reduced dietary intake, resulting from postprandial
abdominal p a i n " " . In the present study, however, the dietary intake of
antioxidants did not differ significantly between active and inactive CD patients,
which may be due to the small group studied (y?-error). In addition, in these
patients, the dietary intake of the previous month was assessed by a food
frequency questionnaire. Patients were studied in an early phase of the
exacerbation and hence the 48-hr recall method would be more appropriate to
assess the dietary intake in these patients". In a previous study we showed
that the intake of antioxidants did not significantly differ between CD patients
clinically in remission and controls". Besides impaired absorption of nutrients in
CD (small bowel resection and/or mucosal damage)", intraluminal factors may
also play a role in the decreased absorption of antioxidants. Divalent cations
such as magnesium, selenium, or zinc may form unabsorbable subcomplexes
with malabsorbed fats^.
An important factor in the diminished antioxidant defense in active CD
patients compared with CD patients with inactive disease may be the increased
utilisation of antioxidants because of increased oxidative stress. The present
study confirmed that the antioxidant status is significantly lower in patients
with active CD and even in CD patients who were clinically in remission
compared with controls®". It could be argued that low levels of endogenous
antioxidants which are found in patients with inactive CD, may increase
oxidative damage and possibly promote inflammation. Under normal
circumstances, the production of reactive oxidative species (ROS) and the
antioxidant defense are in balance. Excess ROS production may overwhelm the
endogenous antioxidant defense system, particularly in the presence of an
antioxidant deficiency.
Maintaining an adequate antioxidant status has been suggested as a useful
approach to attenuate the cellular injury and dysfunction observed in CD.
Antioxidant administration has been successful in experimental models of
intestinal inflammation"^. In a recent study, it was shown that antioxidants
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inhibit />? wfro production of inflammatory cytokines in IBD patients". We
recently showed that antioxidant status was significantly improved in patients
receiving antioxidant supplementation for three months in addition to their
regular diet*°. It remains to be determined whether antioxidant supplementation
will have any effect on the course of the disease in CD patients.
In the present study, SOD activity in whole blood was significantly increased
in patients with active CD compared with inactive disease. One other study also
found increased activity of SOD in patients receiving lipid-based home parenteral
nutrition*'. SOD can be induced rapidly after exposure to oxidative stress, such
as lipid peroxidation. Other studies have found reduced levels of SOD and
copper in inflamed intestinal tissue from IBD patients***^. Copper and zinc are
co-factors for the intracellular cytosolic copper-zinc SOD enzyme. It has been
shown that copper deficiency reduces the activity of SOD in the liver and the
lung". The increased serum copper concentration observed in CD patients with
active disease in our study may be explained by the increased production of the
acute-phase protein ceruloplasmin*^. However, this could not explain the higher
SOD activity, as ceruloplasmin is found in blood plasma and extracellular fluids
and is not part of the exchangeable copper plasma pool. The increased SOD
activity in these patients, in the presence of sufficient copper, may be caused
by increased requirements due to oxidative stress related to inflammation.
In a previous study we reported an aberrant fatty acid profile in CD patients
who were clinically in remission, and showed that the disturbed fatty acid
pattern was a result of altered metabolism rather than of essential fatty acid
malabsorption*®. The results of the present study confirmed these findings and
showed that the fatty acid pattern was even more disturbed in patients with
active CD than in inactive CD patients compared to controls.
Conditions of oxidative stress may accelerate the consumption of PUFAs,
which are the main target of lipid peroxidation*'. It has been suggested that the
presence of antioxidants might influence fatty acid composition because they
prevent lipid peroxidation in cell membranes". In the multivariate analysis, we
did indeed find significant correlations between fatty acid indices in plasma
phospholipids and several antioxidants in CD patients, however, not in controls.
In the patients, the sum of PUFA was significantly related to the concentrations
of /?-carotene, vitamin E and the activity of the enzyme glutathione peroxidase,
which are all essential in the control of membrane damage initiated by free
radicals'*.
Vitamin E and /S-carotene concentrations were inversely related to the sum of
MUFA in plasma phospholipids. It has been hypothesized that patients with
essential fatty acid deficiency compensate by producing more MUFAs", which
means that essential fatty acids are substituted by MUFAs in an attempt to
maintain membrane fluidity. In the present study, patients with active CD
showed a significantly lower essential fatty acid status compared with inactive
disease and controls. This observation along with the above hypothesis may
explain the inverse relation between antioxidants and MUFA.
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Selenium was not found to be associated with the fatty acid pattern in CD
patients. In a study of healthy subjects, however, selenium was significantly
related to the percentages of EFA and n-6PUFA'^. The significant number of
subjects with marginal selenium status may explain the discriminant role of
selenium in that study. Serum selenium concentrations of CD patients in the
present study, including patients with active CD, as well as the selenium
concentrations reported in another Dutch study on antioxidants and
cardiovascular mortality*®, were higher than those in the healthy subjects in the
study by Cabre et al^. It is also known, that antioxidant defenses are highly
interactive; vitamin E, vitamin C and glutathione are integral components of a
regenerating redox cycled Selenium is a co-factor for the enzyme glutathione
peroxidase and is of major importance in the overall mechanism protecting
against oxidative stress^. A change in any of these antioxidants may be
counter-balanced by alterations in the others. The multivariate regression
analysis used in the present study showed the individual antioxidants which
may contribute to the aberrant fatty acid profile in CD patients.
In a study by Esteve-Comas et al^°, the most important factor influencing
plasma fatty acid profile in IBD was the activity of the disease, but they did not
assess antioxidant parameters in their group of patients. Our results also show
that disease activity, as measured by C-reactive protein level, was inversely
correlated with the sum of PUFA, SAFA, n-6 fatty acids and linoleic acid. The
Van Hees index was not associated with the fatty acid profile in CD patients.
We studied patients with active CD in an early phase of the exacerbation. It is
known that the synthesis of C-reactive protein is extremely rapid during the
onset of an inflammatory response, while changes in ESR and albumin
(important factors contributing to the Van Hees index) due to inflammation
progress slower*'. This may explain the significant correlation between C-
reactive protein levels and changes in fatty acid profile in CD patients in spite of
the lack of correlation with the Van Hees index.
The fatty acid pattern in red blood cell phospholipids did not significantly
differ between patients with active and inactive CD. Patients with active CD
were studied in an early phase of the exacerbation episode. Hence, it is possible
that changes in the fatty acid profile were not found because lipid turnover and
fatty acid changes in this compartment are slower and are rather a marker of
the long-term fatty acid pattern.
To summarize, this study showed that changes in plasma phospholipid fatty
acid profile were significantly related to several serum antioxidants and disease
activity in CD patients. Furthermore, it was shown that the deteriorated
antioxidant status may contribute to the imbalance of antioxidant defense and
ROS production in CD patients. These results suggest that antioxidants may
play an important role in the pathophysiology and potentially also in the
treatment of CD inflammation.
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Abstract
Background
In patients with Crohn's disease (CD), malnutrition is frequently observed and is
generally accepted to be an important issue. The aim of this study was to investigate
the effects of 3 months of supplementation with a liquid formula containing either
antioxidants or n-3 fatty acids plus antioxidants on nutritional status and fatty acid
profile of plasma phospholipids and adipose tissue, respectively in patients with long-
standing CD currently in remission.
Patients and methods
In a randomized, double-blind placebo-controlled study, CD patients received either
placebo, antioxidants, or n-3 fatty acids plus antioxidants for three months in addition
to their regular diet. In all, 25/37 CD patients completed the study. Nutritional status
was assessed by body composition, dietary intake, biochemical parameters and muscle
strength. A statistical per-protocol analysis was performed.
Results
Antioxidant status was significantly (P<0.05) improved and muscle strength was
significantly (P<0.05) restored after supplementation with n-3 fatty acids and/or
antioxidants. n-3 Fatty acids plus antioxidants supplementation significantly (P<0.05)
decreased the proportion of arachidonic acid, and increased the proportion of
eicosapentaenoic acid and docosahexaenoic acid in both plasma phospholipids and
adipose tissue.
Conclusions
Supplementation with n-3 fatty acids and/or antioxidants improved nutritional status
and antioxidant status in patients with CD in remission. In addition, supplementation
with n-3 fatty acids plus antioxidants significantly changed the eicosanoid precursor
profile, which may lead to the production of eicosanoids with attenuated
proinflammatory activity. This study indicates that an immunomodulating formula
containing n-3 fatty acids and/or antioxidants may have the potential to play a role in
the treatment of CD.
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Introduction *ir.v; «s
Crohn's disease (CD) is a chronic inflammatory process of unknown etiology,
which may affect any part of the gastrointestinal tract. Malnutrition and nutrient
malassimilation have often been described as a consequence of substantial
inflammation and of malabsorption, especially in patients with active C D ' " .
In a recent study, we assessed a comprehensive nutritional status in patients
with long-standing (>10 years) CD, clinically in remission, and observed a
variety of nutritional and functional deficiencies'*. Moreover, a deteriorated
antioxidant status, which may negatively affect the inflammatory process, was
evident in this group of CD patients compared with matched healthy controls.
It has been shown that nutritional deficiencies are associated with reduced
immunological competence in CD patients"'*. Nutritional support may therefore
be an important therapeutic tool in regulating the inflammatory process. Studies
reported beneficial effects of immunomodulating nutrients, e.g. fish oil, by
modifying cell membrane structure and by altering eicosanoid metabolism in CD
patients'^'^ or by improving host immune response in intensive care unit
patients with trauma, sepsis or cancer"*".
Two studies have so far examined whether orally administered fish oil could
prolong remission in CD patients, but results have been contradictory'"'. A
German study showed no significant effects of fish oil *', while an Italian study
found that an increased percentage of fish oil treated CD patients remained in
remission compared to placebo'*. However, the mechanism by which fish oil
may exerts its effect is still unknown, and it remains to be established whether
the possible beneficial effects of n-3 fatty acids supplementation in CD patients
are caused by the change of fatty acid profile and the subsequent shift to the
less inflammatory active 5-series leukotrienes at the expense of the 4-series
leukotrienes.
Antioxidants have been used successfully in experimental models of
intestinal inflammation**. Recently, it was shown that the antioxidants butylated
hydroxyanisol, tetrahydropapaveroline and nordihydroguaiaretic acid inhibit in
vitro production of inflammatory cytokines in CD and ulcerative colitis
patients*"'. It is unknown whether supplementation with dietary antioxidants
may improve the deteriorated antioxidant status of CD patients. Furthermore, it
would be interesting to know whether immunomodulating supplements, e.g.
fish oil or antioxidants, may improve the nutritional status of CD patients.
As disease activity and nutritional status are highly correlated**, the above
question should be studied in CD patients without disease activity. The aim of
the present study was to investigate effects of a liquid supplement during 3
months containing either antioxidants or antioxidants plus n-3 fatty acids in
addition to a regular diet in patients with long-standing CD, clinically in
remission, with as primary endpoints effects on the nutritional status and the
fatty acid profile.
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Subjects and methods
The study protocol had been approved by the Ethics Committee of the
University Hospital Maastricht and all patients gave their informed consent
before the start of the study.
Study design
A randomized double blind, placebo controlled study design was used. The
nutritional supplements were orally administered for three months in addition to
the patients' regular diet. The composition of the isocaloric nutritional
supplements is shown in Table 9.1. The patients were instructed to take 2
sachets a day. Nutritional status, fatty acid composition of plasma
phospholipids and adipose tissue, disease activity, lipid peroxidation, and quality
of life were assessed before and after 3 months of supplementation. During the
study, patients were monitored by routine visits to the Gastroenterology
outpatient department and by telephone calls. In addition, compliance was
assessed by checking a patient diary and by counting returned sachets of the
nutritional supplement each month.
Patients
Outpatients of the department of Gastroenterology who met the inclusion
criteria of having suffered from small bowel CD for more than 5 years, and who
were clinically in remission were consecutively asked to participate in the study.
The diagnosis of CD was based on the criteria developed by Lennard-Jones".
Thirty-seven patients were first stratified by sex and age and then randomly
assigned to receive either placebo, the antioxidants formula, or the n-3 fatty
acids plus antioxidants formula (IMPACT*) (Table 9.1). During the study, 10
patients (3/14 males and 7/23 females) dropped out because of diarrhea (n = 2),
dyspepsia (n = 4) or intolerance due to satiety induced by the supplement
(n=4). However, the drop-out rate was not specific for any of the nutritional
supplements (4 patients who were assigned to the placebo treatment, 3
patients who received the antioxidant formula and 3 patients who were
assigned to the n-3/antioxidant formula did not complete the study). Two other
patients were excluded from the study due to an exacerbation of CD (n = 1) or
intercurrent gastritis (n = 1). In all, 25 patients (15 females, 10 males)
completed the study (median age 41 years (32-53)). Characteristics of the
patients before supplementation are shown in Table 9.2. Treatment groups did
significantly differ in disease duration, but were comparable for other variables.
Medical treatment was not changed during the study period.
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Table 9.1 Composition of the supplements (1
Content
Energy
- Protein/fat/carbohydrates
Protein
- whey-protein
- L-arginine
Fat ;. .
- n-6 FS (LA)
- SAFA
- MUFA
- PUFA
- n-3 FS (EPA + DHA + INS)
Carbohydrates
Lactose
Fiber
Calcium
Magnesium
Copper
Zinc
Selenium
Vitamin A
- from ^carotene
Vitamin D3
Vitamin E
- as antioxidant
Vitamin K
Thiamin
Riboflavin
Pyridoxine
Vitamin C
- as antioxidant
Folic acid
g
kcal
%
g
0
a
g
g
g
g
g
g
g
g
g
ma
mo
mg
mg
X*l
mg
mg
Ml
mg
mg
«J
mg
mg
mg
mg
mg
/;g
sachet)
Placebo
74
306
18/24/57
13.6
13.6
-
8.5
3.00
3.9
1.6
3.0
0.05
43.8
0.68
2.7
251
71
0.003
0.005
0.02
-
0.02
-
3.3
3.1
0.20
1.16
0.31
4.5
-
60
Antioxidants
74
307
18/24/58
13.7
13.7
8.5
3.00
3.9
1.5
3.0
0.05
44.0
0.68
2.7
251
71
0.55
4.6
12.4
0.38
0.15
1.3
4.0
17.0
21
0.61
1.70
0.81
20
86
124
n-3 FA/AO (IMPACT®)
74
324
21/24/55
17.4
13.7
3.7
8.5
0.86
4.6
1.7
1.9
1.02
44.5
0.68
2.9
259
75
0.55
4.6
12.4
0.38
0.15
1.4
4.0
16.2
19.4
0.62
1.70
0.81
20
88
124
FA: fatty acids; AO: antioxidants; SAFA: saturated fatty acids;
PUFA: polyunsaturated fatty acids; LA: linoleic acid (18:2n-6);
eicosapentaenoic acid; DHA: docosahexaenoic acid.
MUFA: monounsaturated fatty acids;
LNS: o-linolenic acid (18:3n-3); EPA:
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Table 9.2 Characteristics of patients at the start of the study
Placebo Antioxidants n-3 FA/AO
(n = 8) (n = 8) (n = 9)
Gender (F/M)
Age' (years)
BMI (kg/m*)'
Disease duration' (years)
CDAI'
C-reactive protein' (mg/U
Medication - mesalazine
- azathioprine
- prednisone
Smoking
6/2
38(30-61)
23.8 (20.3-30.8)
16.0 (11.5-18.5)
79 (47-120)
7.0(2.0-15.0)
n = 5
n=1
n = 1
n = 3
4/4
43 (33-52)
21.2 (19.4-26.2)
20.5 (11.8-31.3)*
119 (37-152)
8.5 (7.0-13.0)
n = 7
n = 2
n - 2
n = 7
41
22.1
11.0
99
10.0
5/4
(31-56)
(19.2-25.4)
(9.0-13.5)
(70-169)
(4.0-11.5)
n = 9
n = 3
n = 3
n = 6
' Data are expressed as medians; 25'" and 75'" percentile in parentheses. j
BMI: body mass index; CDAI: Crohn's disease activity index; FA: fatty acids; AO: ;
antioxidants. . , .7
* Significantly different from other treatment groups (Chi-square): P<0.05.
Nutritional status
The nutritional status assessment comprised assessment of body composition,
dietary intake, biochemical parameters of nutrition and muscle strength as a
functional parameter. All measurements were performed during one day, after
an overnight fast. .;
Body height (BH) was measured to the nearest millimeter using a wall-mounted
stadiometer, while body weight (BW) was measured using an electronic scale
with a digital readout to an accuracy of 0.01 kilogram. Body mass index (BMI)
was calculated from weight and height (kg/m*). Body fat, fat-free mass, and
percentage body fat were determined using a dual-energy X-ray absorptiometer
(DPX-L, Lunar Corp., Madison, Wl; using DPX-L 1.3 software)". A total body
scan over the entire length of a subject's body was performed. Any materials
that could attenuate the X-ray beam, e.g. jewelry, watches or clothing with
zippers, were removed before the examination.
D/era/y
Regular dietary intake was assessed using a food-frequency questionnaire
(FFQ)". The FFQ dealt specifically with the dietary intake of fat (total fat (TF),
saturated fatty acids (SAFA), mono-unsaturated fatty acids (MUFA),
polyunsaturated fatty acids (PUFA) and linoleic acid (LA)) and antioxidants Off-
carotene, vitamin C and zinc) over the previous month. All types of food and
drink were coded by an experienced dietician according to the system used by
the Netherlands Nutrient Databank (NEVO), and subsequently converted into
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energy and nutrients using the extended computerized version of the
Netherlands Food Table".
a/73/yses
After an overnight fast, a venous blood sample (90 ml) was obtained and plas-
ma and serum were stored at -80°C until analysis. Serum cholesterol, total
protein, magnesium and whole blood thiamin were determined by routine
methods in use at the hospital, on a Beckman Synchron CX* system (Brea, CA,
USA). Serum pre-albumin was measured using a radioimmunodiffusion
technique (Beckman immunochemistry systems (Brea, CA, USA). Antioxidant
status was assessed by serum concentrations of copper, zinc, selenium, vitamin
A and E, /?-carotene and by the activities of the enzymes glutathione peroxidase
(GpX) and Superoxide dismutase (SOD). In addition, total antioxidant status
(TAS) was measured using the Randox Total Antioxidant Status Kit (RANDOX
Laboratories Ltd., Antrium, United Kingdom). Serum copper, zinc and selenium
were determined by Zeeman-corrected electrothermal atomic absorption
spectrometry. The assessment of whole blood activity of GpX was based on the
method developed by Paglia and Valentine**, and the activity of SOD was
assessed using a RANSOD kit (RANDOX Laboratories Ltd., Antrium, United
Kingdom). Vitamins A and E (o-tocopherol) were determined with High Pressure
Liquid Chromatography (HPLC) and /?-carotene by spectrophotometric
assessment at 450 Nm.
Mt/sc/e
Strength of extensor (quadriceps) muscles (mm. vastus lateralis, vastus
medialis, vastus intermedius and rectus femoris), and flexor (hamstrings)
muscles (mm. biceps femoris, semi tendinosis and semi membranosis) were
measured using an isokinetic dynamometer (Cybex II, Eagle Performance
Systems, Owatonna, MN) with angular velocities of 60 and 180°/s^°. Peak
torque (PT) was determined from a fivefold measurement at each angular
velocity. In addition, the strength of m.quadriceps and hamstrings was assessed
in 25 population controls (15 females and 10 males), matched for age and sex
with the CD patients (median age 40 years(33-53)). Controls were randomly
selected from the population database of a general practitioner in the same
study area.
Fafry ac/tfs ana/ys/s
Adipose tissue biopsies were taken by needle biopsy from the outer quadrant of
the right buttock and samples were stored at -80°C until analysis (<3 months).
Fatty acid composition of plasma phospholipids and adipose tissue was
analyzed as described by AI et a l ' \ The amounts of the various fatty acids are
expressed as percentages (wt/wt). --v : . •, :• •;.' ••••'; ^ ; ' \ '" y -
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Disease activity M*-" >-••" . -•
Disease activity was assessed according to the Crohn's disease activity index
(CDAI) at the time of the nutritional assessment". In addition, C-reactive protein
(CRP) was determined by routine methods in use at the hospital, on a Beckman
Synchron CX* system (Brea, CA, USA).
Lipid peroxidation ' '
Lipid peroxidation was determined by means of the thiobarbituric acid (TBA)
reaction described by Naito et a l " . The TBA reaction is a reaction between TBA
and malondialdehyde, which is produced from lipoperoxides during heating. TBA
reactive substances (TBARs) were measured at 535 Nm.
Quality of life
Quality of life was measured using the validated Dutch version of the
Inflammatory Bowel Disease Questionnaire (IBDQ)^*. It considers the patient's
situation over the preceding two weeks and includes 32 questions, grouped into
four dimensions: "bowel symptoms" (10 items), "systemic symptoms" (5
items), "emotional function" (12 items) and "social function" (5 items).
Response options are consistently presented as seven-point Likert scales in
which '7 ' represents best function and ' 1 ' represents worst function. Thus, the
maximum (best) total IBDQ score is 224.
Statistical analysis
Data are expressed as median (25th and 75th percentile) or as indicated. The
effects of nutritional supplementation on the various variables were analyzed
using a Wilcoxon matched-pairs signed-rank test. Spearman's correlation
coefficients were calculated by linear regression analysis. Data in figures are
presented in Box & Whiskers plots: median (line in box), 25th and 75th
percentile (box) and range (minimum and maximum value). The results were
analyzed by means of a 'per-protocol analysis', because the physiological
effects of 3 months of nutritional supplementation were assessed. All statistical
analyses were performed with the SPSS 7.0 for Windows package (SPPS Inc,
Chicago).
Results
Nutritional status
compos/f/on
Table 9.3 shows the body composition results, before and after 3 months of
supplementation, for the three different treatment groups. After 3 months of
supplementation, body weight as well as body fat were significantly (P<0.05)
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increased in patients receiving placebo and n-3 fatty acids plus antioxidants,
whereas FFM and percentage body fat had not significantly changed after
supplementation. No significant body composition changes were observed in
patients supplemented with the antioxidants formula.
D/efa/y //?fa/re ^ >• ;' ,,'
Table 9.4 shows fat intake (regular fat intake of the diet assessed by FFQ and
the fat amount in the supplement). Regular fat intake significantly (P<0.05)
decreased in patients receiving placebo or antioxidants. In patients receiving
placebo or n-3 fatty acids plus antioxidants, total fat intake (regular +
supplement) had increased after 3 months of supplementation. After
supplementation with antioxidants, total fat (regular + supplement) intake had
decreased. Total SAF intake (regular + supplement) had significantly increased
in patients receiving n-3 fatty acids plus antioxidants. However, between
treatment groups, we observed no significant differences in the various (SAFA,
MUFA, PUFA or LA) total fatty acid intakes (regular fat intakes + amounts in
the supplements) after 3 months supplementation.
Regular antioxidant intake had not changed significantly in either group after
3 months supplementation. Hence, total antioxidant intake (regular intake +
amounts in the supplement) increased significantly in patients receiving either
antioxidants or n-3 fatty acids plus antioxidants (Table 9.4).
ß/'oc/7em/ca/ parameters of ni/fr/Y/o/7
Results regarding the biochemical parameters of nutrition are shown in Table
9.5. Serum vitamin E and vitamin C concentrations and whole blood SOD
activity increased significantly in the patients supplemented with either
antioxidants or with n-3 fatty acids plus antioxidants. Whole blood GpX activity
decreased significantly (P<0.05) in the n-3 fatty acids plus antioxidants group.
TAS increased in the n-3 fatty acids plus antioxidants supplementation group,
but this increase did not reach significance (P = 0.07).
/Wt/sc/e
Peak torques had not changed in CD patients after 3 months of supplementation
in either treatment group. At baseline, however, hamstrings and quadriceps
peak torques measured at 60 and 180°/s were significantly (P<0.01) lower in
CD patients (n = 25) than in the matched controls (Figure 9.1). After 3 months
of supplementation with either antioxidants or n-3 fatty acids plus antioxidants,
hamstrings and quadriceps PTs in CD patients did not differ significantly from
controls. In contrast, after placebo supplementation, hamstrings and quadriceps
PTs in CD patients still were significantly (P<0.05) lower than in controls
(Table 9.6).
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Table 9.3 Body composition in Crohn's disease patients before and after 3 months of nutritional supplementation with placebo,
antioxidants or n-3 fatty acids plus antioxidants'.
Placebo (n = 8) Antioxidants (n - 8) n-3 fatty acids/antioxodants (n = 9)
before after before after before after
Weight (kg)' 63.4(55.4-84.4) 64.4 (55.9-85.2p 64.5(55.7-72.8) 64.4(56.2-73.1) 68.0(60.2-77.2) 69.4(61.9-77.4)'
Body fat (kg) 22.7(11.9-30.6) 23.8(12.2-31.5)* 17.2(9.2-27.9) 17.3(10.6-25.4) 18.2(11.9-28.2) 18.5(11.6-29.4)'
Fat-free mass (kg) 45.2(38.4-54.0) 45.4(38.5-53.7) 45.6(42.8-56.2) 45.3(40.8-55.3) 50.8(43.4-53.1) 50.0(43.7-53.2)
Percentage body fat 34.9(22.2-37.2) 35.0(22.5-37.8) 24.7(15.5-38.2) 24.7(15.6-37.9) 24.2(20.8-37.9) 24.2(20.8-37.5)
' Data are expressed as median; 25th and 75th percentile in parentheses.
' Body fat plus fat-free mass assessed by dual-energy X-ray absorptiometry does not correspond with body weight because median values are given.
' Significantly different from before 3 months of supplementation (Wilcoxon matched-pairs signed-rank tests): P<0.05.
Table 9.4
Total fat (g)
SAFA (g)
MUFA (g)
PUFA (g)
Linoleic acid (g)
^-Carotene (mg)
Vitamin C (mg)
Zinc (mg)
Dietary intake of fat and antioxidants in Crohn's disease patients before and after
supplementation with placebo, antioxidants or n-3 fatty acids plus antioxidants'
before
80.1
(56.8-148)
28.1
(22.9-55.3)
27.0
(20.8-55.0)
18.6
(6.9-26.1)
14.0
(3.9-19.2)
0.41
(0.21-0.53)
43.8
(27.5-135)
8.4
(7.4-13.2)
Placebo (n =
after
70.6'
(45.8-105)
27.3*
(16.5-46.4)
26.8
(15.8-42.6)
10.6'
(5.8-16.7)
7.1'
(4.2-10.8)
0.56
(0.29-0.71)
54.0
(40.3-95.3)
8.6
(5.7-9.5
8)
after + suppl
83.4
(56.4-122)
32.9
(22.6-54.0)
29.0
(18.4-45.6)
15.1
(11.1-22.7)
11.7
(8.9-16.8)
0.56
(0.29-0.71)
63.0
(45.9-103)
8.6
(5.7-9.5
before
113
(82.6-138)
37.5
(29.8-46.2)
47.3
(33.9-57.3)
19.9
(11.4-27.1)
13.1
(7.9-21.9)
0.49
(0.31-0.77)
68.9
(49.9-82.8)
9.2
(7.7-10.81
Antioxidants
after
83.4'
(68.0-109)
33.9
(23.2-40.6)
31.2'
(25.9-45.9)
15.2
(10.5-19.5)
12.1
(7.4-14.1)
0.48
(0.29-0.86)
49.9
(35.6-85.6)
9.0
(8.1-9.6)
(n = 8)
after + suppl
99.8
(83.2-126)
39.6
(30.8-48.2)
34.2
(28.6-48.9)
21.2
(14.5-24.5)
18.1
(12.1-20.1)
0.79'
(0.60-1.16)
89.9'
(75.7-121)
17.7'
(14.6-18.4)
3 months of rlutritional
n-3 fatty acids/antioxidants (n = 9)
before
88.9
(83.8-137)
36.7
(31.1-50.7)
34.8
(28.9-46.1)
16.0
(12.5-19.7)
10.1
(7.9-14.9)
0.39
(0.23-0.68)
84.2
(42.6-125)
8.6
(6.7-10.4)
after
103
(70.2-120)
38.7
(27.9-46.4)
31.9
(26.2-44.2)
13.4
(11.1-18.6)
9.2
(7.3-13.5)
0.73
(0.39-0.91)
91.9
(25.7-118)
7.6
(5.8-12.2)
after + suppl
115
(83.8-137)
43.9'
(34.9-55.6)
35.3
(28.8-46.7)
16.4
(14.5-21.6)
10.9
(8.9-14.8)
1.03*
(0.61-1.05)
126
(65.1-158)
16.8*
(14.0-21.4)
Data are expressed as median; 25th and 75th percentile in parentheses. Before: regular dietary intake before supplementation; After:
regular dietary intake after supplementation. After + suppl: regular dietary intake after supplementation + dietary intake of supplement; SAFA:
saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.
Significantly different from before nutritional supplementation (Wilcoxon matched-pairs signed-rank tests): ' P<0.05, ' P<0.02, *P<0.01.
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Table 9.6 Serum and whole blood concentrations of nutritional biochemical parameters in Crohn's disease patients before and
after 3 months of nutritional supplementation with placebo, antioxidants or n-3 fatty acids plus antioxidants'.
Placebo (n = 8)
before after
antioxidants (n = 8)
before after
n-3 fatty acids/antioxidants (n = 9)
before after
Total protein (g/L)
Pre-albumin (g/L)
Vitamin A (//mol/L)
/8-Carotene (//mol/L)
Thiamin (nmol/L)
Vitamin C (//mol/L)
Vitamin E (//mol/L)
Magnesium (mmol/LI
Selenium (//mol/L)
Zinc (//mol/L)
Copper (//mol/L)
GpX (U/mmolHbl
SOD (U/mmolHb)
TAS (//mol/L)
68.2 (64.6-71.5)
0.26 (0.21-0.29)
2.30 (1.35-2.58)
1.77 (1.48-2.19)
128 (92.8-138)
31.5 (15.2-55.8)
29.0 (26.5-33.8)
0.70 (0.64-0.76)
0.99 (0.87-1.11)
12.6 (9.5-14.0)
21.8 (20.7-25.3)
867 (735-976)
15.6 (13.6-16.1)
1.21 (1.11-1.28)
66.8 (62.1-69.0)
0.27 (0.21-0.31)
2.50 (1.50-3.10)
1.36 (1.08-2.04)
98 (87.5-123)'
37.0 (26.0-47.3)
33.0 (30.0-36.0)
0.78 (0.72-0.85)
0.90 (0.77-1.08)
12.4 (11.6-12.8)
18.6 (17.4-22.7)
744 (647-978)
17.7 (17.0-18.7)
1.21 (1.02-1.27)
68.9 (65.6-72.6)
0.23 (0.21-0.35)
2.00 (1.53-3.20)
1.53 (0.77-2.53)
135 (129-142)
30.5 (23.8-47.0)
29.0 (15.5-48.3)
0.66 (0.58-0.73)
0.92 (0.72-0.95)
12.8 (12.0-13.1)
19.6 (17.1-23.1)
714 (606-904)
14.4 (12.6-15.8)
1.19 (1.14-1.26)
68.3 (64.9-70.1)
0.25 (0.22-0.39)
2.10 (1.67-2.98)
2.09 (0.79-2.96)
127 (105-158)
55.5 (15.5-48.3)'
37.5 (22.3-53.3)«
0.76 (0.69-0.84)'
0.96 (0.75-1.16)
12.8 (11.9-13.6)
18.4 (15.4-22.8)
714 (644-1079)
16.7 (14.8-18.7)'
1.22 (1.20-1.37)
66.6 (64.4-73.2)
0.27 (0.24-0.29)
1.90(1.45-2.50)
1.74 (0.76-2.77)
124 (113-129)
40.0 (23.5-56.5)
29.0 (17.0-35.5)
0.72 (0.62-0.86)
0.80 (0.68-1.01)
13.0 (11.3-14.0)
17.1 (16.3-21.9)
876 (724-1039)
14.2 (13.4-16.3)
1.20 (1.12-1.24)
66.7 (62.5-72.0)
0.27 (0.25-0.30)
2.25 (2.03-2.85)
1.52 (1.07-2.66)
93.0 (89.5-145.5)
68.0 (50.0-73.5)'
34.5 (25.8-45.5)'
0.82 (0.73-0.88)
1.00 (0.82-1.14)
12.1 (10.8-13.3)
17.6 (15.3-20.8)
700 (642-962)'
17.7 (1 5.6-20.7)'
1.27 11.20-1.38)'
Data are expressed as median; 25th and 75th percentile in parentheses.
GpX: glutathione peroxidase; SOD: Superoxide dismutase; TAS: total antioxidant status.
P = 0.07 for difference between before and after nutritional supplementation.
Significantly different from before nutritional supplementation (Wilcoxon matched-pairs signed-rank tests): ' P < 0 . 0 5 , * P<0.02.
Table 9.6 Isokinetic muscle strength measured by Cybex after 3 months of supplementation for different treatment groups compared
with matched healthy controls'.
Placebo Antioxidants n-3 fatty acids/antioxidants
CD patients (n = 8) Controls (n = 81 CD patients In = 8) Controls (n = 8) CD patients In = 9) Controls In = 9)
PT extension 98.5(73.0-124)' 116(82.5-142) 112(98.7-141) 136(123-149) 119(88.0-147) 123(95.0-154)
(60°/sec) (Nm)
PT extension 64.5(41.0-79.0)' 76.0(50.8-95.8) 66.0(56.8-93.3)' 87.0(77.0-101) 74.0(42.0-105) 80.0(58.5-108)
(180<7sec) (Nm)
PT flexion 57.5(4.5-75.51* 74.0(55.0-101) 70.0(51.5-83.0) 88.0(71.5-105) 62.0(50.0-93.0) 76.0(64.0-98.5)
(60°/sec) (Nm)
PT flexion 29.0(13.3-52.0)' 51.0(33.0-67.3) 36.0(23.0-59.3) 53.0(45.0-84.5) 29.0(18.0-65.0)* 53.0(41.0-72.0)
(180°/sec) (Nm)
' Data are expressed as median; 25th and 75th percentile in parenthese.
PT: peak torque; Nm: Newton meter. Quadriceps muscle strength was measured by peak torque extension, and hamstring muscle strength by
peak torque flexion.
* P = 0.05 for difference between Crohn's disease patients and controls.
' Significantly different from controls (Wilcoxon matched-pairs signed-rank tests): 'P<0.05.
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Figure 9.1 Box & Whiskers plot of muscle function in CD patients (n = 25) before nutritional
supplementation compared with matched healthy controls (n = 25); peak torque
flexion: peak torque of hamstring muscles, peak torque extension: peak torque of m.
quadriceps femoris. Significance level of difference in muscle strength between
patients and controls (Wilcoxon matched-pairs signed-rank test):' P<0.05.
Fatty acid analysis
P/asma p/7osp/?o//p/ds
After 3 months of supplementation with n-3 fatty acids plus antioxidants, a
significant (P<0.01) increase of 57.8% for the sum of the n-3 fatty acids was
observed. Figure 9.2 shows the results for some individual fatty acids:
arachidonic acid (18:4n-6) significantly (P<0.05) decreased (6.6%) in the
patients receiving n-3 fatty acids plus antioxidants, while eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) had significantly (P<0.03) increased
(163% and 37.1%, respectively) after 3 months of supplementation with n-3
fatty acids plus antioxidants. No changes in fatty acid profile of plasma
phospholipids were observed in patients who had been supplemented with
placebo or antioxidants.
/W/pose r/sstye
In patients supplemented with n-3 fatty acids plus antioxidants, the sum of the
n-3 fatty acids had significantly (P<0.02) increased with 15.5% after 3 months
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of supplementation. EPA and DHA had significantly (P<0.05) increased (125%
and 80.0%, respectively) after 3 months of supplementation with n-3 fatty
acids plus antioxidants. DHA also increased significantly (P<0.05) with 60% in
patients receiving antioxidants.
change in linoleic acid
(18:2n-6)
change in eicosapentaenoic
acid (20:5n-3)
7.5^
5.0.
25 .
on
B A
piacwbo
8 A
• £ *
vtKModants
B A
* T
n I
IVJFA/AO
150.
12 5.
100.
75.
SO.
25.
00
change in arachidonic acid
<20:4n-6)
change in docosahexaenoic
acid (22:6n-3)
Figure 9.2 Box & Whiskers plot of plasma phospholipids fatty acid profile (% of total fatty
acids) in CD patients before ( = B) and after (=A) 3 months of supplementation with
placebo (n = 8), antioxidants (n = 8) or n-3 fatty acids plus antioxidants (n = 9). EPA:
eicosapentaenoic acid; DHA: docosahexaenoic acid; Significance level of change in
plasma phospholipid fatty acid profile before and after 3 months of supplementation
for the three treatment groups (Wilcoxon matched-pairs signed-rank test): ' P<0.05.
Lipid peroxidation
Lipid peroxidation did not change significantly after supplementation in either
treatment group (placebo: 2.1 //mol/L (1.9-2.5) to 2.2 //mol/L (2.0-2.4);
antioxidant group: 2.6 //mol/L (2.3-2.7) to 2.7 //mol/L (2.3-3.2); n-3 fatty acids
plus antioxidant group: 2.1 //mol/L (2.0-2.6) to 2.3 //mol/L (2.1-2.7)). At
baseline, levels of TBARs showed a significant negative correlation with serum
selenium (r = -0.59, P<0.01), and with serum 0-carotene (r = -0.49, P<0.02).
We did not observe any significant correlations between levels of TBARs and
antioxidants or fatty acids after 3 months of supplementation.
Disease activity
At baseline, patients did not differ significantly as regards disease activity
measured by CDAI and CRP levels. CDAI significantly (P<0.05) decreased from
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99.6 (69.5-169) to 78.1 (45.9-154) in patients receiving n-3 fatty acids plus
antioxidants, compared with no significant change in CDAI for those receiving
antioxidants (119 (36.7-153) to 85.1 (21.3-179); P = 0.58) or placebo (79.2
(47.1-120) to 56.3 (34.4-111); P = 0.20). Less abdominal pain, improved well-
being and increased body weight, which are factors used in the calculation of
CDAI, explained the reduced CDAI in patients receiving n-3 fatty acids plus
antioxidants. CRP levels had not changed significantly in either treatment group
after 3 months supplementation.
Quality of life
At baseline, treatment groups did not differ significantly in total IBDQ score.
Furthermore, the total IBDQ scores had not changed significantly after 3 months
of supplementation in either treatment group. In the total patient group, we
observed significant correlations between the change in CDAI (CDAI before
supplementation minus CDAI after supplementation) and the change in the
"bowel symptoms" dimension of the IBDQ (r = -0.54, P<0.01), and in addition,
with the change of the "systemic symptoms" dimension of the IBDQ (r = -0.51,
P<0.01), respectively.
Discussion
This study showed an improved nutritional status and antioxidant status in CD
patients, currently in remission, after 3 months of supplementation with a liquid
formula containing either antioxidants or n-3 fatty acids plus antioxidants
(IMPACT®) in addition to the regular diet. The latter formula contained a
sufficient amount of n-3 fatty acids to significantly decrease the eicosanoid
precursor arachidonic acid and to increase eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) in both plasma phospholipids and adipose tissue.
This may eventually lead to the production of eicosanoids with attenuated
proinflammatory activity'^ and to a reduction of inflammatory cytokines^.
We performed a 'per-protocol' analysis because the primary aim of the
present study was to investigate the physiological effects of 3 months of
supplementation with either antioxidants or with antioxidants plus n-3 fatty
acids, rather than to evaluate the efficacy of the supplementation on disease
parameters. Patients who dropped out of the study were not investigated after
3 months. Absence of a significant difference after 3 months of
supplementation with either formula may be caused by a /?-error (type II error),
because of the small number of patients studied.
Many studies have shown low compliance in dietary intervention studies,
probably because of food intolerance, frequently reported in CD patients^.
There was a 30% patient drop out rate in the present study during intervention.
However, this rate was not specifically related to one of the nutritional
supplements. Most patients reported intolerance due to satiety induced by the
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supplement, indicating that it was difficult to consume calories in addition to the
regular diet. It was shown that the fat intake of the regular diet had decreased
after supplementation in patients receiving placebo and the antioxidant formula.
Regular antioxidant intake had not significantly changed in either treatment
group after 3 months supplementation. This shows that with nutritional
supplementation, patients can positively adapt their regular food intake by
reducing their fat intake, while preserving their regular antioxidant intake,
resulting in significantly higher total intakes of antioxidants.
The metabolic events that occur during inflammation cause increased
demands for certain nutrients which are involved in the elaboration and
maintenance of antioxidant defenses". Studies have indicated that an
imbalance between increased reactive oxidative species production and reduced
antioxidant defenses is involved in the pathogenesis of tissue injury in CD"'**.
Several studies have reported low concentrations of circulating antioxidant
vitamins*-' and antioxidant minerals^'** in CD patients. In a recent study, we
characterized the antioxidant status in patients with CD in remission compared
with controls and found deficiencies for vitamin C, vitamin E, /?-carotene,
selenium and zinc'*. Maintaining an adequate antioxidant status has been
suggested as a useful approach to attenuate the cellular injury and dysfunction
observed in CD. To our knowledge, the present study is the first intervention
trial with dietary antioxidants in CD patients. Antioxidant status was
significantly improved in patients receiving antioxidant or antioxidant plus n-3
fatty acid supplementation for three months in addition to the regular diet. In
the latter groups, the antioxidant status after supplementation was comparable
with the antioxidant status of controls assessed in our previous study'*.
A significantly decreased activity of the enzyme glutathione peroxidase was
observed in patients receiving n-3 fatty acids plus antioxidants. Studies have
shown that lipid peroxidation may increase after n-3 fatty acids supplementation
because PUFAs are particularly vulnerable to free-radical attack caused by the
process of hydrogen abstraction."""* Glutathione peroxidase is involved in
detoxification of lipid hydroperoxides"®"', and it is therefore possible that the
decreased activity of glutathione peroxidase in patients receiving n-3 fatty acids
is explained by an increased use of glutathione peroxidase to prevent lipid
peroxidation. Adequate nutritional selenium intake is also of major significance
in patients supplemented with n-3 fatty acids, as the activity of glutathione
peroxidase is dependent on selenium. Selenium concentrations had not
increased significantly after 3 months of supplementation with n-3 fatty acids
and/or antioxidants, which may indicate that more selenium is necessary for the
overall protective mechanism of glutathione peroxidase. Fat malabsorption and
steatorrhoea may also be involved"®, as divalent cations such as selenium,
magnesium or zinc may form unabsorbable subcomplexes (soaps) with
malabsorbed fats.
The present study was not designed to examine the rate of relapse after n-3
supplementation in CD patients, but to estimate the absorption of n-3 fatty
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acids administered in a food supplement. EPA and DHA were incorporated into
plasma phospholipids and adipose tissue at the expense of n-6 fatty acids,
especially arachidonic acid. Pereira et al showed that circulating arachidonic acid
levels in phospholipids fell significantly during successful treatment, induced by
either elemental diet or steroids*'. In a previous study we found that patients
with long-standing CD, clinically in remission, who did not obtain fish oil
supplementation, showed significantly lower concentrations of arachidonic
acid*°. Results of a recent study suggested that fish oil is anti-inflammatory,
principally through a reduction in the arachidonic acid content of
phospholipids^'. We hypothesize that these patients develop a mechanism to
regulate eicosanoid synthesis in order to remain in remission. The results of the
present study underline the possible beneficial effects of n-3 fatty acids in
changing the precursors of the eicosanoids.
The formula with n-3 fatty acids and antioxidants also contained arginine.
Dietary arginine has been shown to increase immune response (increased
thymic weight, increased thymic lymphocyte content and increased lymphocyte
interleukin 2 production and receptor activity)**. In addition, arginine is the
precursor for nitric oxide which is now recognized to be a cellular messenger
with important immunological functions. Hence, arginine could theoretically
influence disease activity and its effect in active CD needs further investigation.
A variety of nutritional and functional deficiencies have been observed in
patients with long-standing CD in remission'*. Nutritional status is influenced by
several factors such as decreased dietary intake, increased energy requirements
or altered metabolism". The pathophysiology of malnutrition is complex and it
seems inappropriate to assess nutritional status on the basis of one set of
parameters, e.g., laboratory parameters or body composition. The present study
therefore assessed a comprehensive nutritional status by measuring body
composition, dietary intake, biochemical parameters of nutrition and muscle
strength as a functional parameter.
Body weight had increased significantly after 3 months of supplementation
with either placebo or n-3 fatty acids plus antioxidants. This increased body
weight was explained by a significant increase in body fat in these patients. The
total fat intake of patients supplemented with the antioxidant formula had
decreased after 3 months, compared with an increase in total fat intake in
patients receiving placebo or n-3 fatty acids/antioxidants. This difference could
explain the stable body weight in patients supplemented with only antioxidants.
Nutritional status had improved in patients supplemented with antioxidants
despite no change in body weight. This indicates that body weight is not a
sensitive indicator of nutritional status in this group of patients.
Malnutrition is associated with reduced muscle strength'*". Lopes et al
showed that skeletal muscle function is a sensitive indicator of the nutritional
status of patients". It was shown that exercise capacity in CD patients who
had undergone proctocolectomy and small bowel resection was significantly
reduced**. In the present study, muscle strength as a functional parameter of
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nutritional status was restored after 3 months of supplementation with either
extra antioxidants or with n-3 fatty acids plus antioxidants. Macronutrient
supplementation (placebo) alone did not change muscle strength in CD patients
compared with controls. These results support the idea that immunomodulating
nutrients may have beneficial effects on the nutritional status of CD patients.
Quality of life as measured by the IBDQ was not affected by either
treatment, indicating that the nutritional supplements were well tolerable and
did not negatively affect the patients' daily life. The improved nutritional status
did not improve their quality of life. It should be noted however, that IBDQ
baseline scores already were comparable with scores in a control population".
The present study was not designed to study the effects on disease activity,
as the patients were already in remission at the start of the study. Nevertheless,
after supplementation with n-3 fatty acids plus antioxidants, the CDAI
significantly decreased within the normal range. This was explained by the
improvement in some of the parameters used to calculate CDAI: less abdominal
pain, improved well-being and increased body weight. It should be noted
however, that the CDAI decreased to about the same extent in the other
treatment groups, however, this did not reach significance.
In summary, this study showed that both the antioxidant formula and the n-3
fatty acids plus antioxidants formula were well absorbed in patients with long-
standing CD clinically in remission; fatty acids were incorporated into adipose
tissue. After 3 months of supplementation with either antioxidants or
antioxidants plus n-3 fatty acids in addition to the regular diet, several measures
of nutritional status and the antioxidant status were significantly improved in
these patients. Furthermore, supplementation with n-3 fatty acids plus
antioxidants significantly decreased the CDAI and changed the eicosanoid
precursors profile, which may lead to the production of eicosanoids with
attenuated proinflammatory activity. The nutritional supplement did not affect
the patients' daily life which was indicated by the absence of a negative impact
on quality of life. This study thus indicates that the administration of an oral
formula containing immunomodulating nutrients such as n-3 fatty acids and
antioxidants, in addition to the regular diet, may have a role in the treatment of
CD. Long-term supplementation studies in large groups of patients will be
required to investigate the effects of these nutrients on achieving remission or
preventing relapse in Crohn's disease.
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The role of nutrition in the pathogenesis of Inflammatory Bowel Disease (IBD)
The increasing incidence of IBD, especially Crohn's disease (CD) over the last
fifty years' coincides with profound changes in life-style and dietary patterns.
An interaction between food intake and mucosal inflammation along the
gastrointestinal tract therefore seems an attractive concept. There are indeed
indications that diet may play a role in the etiology of IBD, but the difficulty in
elucidating this hypothesis is related to the study design necessary to obtain the
appropriate information. The incidence of IBD is too low to perform an
acceptable prospective cohort study, hence a case-control study is the most
appropriate method to investigate the etiological role of dietary factors in the
development of IBD. The nature of this design, however, introduced the risk of
recall bias^. In an effort to reduce this bias, we included only newly diagnosed
patients (within 6 months of diagnosis) in the study described in Chapter 3.
Objective biochemical indicators of dietary intake may be used to further
overcome the problem of recall bias in case-control studies. Adipose tissue
biopsies assessing fatty acid composition have been used as a biomarker of
long-term polyunsaturated fatty acid intake, reflecting the fat intake over the
previous 2-3 years'. The increased risk to develop ulcerative colitis (UC) which
was associated with high consumption of polyunsaturated fatty acids as
assessed by the dietary history method (Chapter 3), was not reflected by the
adipose tissue results in that study. In IBD patients, however, especially those
with CD, duration of disease symptoms before establishing the diagnosis may
be months to years. This may influence dietary intake and therefore adipose
tissue composition. Furthermore, medication administered in the early post-
diagnosis period to achieve remission (especially corticosteroids) may influence
the fatty acid pattern in adipose tissue. Adipose tissue biopsies, taken at the
time of diagnosis as in our study (Chapter 3), therefore seem to be less useful
for assessing pre-illness diet in IBD patients.
Reducing selection and information bias in a case-control study requires
adequate controls. Many studies have used hospitalized controls who suffer
from other diseases, which may influence dietary intake. The controls in our
study were selected from a database of one general practice in the study region.
In the Netherlands, almost every resident is registered by a general practitioner
and the population database used in the present study is therefore a sample
frame of the population within the study region. Subjects with a history of IBD
were excluded. However, it cannot be ruled out that patients make a greater
effort to remember their previous dietary habits than controls do, leading to
differential misclassification.
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The study described in Chapter 3 concluded that a high consumption of
monounsaturated and polyunsaturated fatty acids and vitamin B6 was
associated with an increased risk of UC. An apparent paradox was found
between previously reported beneficial effects of fish oil (n-3 fatty acids) in
treating active UC*'* and the observed increased risk of developing UC following
a high consumption of polyunsaturated fat (n-6 + n-3 fatty acids) (Chapter 3).
The pre-illness fish consumption was, however, very low, indicating that fish
consumption makes a negligible contribution to the total polyunsaturated fat
intake. Hence, on the basis of the study presented in Chapter 3, fish
consumption cannot be regarded as a risk factor for the development of UC.
Furthermore, it is important to realize that dietary factors, which may be
involved in the etiology of UC do not necessarily modulate the clinical course of
the disease. The study presented in Chapter 3 was not designed to reveal a
particular dietary pattern as a risk factor in the development of UC. However, it
would be interesting to investigate whether the observed increased UC risk
upon high consumption of the specific nutrients mentioned above may reflect a
certain dietary pattern. In future studies, the role of specific food items or a
particular dietary life-style in the etiology, clinical course or prognosis of UC
needs to be investigated.
This thesis did not describe the role of diet in the pathogenesis of CD, because
the number of newly-diagnosed CD patients (n = 23) included was too small to
perform the appropriate analysis (conditional logistic regression). Furthermore,
the duration of disease symptoms before diagnosis was much longer than in UC
patients. The data obtained were therefore less reliable, as the necessary dietary
recall period of the pre-illness diet could exceed five years.
As the etiology of IBD is still unknown, it is possible that IBD is primarily
initiated a long time before inflammation and complaints appear. The diet during
childhood could be more important than the diet prior to disease complaints in
order to identify risk factors in the development of IBD. However, reliable data
on this subject are lacking.
Assessment of nutritional status
The nutritional status in IBD is influenced by several factors, including dietary
intake, increased requirements, altered metabolism and disease activity'. The
pathophysiology of malnutrition is complex and the necessity of assessing a
comprehensive nutritional status in IBD patients was confirmed in the study
described in Chapter 4. We found no significant associations between the
various dimensions (body composition, dietary intake, biochemical parameters
of nutrition and muscle strength) determining nutritional status. This implies that
the assessment of just one dimension of nutritional status is a poor predictor of
the other indices of nutritional status.
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A deteriorated nutritional status is expected especially in patients with long-
standing CD with small bowel involvement, because active inflammation and its
sequelae may interfere with nutrient absorption. As our aim was to investigate
the relation between CD and malnutrition per se, we assessed the nutritional
status in patients with long-standing CD with small bowel involvement, who
were currently in remission. We observed several nutritional and functional
deficiencies in these patients (Chapter 4).
The next goal was to assess the nutritional status in patients with recently
diagnosed IBD to see whether disease duration might be an important
determinator of the nutritional status (Chapter 5). It should be noted that these
patients recently had gone through an inflammatory process, although the
majority of the patients were clinically in remission at time of investigation. We
showed that in patients with recently diagnosed IBD (within 6 months of
diagnosis), the nutritional status had deteriorated, although not as severely as in
patients with long-standing CD. This may imply that disease duration and
subsequent malnutrition are important factors affecting nutritional status in IBD.
The study described in Chapter 5 stresses the importance of assessing a
comprehensive nutritional status in IBD patients at the time of diagnosis. One
should be aware of the deteriorated antioxidant status in these patients.
Furthermore, the observation that vitamin B12 concentration was already
significantly decreased in patients with recently diagnosed CD compared with
controls, warrants attention to the vitamin B12 status at an early stage. The
subclinical disease may have affected the ileal vitamin B12 uptake during many
months or even years before diagnosis.
However, whether nutritional supplementation with eg. antioxidants during an
early phase of IBD may be beneficial to the clinical course of the disease needs
further investigation.
5/oc/7e/7?/ca/ paramerers of r/?e
Decreased serum or plasma zinc concentrations have frequently been reported
in CD, especially in patients with active inflammation*'^. We showed in the
study presented in Chapter 4 that 50% of patients with long-standing CD
clinically in remission have serum zinc concentrations below the 15th percentile
of controls, indicating a zinc deficiency'". Zinc is an essential trace element and
has a key role in more than 200 enzymes. It has been shown that zinc
deficiency is associated with growth failure, delayed wound healing, decreased
protein synthesis, and impaired cell-mediated immunity (impaired antibody-
mediated responses to both T-cell-dependent and T-cell-independent antigens,
and impaired natural killer-cell activity)". This indicates that zinc deficiency may
have negative consequences in IBD.
It is important to note, however, that a decreased serum or plasma zinc
concentration does not always indicate a true zinc deficiency. Serum zinc is also
decreased during inflammatory stress as a result of a decrease in serum
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albumin, enhanced interleukin-1 activity, or redistribution of zinc towards the
liver^. It seems therefore difficult to assess a reliable zinc status in patients with
active disease. Several alternative methods for assessing the true zinc status
have been suggested, such as the assessment of serum alkaline phosphatase
activity^'*, the activity of zincdependent enzymes", zinc concentration in blood
cells*, hair and urinary zinc concentrations'*, or in vitro uptake of zinc by blood
cells'*. However, most of these methods are not suitable for clinical practice.
In a patient population with quiescent disease, however, serum zinc
concentrations may provide adequate information about the true zinc status
because the circulating zinc reflects the metabolizable or exchangeable zinc that
is delivered to metabolically active tissues'*.
Besides serum zinc, serum concentrations of fat-soluble vitamins may also be
influenced by the activity of the disease. Fat-soluble vitamins have been found
to be closely related to serum lipids, and in addition, hypolipidemia have been
reported during active inflammation'^. We therefore calculated the ratio of these
fatsoluble vitamins to serum lipids or cholesterol to accurately assess fat-soluble
vitamins status in IBD patients (Chapter 4, 5, 9).
Selenium is considered an essential element for humans. It is a constituent of
the antioxidant enzyme glutathione peroxidase (GpX) which plays an important
role against oxidative injury. A reduced GpX activity is thought to be a sensitive
indicator of selenium deficiency"''®. This thesis showed that selenium
concentrations and GpX activity were significantly lower in patients with long-
standing CD in remission than in controls (Chapter 4). Furthermore, we
observed a significant correlation between serum selenium and GpX activity in
patients with recently diagnosed UC, but not in age-and sex-matched controls
(Chapter 5). This suggests that the selenium requirement for enzyme activity
was met in the majority of the controls but not in the UC patients, indicating
real selenium deficiency in the latter.
>4ssessme/7f o/ /irj/ya/nmafo/y acr/V/ry
Since one of the aims of this thesis was to investigate the relation between CD
and malnutrition per se, we included patients with long-standing CD who were
clinically in remission. The criteria used were the absence of a significant acute
phase response and stable body weight and no change in medication during the
3 months preceding the study. The Crohn's disease activity index (CDAI) is the
most widely used parameter of disease activity, and remission of CD is usually
defined as a CDAI score below 150'^. The CDAI includes several components,
such as the number of soft/ liquid bowel movements, abdominal pain, sense of
general well-being, and ideal body weight. In CD, one or several of these factors
may well be negatively affected in the absence of inflammatory activity™. For
example, a CD patient with ileal dysfunction after extensive small bowel
resection, but without histological evidence of active inflammation, may report a
very high frequency of liquid stools, no abdominal pain, good general well-being,
and a low body weight, resulting in a CDAI of 190. Following the CDAI criteria,
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this patient would have been considered having active disease. According to our
criteria, however, this patient would have been clinically in remission due to a
low C-reactive protein level (<9 mg/L), stable body weight and stable
medication. In our opinion, indices like the CDAI often reflect the extent or
severity of the disease rather than the inflammatory activity.
The use of C-reactive protein has its limitations too. C-reactive protein
increases non-specifically in response to inflammation and to an intercurrent
common infection. Hence, C-reactive protein levels may increase without the
presence of gastrointestinal inflammation, indicating that acute phase response
is not a specific disease activity parameter in CD patients.
There is a need for new indices or parameters to accurately assess current
inflammatory activity in IBD patients, although it may be wishful thinking that a
parameter could be found that is sensitive and specific at the same time.
Energy
Increased energy expenditure associated with active inflammation has been
suggested as an additional mechanism contributing to malnutrition in IBD.
However, the available literature is unequivocal^"**. It has been assumed that
weight loss in CD patients could be caused by an increased resting metabolic
rate. However, Stokes and Hil l" showed that total energy expenditure was not
raised in CD patients. In this thesis we assessed energy intake of IBD patients,
however measurement of energy expenditure was not performed. To get a
complete picture of the nutritional status of IBD patients and of the factors
influencing it, energy balance (energy expenditure and energy intake) should be
investigated in future studies.
/Wt/sc/e sfrengrf/j
In the studies described in Chapters 4, 5, 9, muscle strength of IBD patients
was measured by isokinetic dynamometry". Using dynamometry, active torque
of different muscle groups spanning one joint can be assessed dynamically. In
the studies described in the present thesis muscle torque of the knee extensor
(m. quadriceps) and knee flexor (the hamstring muscle group) muscles were
determined.
Other devices to study muscle function, like the more commonly used hand-grip
test", mostly measure muscle contractile performance under static, isometric
conditions, not taken into account the potential bias of muscle length. Dynamic
muscle testing provides clear insight in the capability of the muscle to generate
work over the entire range of motion and is therefore to be preferred.
Furthermore, dynamometry as used in the present study permits testing of both
knee flexor and extensor muscle in one experimental set-up. Since knee flexor
and extensor differ in fiber typing, potential selective wasting of either muscle
fiber type will be reflected in alterations in the flexor/extensor ratio. The
flexor/extensor ratio provides information about muscle function and selective
reduction of muscle strength in either the extensor or the flexor muscle group,
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and hence may serve as a functional parameter of the nutritional status.
Patients with long-standing CD who were clinically in remission showed a
significantly decline in peak torque of the hamstrings muscle group, while the
peak torque of the m. quadriceps was preserved (Chapter 4). It is interesting to
note that the muscle function (flexor/extensor ratio) did not significantly differ
between recently diagnosed IBD patients and controls (Chapter 5). It has been
shown that both corticosteroid therapy and malnutrition may induce atrophy of
type lib muscle f ib res"" . The hamstring muscles have a higher percentage of
type Mb muscle fibres'" than do the m. quadriceps. This may explain the
selectively decline in peak torque of the hamstrings muscle group in patients
with long-standing CD. Furthermore, a recent study showed that in
malnourished patients the phosphocreatine/ ATP-ratio measured in muscles with
nuclear magnetic resonance was signficantly lower compared with controls,
indicating a reduction in total creatine^. The effect of malnutrition on muscle
function may also be mediated by altered mitochondrial energetics. The
observed abnormalities of muscle function in CD patients with long-standing CD
in remission may therefore be attributed to steroid use or malnutrition. Physical
activity may also influence muscle function but was not taken into account in
the present thesis. However, patients as well as controls were both sedentary
with a few of them performing regular physical activity.
The peak torque of both the hamstring muscles and the m. quadriceps were
significantly lower in the CD patient population included in the intervention
study compared with controls (Chapter 9). The results of the intervention trial
suggest that malnutrition is involved in the impaired muscle function, as muscle
strength was restored in those patients in whom the nutritional status had
improved after nutritional supplementation with n-3 fatty acids and/or
antioxidants (Chapter 9). However, the distinct effects of both corticosteroids
and malnutrition on muscle contractile performance remains to be elucidated.
Muscle fatigue of unknown origin is frequently observed in CD patients and this
stresses the importance to gain more insight into the relation between muscle
function and IBD.
Nutritional intervention
We observed a deteriorated nutritional status in patients with long-standing CD
who were clinically in remission (Chapters 4, 6), which prompted us to try and
improve their nutritional status. Several nutritional interventions have been
considered to achieve this goal. In view of the results presented in this thesis
(Chapters 4, 7, 8), we performed a randomized, double-blind, placebo-controlled
study to assess the nutritional and metabolic effects of supplementation with
energy, n-3 fatty acids and antioxidants for three months in addition to the
regular diet in patients with long-standing CD, clinically in remission (Chapter 9).
This intervention may regarded as nutritional support to improve e.g. the
antioxidant status of CD patients, but the supplement also contained potentially
immuno-modulating nutrients. These nutrients (antioxidants, arginine, n-3 fatty
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acids and nucleotides) may have interacted with the immune system and may
have resulted in immunologic benefits". In order to evaluate the immuno-
modulating effects of these nutrients on inflammatory activity and the course of
the disease in CD patients, it has to be established whether these nutrients are
absorbed and utilized. We therefore investigated the effects of the nutritional
supplement in patients with long-standing CD who were clinically in remission,
to exclude effects of inflammatory activity on the nutritional status.
Antioxidants and fish oil were well absorbed, as was shown by the improved
antioxidant status and increased proportions of eicosapentaenoic acid and
docosahexaenoic acid in plasma phospholipids and adipose tissue in
supplemented CD patients (Chapter 9). However, we do not know the influence
of active inflammation on the absorption and metabolism of these nutrients in
CD patients. Furthermore, the effect of nutritional supplementation with n-3
fatty acids and antioxidants in UC patients is unknown, however, the intestinal
absorption of nutrients will not be affected by disease activity in the latter
group.
Fish oil (eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3))
may have anti-inflammatory activity because n-3 fatty acids are thought to
compete in the substrate pool of the lipoxygenase pathway, thus reducing the
production of eicosanoids with high inflammatory activity". These fatty acids
are also able to suppress the synthesis of other inflammatory cytokines,
including interleukin-1/ff and tumor necrosis factor-tr"*. As was shown in Chapter
7, we observed no eicosapentaenoic acid deficiency in plasma phospholipids in
patients with long-standing CD who were clinically in remission. On the other
hand, patients with active CD tended to have a lower proportion of
eicosapentaenoic acid in plasma phospholipids compared with CD patients
clinically in remission (borderline significance, P = 0.06). This may support the
beneficial role of fish oil in achieving remission in CD patients with active
disease and could explain the contradictory results of fish oil supplementation in
preventing a relapse"'^. The studies presented in this thesis do not give an
answer to this hypothesis. However, we reported a significantly decreased
arachidonic acid proportion after n-3 supplementation (Chapter 9), which may
have an attenuating effect on inflammation.
We found no significant change in quality of life after n-3 supplementation in
CD patients in remission. Furthermore, the CDAI significantly decreased within
the normal range after n-3 supplementation. It should be noted, however, that
the CDAI decreased to about in the same extent in the other treatment groups
(placebo or antioxidant supplementation), however, this did not reach
significance. This may underline the earlier mentioned disadvantages of using
the CDAI for assessment of inflammatory activity in CD patients.
One of the well-known drawbacks of nutritional intervention is non-
compliance". We also found a 30% patient drop-out rate, which was, however,
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not specifically related to one of the nutritional supplements (Chapter 9). Most
patients found it difficult to consume the energy-rich and nutrient-rich
supplement in addition to the regular diet. Motivation and compliance of
patients will be hard to achieve with long-term nutritional supplementation. We
therefore recommend to supplement IBD patients with specific
immunomodulating nutrients without a high energy content. The supplement
should be refreshing, with an acceptable taste. In a selective group of IBD
patients with low body weight, however, an energy-rich supplement may be
recommended.
Implications for future research
Nutrients may be involved in the pathogenesis of IBD, as was shown for UC
patients in Chapter 3. However, as we did not study the nutritional pattern
which may be responsible for the development of UC, it will be necessary to
investigate dietary behavior and life-styles in the etiology of UC patients, as well
as in CD patients.
Disease duration was found to influence the nutritional status of CD patients
in our studies. Although we found a deteriorated nutritional status in UC
patients at the time of diagnosis, the comprehensive nutritional status in
patients with long-standing UC is unknown and needs further research.
The selectively reduced muscle function observed in patients with long-
standing CD warrants further studies to investigate the specific effects of
malnutrition and corticosteroid therapy on muscle function. This can be
achieved by assessing muscle function in patients with obvious malnutrition
without other concomitant inflammatory disease (e.g. anorexia nervosa) and in
patients without obvious signs of malnutrition but with chronic corticosteroid
use (a selected group of patients with chronic obstructive pulmonary disease or
giant cell arthritis). Furthermore, it should be elucidated whether the selectively
decreased muscle function is accompanied by increased muscle fatigue in CD
patients.
Studies of energy balance should be performed in order to investigate the
effects of energy metabolism on the body composition and metabolism of IBD
patients.
Nutritional status was significantly improved after supplementation with n-3
fatty acids and/or antioxidants in addition to the regular diet in CD patients with
quiescent disease. It should be investigated whether these nutrients may have
an effect on the clinical course of the disease of CD patients as well as UC
patients with a view to prolonging the remission phase of the disease.
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This thesis describes the role of nutrition in patients with Crohn's disease (CD)
and ulcerative colitis (UC), collectively referred to as Inflammatory Bowel
Disease (IBD). Three main topics which can be distinguished with regard to the
relation between nutrition and IBD are addressed: the role of specific dietary
components in the pathogenesis of IBD; the prevalence of malnutrition in the
course of the disease; and nutritional therapy to improve nutritional status.
Chapter 2 critically reviews the current knowledge about the role of nutrition in
IBD. In summary, there is still very little conclusive evidence regarding the role
of specific dietary components in the pathogenesis of IBD. Many studies
published so far have been subject to methodological flaws. Nutritional
deficiencies in IBD patients, especially in CD, have been documented. It is,
however, hard to discriminate between disease-induced and malnutrition-
induced changes in nutritional parameters. Maintaining an adequate nutritional
status has been suggested to be beneficial for the disease course in IBD.
Several studies have provided further insights into the possible beneficial effects
of nutritional supplementation as an adjunctive therapy in IBD. Polyunsaturated
n-3 fatty acids, as in fish oil, may have anti-inflammatory activity because they
compete with polyunsaturated n-6 fatty acids in the substrate pool of the
lipoxygenase pathway, thus reducing the production of leukotrienes with high
inflammatory activity.
In Chapter 3 the role of dietary factors in the etiology of UC is described using a
case-control study. Pre-illness diet of UC patients and population controls was
assessed using a cross-check dietary history. It was shown that high intakes of
monounsaturated fatty acids and polyunsaturated fatty acids and vitamin B6
were associated with a significantly increased UC risk. This may reflect a
particular, as yet unidentified, dietary life-style. It is unclear whether fish
consumption, which may be useful in the treatment of inflammation, is involved
in the etiology of UC, because both patients and controls reported very low fish
intake. This may indicate that fish (n-3 fatty acids) intake makes a negligible
contribution to the total polyunsaturated fatty acid intake (n-6 and n-3 fatty
acids).
The association between long-standing (>10 years) CD and malnutrition is
reported in Chapter 4. The nutritional status of patients with long-standing CD
who were currently in remission, as well as that of age- and sex-matched
population controls was comprehensively assessed by 1) dietary intake, 2) body
composition, 3) biochemical parameters of nutrition, and 4) muscle strength.
This study showed a variety of nutritional and functional deficiencies in patients
compared with controls. Serum concentrations of ^-carotene, vitamin C, vitamin
E, selenium and zinc, and activity of glutathione peroxidase were significantly
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lower in CD patients than in controls. Furthermore, a selectively reduced
strength of the hamstring muscles was reported in these patients, especially in
males. We did not found significant associations between the various
dimensions determining nutritional status. This implies that a comprehensive
nutritional assessment is superior to the assessment of a single dimension of
nutritional status.
A study on the nutritional status of recently diagnosed IBD patients (within 6
months of diagnosis) and age- and sex-matched population controls was
performed in order to investigate whether malnutrition was associated with
disease duration (Chapter 5). This study revealed that even at the time of
diagnosis, IBD patients were at risk of developing several nutritional
deficiencies, especially antioxidant deficiency. The decrease in serum
antioxidants in UC patients seem to be explained by an increased use of
antioxidants by the inflamed tissue rather than by a deficient intake or impaired
digestion and absorption of nutrients. The present data support the hypothesis
that a reduced antioxidant defense in IBD patients may be important with regard
to the pathogenesis of early tissue injury in IBD.
In Chapter 6 the results of a study on body composition in various groups of
IBD patients are presented. Measurement of body composition is an essential
part of nutritional assessment in IBD, as malnutrition and inflammation may lead
to aberrations in the size of body water compartments. However, no data about
body water distribution in IBD had been reported. We reported an altered body
water distribution and body hydration in female IBD patients. Fluid shifts were
most pronounced in female patients with recently diagnosed CD, which
suggests that a recent acute inflammatory process, in addition to malnutrition,
could be a major factor contributing to the altered body composition. In male
IBD patients, no significant changes in body water distribution were observed,
but body weight, body fat and fat-free mass were significantly lower than in
age- and sex-matched population controls. The mechanism for the observed
gender-based differences in body water distribution in IBD is as yet unclear. Our
findings illustrate the importance of a comprehensive body composition
assessment in IBD patients.
Fatty acid metabolism is involved in the immune response and inflammation
processes in CD patients and may be relevant to the clinical course of the
disease. A study describing the qualitative and quantitative fat intake as well as
the fatty acid profile of plasma phospholipids and adipose tissue in various
groups of CD patients and age- and sex-matched population controls is
presented in Chapter 7. Although the quatitative or qualitative fat intake did not
differ significantly between patients and controls, an aberrant essential fatty
acid profile was found in CD patients, especially in patients with long-standing
CD. We observed a significantly lower percentage of the sum of the n-3 fatty
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acids, with significantly higher levels of clupanodonic acid (22:5n-3) and
significantly lower levels of docosahexaenoic (22:6n-3) and arachidonic acid
(20:4n-6). This aberrant fatty acid profile may be the result of an altered
metabolism rather than of malabsorption of essential fatty acids. The reported
findings may be important with regard to the pathophysiology of CD, and
hence, in the choice of fatty acids to be used when therapeutic administration is
considered in CD patients.
The relations between the results presented in Chapters 6 and 7 are discussed
in Chapter 8. In addition, the fatty acid profile in plasma phospholipids and the
antioxidant status were assessed in CD patients during an exacerbation of the
disease and subsequent remission. The plasma phospholipid fatty acid profile
differed significantly between patients with active compared with inactive
disease, as was illustrated by the increased sum of the saturated fatty acids,
the decreased sum of the unsaturated fatty acids and the decreased EFA status
in the former group. We observed a significantly diminished antioxidant status in
patients with active CD compared with inactive CD and controls, respectively.
In addition, the antioxidant defence was depleted in patients with inactive CD
compared with controls. Furthermore, the fatty acid profile in CD patients was
significantly associated with inflammatory activity and serum antioxidant
concentrations. This observation, along with the diminished antioxidant defense
in patients with active and inactive CD, supports the hypothesis that
antioxidants should be considered in the therapy of inflammation in CD.
The results of the studies presented in this thesis (Chapters 3-8) led to an
intervention study described in Chapter 9. The primary aim of this study was to
assess the effects of supplementation with n-3 fatty acids and antioxidants in
addition to the regular diet on the nutritional status of CD patients. To eliminate
effects of disease activity on the nutritional status, inclusion was restricted to
CD patients who were clinically in remission. The randomized, double-blind,
placebo-controlled study showed that the antioxidant status and the nutritional
status improved significantly after 3 months of supplementation with anti-
oxidants or with n-3 fatty acids plus antioxidants, compared with placebo.
Supplementation with n-3 fatty acids plus antioxidants significantly changed the
eicosanoid precursor profile, which may result in the production of eicosanoids
with attenuated proinflammatory activity; the proportions of eicosapentaenoic
acid and docosahexaenoic acid in plasma phospholipids and adipose tissue
increased significantly and the proportion of arachidonic acid decreased
significantly after n-3 fatty acids plus antioxidant supplementation. This study
indicates that an immuno-modulating formula containing n-3 fatty acids and/or
antioxidants may potentially play a beneficial role in the treatment of CD.
In conclusion, this thesis shows that specific nutrients may play a role in the
development of UC, however it remains to be elucidated whether a specific
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dietary pattern is associated with an increased UC risk. It was furthermore
shown, that the nutritional status of patients with long-standing CD who were
clinically in remission, and that of recently diagnosed (within the previous 6
months) IBD patients was significantly deteriorated. Finally, nutritional
supplementation with n-3 fatty acids and/or antioxidants improved the
nutritional status of patients with long-standing CD, and such immuno-
modulating formula may potentially play a beneficial role in the treatment of
IBD.
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Samenvatting
Samenvatting
Dit proefschrift beschrijft de rol van voeding bij patienten met de ziekte van
Crohn (CD) en colitis ulcerosa (UC). Beide ziektebeelden vormen samen het
begrip 'Inflammatory Bowel Disease' (IBD, inflammatoire darmziekten). Drie
belangrijke gebieden op het terrein van voeding en IBD worden behandeld: de rol
van specifieke voedingscomponenten bij het ontstaan (etiologie) van IBD; de
prevalentie van een siechte voedingstoestand (malnutritie) tijdens het
ziekteverloop; en voedingstherapie om de voedingsstatus te verbeteren.
Na een körte introduktie in hoofdstuk 1 wordt in hoofdstuk 2 een kritisch
overzicht gepresenteerd van de huidige kennis over de rol van voeding bij IBD.
Er zijn op dit moment geen duidelijke aanwijzingen dat voedingscomponenten
een rol speien bij de pathogenese van IBD. Veel studies die over dit onderwerp
zijn gepubliceerd hebben methodologische zwakheden. Voedingsdeficienties bij
IBD patienten, speciaal bij de ziekte van Crohn zijn vaak gerapporteerd. Het blijkt
echter moeilijk om onderscheid te maken tussen ziekte-ge'induceerde en
malnutritie-geinduceerde veranderingen van voedingsparameters. Er zijn
aanwijzingen dat handhaving van een goede voedingsstatus een gunstige
invloed kan hebben op het ziekteproces van IBD. Resultaten van verscheidene
studies hebben een beter inzicht gegeven over de mogelijke positieve effecten
van voedingssuppletie als aanvullende therapie bij IBD. Meervoudig
onverzadigde n-3 vetzuren, zoals die voorkomen in visolie, hebben een anti-
inflammatoire werking o.a. doordat ze het substraat zijn voor de productie van
eicosanoiden met een verminderde inflammatoire activiteit. De meervoudig
onverzadigde n-3 vetzuren concurreren om de enzymen 5-lipoxygenase en
cyclooxygenase met de meervoudig onverzadigde n-6 vetzuren welke
eicosanoiden produceren met een hoge inflammatoire activiteit.
In hoofdstuk 3 wordt de rol van voeding in het ontstaan (de etiologie) van UC
beschreven waarbij gebruik is gemaakt van een case-control design. Een cross-
check dietary history is gebruikt om de voedselconsumptie van 5 jaar tevoren te
bepalen in UC patienten en populatie-gebaseerde controle personen. De
resultaten van dit onderzoek toonden aan dat een hoge consumptie van
meervoudig- en enkelvoudig onverzadigde vetzuren en Vitamine B6 geassocieerd
waren met een significant verhoogd risico op het ontwikkelen van UC. Dit kan
een afspiegeling zijn van een bepaalde levensstijl, welke tot op heden nog niet is
geTdentificeerd. Het is niet duidelijk of de consumptie van visolievetzuren, die
een gunstige invloed lijken te hebben bij de behandeling van UC, een rol spelen
bij het ontstaan van UC. Zowel patienten als controle personen aten zulke
geringe hoeveelheden vis dat visconsumptie (n-3 vetzuren) een verwaarloosbare
bijdrage levert aan de totale consumptie van meervoudig onverzadigde vetzuren
(n-6 + n-3 vetzuren).
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De relatie tussen langdurige ziekte van Crohn en malnutritie wordt beschreven in
hoofdstuk 4. De voedingsstatus werd uitgebreid bepaald bij patienten die meer
dan 10 jaar aan de ziekte van Crohn lijden maar geen recente klinische
ziekteactiviteit hadden en bij leeftijd- en geslacht gematchte controle personen
door middel van 1) de voedselconsumptie, 2) lichaamssamenstelling, 3)
biochemische parameters van voeding, en 4) spierkracht. Bij patienten met de
ziekte van Crohn werden verscheidene voedings- en functionele deficienties
gerapporteerd vergeleken met controle personen: serum concentraties van /?-
caroteen, vitamine C, vitamine E, selenium en zink en de activiteit van
glutathione peroxydase waren significant lager. Bovendien werd in deze
patientengroep, vooral bij de mannen, een selectief verminderde spierkracht van
de hamstrings spieren gerapporteerd. Er werden geen significante relaties
gevonden tussen de verschillende dimensies die de voedingsstatus bepalen. Dit
geeft aan dat een uitgebreide bepaling van de voedingsstatus de voorkeur
verdient boven de bepaling van een enkele dimensie van de voedingsstatus.
Om vast te stellen of malnutritie geassocieerd is met de ziekteduur is de
voedingsstatus van een groep nieuw gediagnostiseerde IBD patienten (binnen 6
maanden na diagnose) en leeftijd- en geslacht gematchte controle personen
bestudeerd in hoofdstuk 5. Deze Studie geeft aan dat IBD patienten, zelfs op het
tijdsstip van diagnose, allerlei voedingsdeficienties hadden, vooral deficienties
van antioxidanten. Een verminderde consumptie of verstoorde vertering en
absorptie van antioxidanten kan niet de verklaring hiervoor zijn. Er werd daarom
aangenomen dat een toegenomen verbruik van antioxidanten door het ontstoken
weefsel bij UC een oorzaak kan zijn voor de verminderde antioxidant status bij
UC patienten. Deze gegevens ondersteunen de hypothese dat bij IBD patienten
een verminderde antioxidanten verdediging een rol kan speien bij de
pathogenese van vroege weefselbeschadiging.
In Hoofdstuk 6 worden de resultaten gepresenteerd van een Studie naar de
lichaamssamenstelling van verschillende groepen IBD patienten en controle
personen. Bij het vaststellen van de voedingstoestand bij IBD patienten is het
belangrijk om de lichaamssamenstelling te bepalen, omdat zowel malnutritie als
ontsteking kunnen leiden tot veranderingen van de omvang van de
lichaamswatercompartimenten. Er zijn echter uit de literatuur weinig gegevens
bekend over de lichaamswaterverdeling bij IBD patienten. In bovengenoemd
hoofdstuk hebben wij een veranderde waterverdeling en hydratie in het lichaam
beschreven bij vrouwelijke IBD patienten vergeleken met controle personen.
Deze waterverschuivingen waren vooral aantoonbaar bij nieuw
gediagnostiseerde vrouwelijke IBD patienten. Dit suggereert dat met name een
recent acuut ontstekingsproces, naast malnutritie, een belangrijke bijdrage levert
aan de veranderde lichaamssamenstelling. Bij mannelijke IBD patienten werden
geen veranderingen van lichaamswaterverdeling gerapporteerd. Echter,
lichaamsgewicht, lichaamsvet en vetvrije massa waren significant lager dan bij
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leeftijd-en geslacht gematchte controle personen. Het mechanisme achter deze
geslacht-gebaseerde verschillen in lichaamssamenstelling is nog onduidelijk en
meer onderzoek is noodzakelijk.
Het vetzuurmetabolisme is betrokken bij het ontstekingsproces van patienten
met de ziekte van Crohn en de immuunrespons. In hoofdstuk 7 wordt een studio
beschreven waarin zowel de kwalitatieve als kwantitatieve vetzuurconsumptie
en het vetzuurprofiel van plasma fosfolipiden en vetweefsel worden bepaald bij
verschillende groepen CD patienten en leeftijd- en geslacht-gematchte controle
personen. Alhoewel de kwantitatieve en kwalitatieve vetzuurconsumptie niet
verschilde tussen patienten en controle personen, werd een afwijkend essentieel
vetzuurpatroon gevonden bij CD patienten, vooral bij die patienten die al
langdurig aan de ziekte lijden. Een significant lager percentage van de som van
de n-3 vetzuren, en een significant lagere concentratie van clupadonzuur
(22:5n-3), docosahexaeenzuur (22:6n-3) en arachidonzuur (20:4n-6) werden in
bovengenoemde patientengroep geobserveerd. Gezien het feit dat malabsorptie
van essentiele vetzuren geen rol lijkt te spelen concluderen wij dat dit
afwijkende vetzuurpatroon het resultaat kan zijn van een veranderd
vetzuurmetabolisme. Deze bevindingen zijn van belang ten aanzien van de
pathofysiologie bij de ziekte van Crohn, maar ook ten aanzien van de keuze van
vetzuren als mogelijke therapeutische suppletie. .
De relaties tussen de resultaten die gepresenteerd zijn in de hoofdstukken 4,5
en 7 worden besproken in hoofdstuk 8. Bovendien worden de antioxidant status
en het vetzuurpatroon in plasma fosfolipiden bij patienten met de ziekte van
Crohn tijdens een exacerbatie en de daaropvolgende remissie periode
beschreven. Het plasma fosfolipiden vetzuurpatroon bij patienten met een
actieve ziekte verschilde van het vetzuurpatroon bij patienten zonder actieve
ziekte en controle personen: in de eerste groep patienten werden een verhoogde
som van de verzadigde vetzuren, een verlaagde som van de onverzadigde
vetzuren en een verlaagde essentiele vetzuur status waargenomen vergeleken
met patienten zonder ontstekingsaktiviteit en controle personen. De antioxidant
status was significant verslechterd in de patientengroep met actieve ziekte
vergeleken met de patienten zonder actieve ziekte en de controle personen. De
antioxidanten verdediging was ook verminderd in patienten met inactieve ziekte
vergeleken met controle personen. Bovendien was het vetzuurpatroon
significant gecorreleerd met de ontstekingsactiviteit concentraties en de serum
antioxidant concentraties. Dit gegeven, samen met de verminderde
antioxidanten verdediging, onderstreept de hypothese dat antioxidanten kunnen
worden overwogen in de therapie ten aanzien van de ontsteking bij de ziekte
van Crohn.
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De resultaten van de studies die in dit proefschrift zijn beschreven (hoofdstuk
3-8) resulteerden in een interventie trial die beschreven is in Hoofdstuk 9. Het
primaire doel van deze Studie was het bepalen van het effect van een voeding
met n-3 vetzuren en antioxidanten op de voedingsstatus bij patienten met de
ziekte van Crohn. Dit supplement werd gegeven naast de normale voeding. Om
de effecten van ziekteactiviteit op de voedingsstatus uit te sluiten werden alleen
patienten geTncludeerd zonder klinische ziekteactiviteit. Deze gerandomiseerde,
dubbel blind placebo gecontroleerde Studie toonde aan dat de antioxidant status
en de voedingsstatus significant verbeterde na 3 maanden suppletie met
antioxidanten alleen of de combinatie van n-3 vetzuren en antioxidanten
vergeleken met placebo. Het aandeel van eicosapentaeenzuur en
docosahexaeenzuur in plasma fosfolipiden en vetweefsel nam significant toe en
het aandeel van arachidonzuur nam significant af na suppletie van n-3 vetzuren
plus antioxidanten. Dit vetzuurpatroon is geassocieerd met een productie van
eicosanoiden met een verminderde pro-inflammatoire activiteit. Deze Studie laat
zien dat een voedingssuppletie met n-3 vetzuren en/of antioxidanten met
immunologisch modulerende effecten potentieel een nuttige rol kan spelen bi] de
behandeling van de ziekte van Crohn.
Samenvattend illustreert dit proefschrift dat specifieke nutrienten een rol kunnen
spelen bij het ontstaan van colitis ulcerosa, maar dat het nog onduidelijk is of
een specifiek voedingspatroon geassocieerd is met een verhoogd risico op het
ontwikkelen van colitis ulcerosa. In dit proefschrift is bovendien aangetoond dat
de voedingsstatus van patienten die al meer dan 10 jaar aan de ziekte van
Crohn lijden, maar ook van nieuw gediagnostiseerde IBD patienten (binnen zes
maanden na diagnose) significant was verslechterd vergeleken met controle
personen. Tevens toonden we aan dat voedingssuppletie met n-3 vetzuren en/of
antioxidanten de voedingsstatus van patienten met de ziekte van Crohn
significant verbeterde hetgeen van belang kan zijn de behandeling van IBD.
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Dankwoord
Uit eigen ervaring weet ik dat dit waarschijnlijk net meest gelezen stuk gaat
worden uit mijn proefschrift. Dat is misschien wel jammer maar het positieve
hiervan is dat ik kan laten zien dat ik met veel mensen en met veel plezier heb
gewerkt aan dit proefschrift.
Graag wil ik een aantal mensen in het bijzonder bedanken.
Als eerste wil ik mijn waardering uitspreken voor alle patienten en controle
personen die hebben meegewerkt aan de studies beschreven in dit proefschrift.
Zonder dat het misschien direct voor jullie zelf merkbaar was, hebben jullie een
bijdrage geleverd aan het verkrijgen van meer kennis over inflammatoire
darmziekten. Bedankt allemaal voor jullie medewerking!
Er zijn twee mensen die zeer betrokken zijn geweest bij dit proefschrift, mijn
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